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Abstract
 
 Introduction 
Recently published studies indicate that matching at the allelic level for human Leucocyte 
antigens (HLA) between donors and recipients in unrelated haematopoietic stem cell 
transplants (HSCT) improves overall patient survival. These contemporaneous multi-
centre studies looked at stem cell transplants for which donors were initially selected 
using low/medium resolution HLA typing. Donor/recipient pairs were then retyped 
retrospectively to the allelic level for HLA and transplant outcomes were analysed. The 
overall effect of prospective allelic matching for HLA upon an active paediatric transplant 
program has not been reported.  
 Cross-sectional study 
In this study, the current practice of allelic matching for stem cell transplantation in the 
United Kingdom and Ireland was reviewed. This cross-sectional analysis showed that 
there is still considerable scope to influence and improve laboratory and clinical practice 
to the benefit of patients undergoing stem cell transplantation. The study established that 
allelic matching was not universally adopted in the United Kingdom and matching 
strategies between transplant units varied considerably between units.  
Impact of prospective allelic matching on haematopoietic stem cell transplant 
programs 
The study aimed to establish the overall impact of introducing allelic matching at HLA -A,  
-B, -C, -DRB1 and -DQB1 in a well established transplant program. This has not 
previously been reported as all previous studies involve retrospective high resolution 
typing post transplant. This study  reviews Human HLA matching over the 20 years of a 
transplant program for 356 paediatric acute lymphoblastic leukaemia (ALL) patients. The 
study shows that the introduction of allelic matching in 2002 resulted in a more than 25% 
improved disease free survival at two and five years post transplant in this cohort of 
patients. It also shows that the outcome for allelic matched unrelated donor transplants 
was comparable to that of sibling transplants. The analysis investigated whether other 
developments in patient treatment might confound the analysis. The analysis showed no 
other factor could explain the improved survival. The 2008 European Bone Marrow 
Handbook  when discussing paediatric ALL transplantation states, there are no reported 
studies that compare HLA identical sibling transplants with unrelated donor transplants 
matched on allele level . The establishment of the importance of allelic matching in 
paediatric ALL stem cell transplants in this study is novel and highly relevant clinical data.  
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 Influencing Professional Practice 
Using the position of chairperson for an inter professional group working party, I wrote the 
first draft of Guidelines for selection and HLA matching of related, adult unrelated donors 
and umbilical cord units for haematopoietic stem cell transplantation . Suggestions and 
comments were received from other contributors for amendments to the document which 
is to be adopted by the professional bodies listed. These guidelines form part of this 
thesis with the author having writen the first draft document and played the major role in 
their research and writing while chairing the writing working party (~90% contribution to 
final document, excluding clinical notes for scientists). The guidelines should impact the 
current practice of those selecting related or unrelated adult stem cell donors and cord 
blood units for haematopoietic stem cell transplantation. The guidelines promote best 
clinical practice and are approved of by a working party from the following professional 
bodies: 
Children s Cancer and Leukaemia Group (CCLG) 
British Society for Histocompatibility and Immunogenetics (BSHI) 
British Society for Blood and Marrow Transplantation (BSBMT) 
British Transplant Society (BTS) 
Royal College of Pathologists (RCPath) 
Institute of Biomedical Science (IBMS)  
 Non-HLA genomic differences in haematopoietic stem cell transplantation  
In the 16th international histocompatibility workshop to be held in 2012, one research 
group aim is to look at the influence of ethnicities and ethnic differences between donors 
and recipients on stem cell transplant outcomes. The research hypothesis of the group is 
Donor-recipient ethnicity may affect the risk of acute GvHD and other transplant 
associated outcomes after HLA matched unrelated HCT . The final part of this thesis 
looks at donor/recipient differences in Short Tandem Repeat (STR) allele lengths at 
multiple STR loci. The weighted average allele size difference (WAASD) is used as a 
proxy for genetic distance between donor and recipient in HLA matched transplants. The 
study examined the effect of this metric on transplant survival. The study argues that this 
may be a more appropriate genetic measure than ethnic difference. This is especially the 
case in societies such as North America, where populations are composed of highly 
variable admixtures of differing ancestral background. The data shows highly significant 
differences in survival for high and low WAASD values.  
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Chapter One  
      
Figure 1.1                                                       Photo by Susie Fitzhugh  
In the face of doubtful medical contemporaries, Dr. E. Donnall Thomas 
began infusing patients with donor bone marrow cells in 1955 (Nobel prize 
laureate 1990).     
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Introduction 
1 Histocompatibility and Immunogenetics (H&I) laboratory in haematopoietic 
stem cell transplantation. 
1.1 Early development of stem cell transplantation 
World War II saw the development, deployment and subsequent stock piling of nuclear 
arsenals. With this and the peaceful development of nuclear energy as a reliable source 
of electricity, an interest in the biological effects of radiation was greatly stimulated. From 
this interest Jacobson and colleagues showed that mice exposed to lethal radiation where 
their spleen was protected with lead foil survived the exposure (Jacobson et al. 
1950;Jacobson et al. 1951). It was later shown that this protective effect could be 
transferred between animals and that spleen cells infused from a healthy animal to an 
irradiated one reversed lethal effects of irradiation (Lorenz et al. 1951). Using supralethal 
radiation and bone marrow grafting as a treatment for murine leukaemia, it was 
demonstrated that allogeneic but not syngeneic transplants could effectively offer a graft 
versus leukaemia effect in mice (Barnes et al. 1956).  
The earliest recorded attempt at infusing a few millilitres of bone marrow in humans was 
into aplastic anaemia patients who failed to engraft (Osgood et al 1939 cited by Thomas 
1994). This publication was followed by bone marrow reconstitution experiments in 
irradiated dogs. In the early dog experiments, engraftment was not achieved (Rekers et 
al, 1950 cited by (Thomas 1994); in retrospect it is thought that the irradiation although 
lethal to the dogs was insufficient to result in immunosuppression of the recipient immune 
system.    
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Billingham and Medawar published the results of animal skin graft experiments. They 
were able to show that the immune system was implicated in the process of graft rejection 
and early concepts of immune tolerance were presented.  These researchers also showed 
that skin grafts between twins were accepted which was indicative of a possible genetic 
component to engraftment (Billingham, Brent, & Medawar 1953;Billingham & Medawar 
1950). Medawar was awarded the Nobel Prize in 1960 for his pioneering work on 
transplantation immunology and immune tolerance.   
Figure 1.2 First published paper presenting bone marrow engraftment in humans.   
The first reported human bone marrow transplants used donor marrow harvested from 
syngeneic twins and infused into their sibling patients transplanted to treat advanced 
leukaemia (Figure 1.2). The patients were shown to rapidly engraft but soon relapsed with 
their leukaemia (Thomas et al. 1957). These transplants demonstrated the feasibility of 
bone marrow engraftment in humans. Further progress in HSCT was inhibited for the next 
twenty years due to lack of knowledge concerning human histocompatability, 
immunosuppressive drugs and the needs of supportive care in immunocompromised 
patients. Between 1958 and 1968 a total of 203 bone marrow transplants (BMT) were 
performed world-wide where 125 patients died from graft failure and 47 from graft versus 
host disease (GvHD) with only 3 surviving (Bortin 1970). BMT in myeloproliferative 
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diseases had a survival rate of less than 1.5% and could not yet be considered a 
successful mode of therapy.    
1.2 Developments in Histocompatibility   
From the 1930s onward, studies into the nature of immune reactivity and its cellular, 
humoral and cytokine base, led to significant advances. In 1937 Peter Gorer published a 
paper identifying histocompatibility regulatory genes in mice (Gorer PA. 1937). He 
presented data on antibodies able to differentiate between the red cells of differing strains 
of mice and show there was an inheritable basis to the antigen expression detected by 
the antibodies. Gorer then went on to describe that the regression of transplanted 
allogeneic sarcomas was under the influence of mismatching for antigens he named 
antigen I and II. He concluded that mismatching for the two antigens determined whether 
a sarcoma transplanted from strain A mice regressed when transplanted into C57 
black strain mice. He also postulated that antibody production against antigen II present 
in strain A was associated with tumour regression in C57 black mice. Gorer was joined in 
his work with G.D.Snell and using backcrossing in the progeny of two strains of mice they 
produced congenic mice, differing genetically at a single or very few loci. In 1948 they 
published a paper identifying and naming the mouse H-2 loci as the first identified 
histocompatibility loci (Gorer PA 1948). They identified the gene coding for the tumour 
resistance gene. In strain A mice this gene was found to be identical to the gene coding 
for antigen II previously described by Gorer and was named gene H.   
One year after Thomas had attempted the first bone marrow transplant, the foundations 
to identifying the genetic loci of the human major histocompatability complex (hMHC; 
equivalence of H-2 in mice) were laid. Three papers published in the same year identified 
antibodies reactive with leucocytes that were not equivalently reactive with red cells. Jean 
Dausset from Paris, identified antibodies in the sera of patients who had been sensitised 
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by transfusion. The antibodies were identified using leucoagglutination methods. The 
antigen detected by the sera was named MAC and was found to be present in 60% of  
individuals tested  in the French population (Dausset 1959). Rose Payne from Stanford 
University observed that febrile transfusion reactions occurred in some multiparous 
women even where they had only received a single transfusion. She concluded that such 
women seemed to be reacting to foetal leucocyte antigens inherited from the father. They 
found leucoagglutinins in 17% of multiparous women tested even though they had no 
history of blood transfusions and postulated that these antibodies could be used to 
characterise human leucocyte antigens (Payne & Rolfs 1958). Van Rood, from Leiden, 
presented data from both patients receiving transfusion reactions and from multiparous 
mothers and was able to say that antibodies found in multiparous mothers reacted with 
leucocytes from the father and some of the children tested. Van Rood stated with some 
insight, that these antigens may be of significance in bone marrow  transplantation (van 
Rood  1958).  
The study of the human major histocompatibility complex (hMHC) called the Human 
Leucocyte Antigen (HLA) system was born. Dausset had originally named it Hu-1.  
Research into HLA  advanced rapidly through a series of international workshops, which 
continue to this day. These international histocompatibility workshops (IHW) have 
continued with collaborative research projects  that a single laboratory would not have 
had the resources to undertake. At the end of each workshop a symposium to summarise 
advances made is held and the results published. Through international collaborative 
efforts, as well as advances by individual research groups, a greater understanding of the 
hMHC has evolved. This was detailed in a recent review of the history of HLA, showing 
that it has become pivotal to understanding all aspects of clinical immunology (Thorsby 
2009).  
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Figure 1.3 indicates that allogeneic bone marrow transplantation did not become a useful 
therapy until the 1980 s where the number of transplants performed rose year on year 
and Table 1.1a and 1.1b list the areas of research advanced  through international 
workshops. 
BMT as it evolved to become a useful therapy for blood malignancies and genetic disorders.    
Figure 1.3. Time line of significant developments in stem cell transplantation  
(Appelbaum 2007)          
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Table 1.1.a  International Histocompatibility Workshops (1964-1983) 
Workshop Year Chair & Venue Focus of collaborative study and workshop outcome 
1st 1964 D.B. Amos, 
Durham, USA 
The assay methods studied were agglutination, cytotoxicity, leucocyte 
and platelet complement fixation, and mixed hemabsorption); the 
mixed lymphocyte culture reaction, the normal lymphocyte transfer 
test, and skin grafting. Paul Terasaki introduced the microcytotoxicity 
test for serologic typing, and described the first positive leucocyte 
antibody crossmatch test associated with hyperacute renal graft 
rejection. Definition of Hu-1 , LA and Four antigen specificity s 
were put forward 
2nd 1965 J.J. van Rood, 
Leiden, The 
Netherlands 
Family and population data studies showed that most of the antigens 
recognised in the workshop belonged to a single genetic system, for 
which there was still no standardised nomenclature. Using skin 
grafting experiments it was demonstrated that the antigens being 
studied behaved as transplantation antigens. 
3rd 1967 R. Ceppellini, 
Torino, Italy 
This workshop confirmed that the antigens under study belonged to a 
single genetic system, with two sub loci. It was decided subsequently 
to name this system HL-A  to designate it as the major system of 
leucocyte antigens in man. 
4th 1970 PI Terasaki,  Los 
Angeles, USA 
Laboratories exchanged  antisera by mail each participating laboratory 
used a standard microlymphocytotoxicity assay. The results of the 
workshop established the existence of 11 official HL-A specificities 
(HL-A1, 2, 3, 5, 7, 8, 9, 10, 11, 12 and 13), and at least eight other 
specificities that were given provisional designations (e.g., W27). 
Thorsby, Sandberg and Kissmeyer-Nielsen postulated the existence 
of a third (HLA-C) locus, and Boyum's method using ficoll hypaque for 
mononuclear cell separation was first used in a workshop format. 
5th 1972 J Dausset,  
Evian, France 
World population HLA  frequency data was generated at this 
workshop. 
6th 1975 F Kissmeyer-
Nielsen,  Aarhus, 
Denmark 
This workshop was the first to include homozygous typing cells (HTC) 
to study determinants of the HLA-D locus The mixed lymphocyte 
reaction was the focus of study. Further identification and 
characterization of specificities belonging to the three previously-
defined HL-A loci (subsequently termed HLA-A, B and C). 
7th 1977 WF Bodmer 
Oxford, UK, 
150 laboratories studied 360 antisera, a panel of 13,000 lymphocytes 
covering all of the world's major racial groups, and 54 homozygous 
typing cells. Based on workshop results, the HLA-DR locus was 
defined and the first seven antigens of the HLA-DR locus (DR1-DR7) 
were named Evidence of a second Ia locus emerged(MT and MB) 
8th 1980 PI Terasaki,  Los 
Angeles, USA 
The HLA-DR locus was more clearly defined and the newly-defined 
"MB" and "MT" specificities,  in subsequent workshops were shown to 
be encoded by genes of the HLA-DQ locus. The number of families 
studied in the workshop permitted gene, antigen and haplotype 
frequencies in 34 different ethnic groups to be recorded. 
Table compiled 9/09/2010 from : 
A Brief History of the International Histocompatibility Workshops. http://www.ihwg.org/history/history.htm              
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Table 1.1b  International Histocompatibility Workshops (1984-2012) 
Workshop Year Chair & Venue Focus of collaborative study and workshop outcome 
9th 1984 EA Albert/W 
Mayr, Munich, 
Germany 
Vienna, Austria, 
14 HLA-A and B locus specificities were given full recognition and 19 
HLA-A, B, DR and DQ specificities were provisionally given WHO 
designations.  Restriction fragment length polymorphism (RFLP) 
method was presented, illustrating the power and utility of DNA  in 
HLA typing. The HLA-DP locus was described, based on cellular 
methods. 
10th 1987 B Dupont, 
Princeton, USA 
RFLP  for HLA class I and class II, with separate analysis of DRA, 
DRB, DQA, DQB, DPA and DPB methods were developed. RFLP 
patterns were found to correlate with the serologically defined HLA 
class II alleles. Changes in HLA nomenclature were introduced to 
accommodate HLA alleles from DNA sequences. 
11th 1991 T Sasazuki/K 
Tsuji/M Aizawa 
Yokohama, 
Japan 
The polymerase chain reaction (PCR) technology with sequence 
specific oligonucleotide probe (SSOP) hybridization as an HLA-DNA 
typing method was extensively used. At this workshop the concept of 
all serological specificities being named on the basis of correlation 
with an identified sequence was introduced. 
12th 1996 D Charron,         
St Malo/Paris, 
France 
The development and implementation of DNA-based typing methods 
for the analysis of HLA specificities at the allele level was the main 
focus of this workshop. A method developed and used in the 
anthropology studies was a modification of the sequence specific 
priming (SSP) typing method to obtain low to medium resolution typing 
of HLA-A, B and C genes and high resolution typing of HLA-A*02 
alleles. The method permitted a comprehensive study of  HLA-C 
alleles and provided data on HLA-B/C linkage associations and 
identifying the anomaly in Cw "blank" antigen assignments. 
13th 2002 J Hansen,  
Victoria, Canada
Seattle, USA 
Virtual DNA analysis; Identification of SNP markers; Anthropology; 
Disease association; HSCT Establishment of a publicly accessible 
MHC database 
14th 2005 J McCluskey, 
Melbourne, 
Australia 
MHC and anthropology; Disease; Infection; ; Haematopoietic stem cell 
transplants  ; Cancer; KIR; Cytokine genes New data on KIR HLA and 
interactions. 
15th 2008 M Gerbase de 
Lima/ME 
Moraes, 
Buzios/Rio de 
Janerio, Brazil 
Three principal areas of analysis, Anthropology; Haematopoietic stem 
cell transplant  outcome analysis in the era of allelic typing - 
confirmation of importance; development of bio-informatics tools for  
histocompatibility and immunogenetics 
16th 2012 SGE Marsh/D 
Middleton 
Liverpool, UK 
Eight study groups with IHWG HCT studies in unrelated donor HSCT 
cover four broad research areas: HLA and clinical outcome, MHC 
region genetics, cytokine and immune response genetics, and NK 
receptors and minor histocompatibility receptors. Work ongoing 
Table compiled 9/09/2010 from : 
A Brief History of the International Histocompatibility Workshops. 
http://www.ihwg.org/history/history.htm    
1.3 Human Leucocyte Antigen genes 
The HLA system is synonymous with the human MHC and is coded for by a cluster of 
genes on the short arm of chromosome 6 at 6p21.3 and spans 4 centimorgans of 
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chromosomal length with over 140 genes identified. This gene cluster codes for proteins 
including cell surface markers, antigen-presenting molecules, and other gene products 
involved in immune function.  HLA antigens are codominantly expressed and the extreme 
polymorphism seen at the HLA genes means a number of variant molecules are possible 
in one individual (Figure 1.4). The number of possible HLA allele combinations at differing 
HLA loci becomes considerably more diverse when seen  throughout a population. In 
terms of the biology of the complex, although this diversity assists in fighting pathogens 
giving survival advantage to the species it provides histocompatibility barriers to stem cell 
and solid organ transplantation.  
Figure 1.4 Codominant expression of HLA genes. Schematic representation of 
codominant expression of parental class I and class II antigens (image downloaded 
10/09/2010; http://en.wikipedia.org/wiki/Major_histocompatibility_complex).  
Table 1.2 summarizes the principal characteristics if the HLA class I, class II and class III 
genes and outlines briefly their expression and function. In matching donors and 
recipients for stem cell transplantation it is the classical class I loci (HLA -A, -B and -C) 
and the class II loci, HLA-DRB1,DQB1 and to a lesser extent DPB1 that are typed to 
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establish compatibility. This study is limited to the HLA class I and class II loci when 
examining the importance of HLA in stem cell transplant outcomes. 
Table 1.2 The MHC region is divided into three subgroups, class I, class II, and class III. 
Name Proteins Expression and function 
HLA 
class I
Codes non-identical pairs of peptide-
binding proteins (heterodimers). Also 
codes for antigen-processing molecules 
such as TAP and Tapasin. 
All nucleated cells. HLA class I proteins contain 
an alpha chain & 2-micro-globulin (not part of 
HLA, encoded by chromosome 15). HLA 
proteins present antigen derived peptides to 
cytotoxic T-cells via the CD8 +ve receptor on the 
cytotoxic T-cells. HLA class I also binds 
inhibitory receptors on NK cells. 
HLA 
class II
Codes for heterodimeric peptide-binding 
proteins and proteins that modulate 
antigen loading onto HLA class II 
proteins in the lysosomal compartment 
during antigen processing such as HLA-
DM,  DQ, DR, and DP. 
On most immune reactive cells, and specifically 
on antigen-presenting cells. HLA class II proteins 
contain  &  chains and they present antigen 
fragments to T-helper cells by binding to the CD4
receptor on the T-helper cells. 
HLA 
class III 
region 
Codes for other immune components, 
such as complement components (e.g., 
C2, C4, factor B) and some that encode 
cytokines (e.g., TNF- ) and also HSP. 
Variable dependant on whether cells are resting 
or reacting to an inflammatory immune reaction. 
Class III proteins have functions very different from that of class I and class II proteins.    
1.4 Genetic organisation of HLA 
The complete sequence of the human MHC was detailed in 1999 and a map of the hMHC 
was described (Rhodes & Trowsdale 1999).  Figure 1.5 uses the published data to 
expand the gene map for HLA class I and Class II. This depicts the relative size of the 
exons and introns in these genes and identifies the protein domains for which the exons 
encode.      
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The class I region lies at the telomeric end of the HLA system and spans 1.8 mega bases 
of DNA. The gene density of this region is approximately one gene every 15 kilo bases 
(Kb). The region codes for the classical HLA-A, B, and C loci and also the non-classical 
HLA-E, F and G loci as well as many non expresed pseudogenes such as HLA-H, J, K, L, 
and X. 
The class II region lies at the centromeric end of the HLA complex and spans 800 Kb of 
DNA. The gene density in this region is approximately one gene every 40 Kb (Cambell et 
al, Immunol Today, 1997 HLA map supplement). The genes for the  and  polypeptide 
chains of the classical class II molecules HLA -DR, -DQ and -DP are coded for in this 
0 200M
b
400M
b
CH 6
0 0.5M
b
1M
b
HUMAN 
0                                                       
CLASS I 
CLASS II 
GENE
0 1k 2k
L                                                                                              1                         2 Tm/C C          C                    
                   L           1                   2                                       3             Tm                      C      C       UT                     
  Class II                                         Class III                                                              Class I 
                                                               DQB2     DQB1          DRB2   
   DPB2    DPB1               DMB    DOB        DQB3       DRB1       DRB3 
     DPA2 DPA1  DNA  DMA               DQA2     DQA1             DRB9 DRA 
MICB    MICA    B        C                                                    X                                                    E                                L            J            A      K     H                        G      F
6p21.3 
Figure 1.5 Map relating relative size of introns and exons of HLA system. 
Taken from:  Ross, J. &  Harvey, J., (2000) HLA Polymorphism, in Human Blood Cells. 
Consequences of genetic polymorphism and variations. (King, M.J. ed.) p280 Imperial College 
Press, London.
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region. The non-classical class II HLA -DRB(3,4,5), -DOB, -DMA, and -DMB proteins are 
also coded for in this region  The genes for several class II pseudogenes including DPA2, 
DPA3, DQB2, DQA3 and a variable number of HLA -DRB pseudogenes are located here. 
The organisation of the DR region is particularly complex with both gene products and 
pseudogenes present varying depending upon the haplotype studied (see Figure 1.6).    
As listed in Table 1.2 HLA class I and class II molecules are distinguished from each 
other by their structure, tissue distribution and the intracellular pathways of their 
biosynthesis and assembly (Ross 2000). 
1.5 Structure of Human Leucocyte Antigens (HLA) 
The tertiary structure of the HLA class I antigen was described by Bjorkman using X-ray 
crystallography. She showed that the membrane distal protein domains combined to form 
an antigen-binding site in which electron dense peptides were co-crystallised in the HLA-
A2  molecules (Bjorkman et al. 1987). The ribbon diagram in Figure 1.7, illustrates the 
Figure 1.6 Genetic organisation of the HLA DR haplotypes. 
Taken from:  Ross, J. &  Harvey, J., (2000) HLA Polymorphism, in Human Blood Cells. 
Consequences of genetic polymorphis and variations. (King, M.J. ed.) p281  Imperial College 
Press, London. 
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peptide binding to the the alpha helices and beta pleated sheets of domains one and two 
of the class one molecule.  
HLA class I molecules are cell surface glycoproteins, comprising a heavy chain (H chain) 
of 45kDa, which is non-covalently associated with a non polymorphic light chain -ß2-
microglobulin (ß2-m), encoded on chromosome 15 (15q21-q22.2). They also differ in 
biological function in terms of T the lymphocyte (CD4+Th or CD8+Tc) activity with which 
they interact to regulate the immune response in processing and presenting endogenous 
and exogenous antigens to the T-cell receptor in immune reactions. Their structure, tissue 
distribution and the intracellular pathways of their biosynthesis and assembly distinguish 
class I and class II molecules from each other. HLA class I molecules are expressed on 
the surfaces of nucleated cells at differing densities; class II molecular expression is 
restricted to cells of the immune system. Cytokines secreted by lymphocytes and 
monocytes during inflammatory immune responses can cause significant increases in 
class II HLA antigen expression, even on cell types that normally have little or no surface 
expression (Cresswell 1987)  
The role of HLA class I molecules is to sample intracellular peptides produced within the 
cell and to signal the physiological state (antigen processing and presentation) of the cell 
to the effector cells of the immune system which can be both T-cells and NK cells 
(Natarajan et al. 1999). These peptides may be derived from pathogens (such as viruses) 
or cellular proteins which have been processed via the proteasome into peptides which 
are able to bind to MHC-1 molecules: a process vital for their folding, stabilisation and 
subsequent transport to the cell surface (Kloetzel 2004).  
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The fact MHC Class I binds endogenous peptide has particular relevance for the binding 
of self as well as non-self peptides. The proteasome is the central proteolytic system of 
the cell playing an important role in the generation of MHC-class I peptides by selective 
ATP-dependent degradation of cytosolic, nuclear and membrane bound proteins. The 
proteasome generates peptides with the essential carboxyl terminus for binding to class I 
molecules with high affinity. In addition, amino peptidases, present in either the cytosol or 
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Figure 1.7  HLA  class I domain structure and its relationship with exon DNA structure  
Taken from:  Ross, J. &  Harvey, J., (2000) HLA Polymorphism, in Human Blood Cells. 
Consequences of genetic polymorphis and variations. (King, M.J. ed.) p283  Imperial College 
Press, London. 
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the endoplasmic reticulum, facilitate the addition of the amino terminus (Yewdell & 
Bennink 2001). Transporters associated with antigen processing convey processed 
peptides to the ER where HLA class I molecules are located. In the ER peptides may be 
trimmed depending upon the available MHC molecules (Paz et al. 1999).    
The HLA-DR / , DQ / and DP / genes encode for the class II molecules each of 
which consist of two transmembrane glycoproteins which form a peptide binding 
hetrodimer as depicted in Fig.1.8.  These proteins assemble from constituent 
glycoproteins in the endoplastic reticulum in association with a chaperon polypeptide 
called the invariant chain (Ia) and form trimeric structures in the Golgi apparatus of the 
cell. The complexes are transported to endosomes for acidified proteolytic processing and 
peptide loading where the enzyme cathepsin S is involved in proteolysis of the Ia chain to 
form Class II associated invariant peptide (CLIP). CLIP occupies the peptide-binding fold 
of nascent class II molecules. The dissociation of CLIP and subsequent loading with 
peptide is catalysed by an HLA protein dimer called HLA-DM. The HLA class II/peptide 
complex is then transported to the cell membrane for expression and recognition by the 
T-cell receptor (TcR) of the immune system. Class I peptides may bend in the middle of 
their main carbon chain in order to conform to the binding stringency of the class I peptide 
binding fold. This is not the same with class II bound peptides, which maintain a relatively 
even elevation from the floor of the peptide-binding fold. Hydrogen bonding is evenly 
spaced throughout the class II peptide binding groove making highly stable complexes 
once formed (Garboczi et al. 1996;Stern et al. 1994)  
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1.6 Cells of the Immune System 
There are two complementary arms to the immune system; adaptive and innate immunity. 
The first line of defence against pathogens is innate immunity and includes physical 
barriers (e.g. skin and mucosal surfaces), phagocytic cells (neutrophils and 
macrophages) and proteins of the complement cascade and cytokine systems (Figure 
1.9).   
The adaptive system differs from the innate by responding with increasing magnitude and 
specificity to pathogens showing immune memory subsequent to repeat infection. The 
adaptive response offers both humoral mediated immunity with antibodies produced by B 
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Figure 1.8 HLA class II domain structure and its relationship with exon DNA structure  
Taken from:  Ross, J. &  Harvey, J., (2000) HLA Polymorphism, in Human Blood Cells. Consequences of 
genetic polymorphis and variations. (King, M.J. ed.) p288 Imperial College Press, London.
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lymphocytes and cell mediated immunity by T-lymphocytes, antigen presenting cells 
(APC) and other effector cells. 
Figure 1.9 Innate and adaptive immunity: this illustrates the relative time relationship 
between the two with innate immunity preceding adaptive immunity (downloaded 
6/12/2010 from http://www.actagainstallergy.co.uk/aaa/_images/system_01.gif)  
1.7 Cells of the Innate Immune System 
The main effector cells of the innate immune system are neutrophils, mononuclear 
phagocytes and NK cells. Neutrophils and monocytes migrate to the site of infection 
attracted by chemokines produced as a result of inflammation. Selectins, which are 
ligands for integrins on endothelial cells, are unregulated by cytokines and chemokines. 
Neutrophils, monocytes and activated T lymphocytes use these ligands as a mechanism 
to migrate to the sites of infection in a process involving rolling, adhesion and migration 
through the endothelium. Neutrophils are phagocytic cells characterised by a segmented 
lobular nucleus and cytoplasmic granules filled with enzymes. The most numerous cell 
type in the blood are polymorphonuclear cells which mediate acute inflammatory 
responses (Antin 2001). 
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1.8 Cells of the Adaptive Immune Response 
Haematopoeisis is outlined in Figure 1.10 and shows the cells from which the adaptive 
and innate immune systems develop. T-cells are produced in the bone marrow as 
progenitor cells. They migrate from the bone marrow to the thymus, express a T-cell 
receptor (TcR) and undergo maturation to become mature T-cells (Figure 1.10). Thymic 
processing of T-cells confering the ability to discriminate betwen self and non-self in the 
context of HLA peptide presentation takes place. In the thymus T-cells with strong binding 
for self HLA are removed by programmed cell death (apoptosis) and those with low 
avidity in interactions with self HLA are positively selected (Mannie 1991).  
T-cells have on their cell surface the TCR for antigen, which is recognised in the context 
of self-HLA as processed peptides. CD4 positive (CD4+) T helper cells (Th) recognise 
exogenous antigen presented by HLA-Class II molecules and CD8 positive (CD8+) that 
are mainly cytotoxic (Tc) and recognise endogenous antigen in the context of HLA-Class I 
molecules (antigen presentation and processing).     
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Figure 1.10 Haematopoeisis: the cells of the immune system develop from pluripotent 
(multipotential) haematopoietic stem cells.  
(downloaded 6/12/2010 from http://en.wikipedia.org/wiki/File:Hematopoiesis simple.svg)  
CD4+ cells recognise peptides presented by HLA class II but have different roles in being 
effector cells or regulatory cells in the immune response. CD4+ effector (Th1) cells are 
required for the priming and maintenance of CD8+ T-cells, thus enhancing the overall 
immune response (Wang 2001).  
The role of CD4+ T-cells in controlling immune responses against cancer cells is 
illustrated in Figure 1.11. CD4+ T-cells prime CD8+ T-cells via activation of APC. They 
secrete cytokines, which are required to maintain CD8+ T-cell function and proliferation. 
CD4+ T-cells can also inhibit tumour growth both directly or indirectly and provide help for 
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B-cell activation. Recently, CD4+ T-cells were shown to be required for the subsequent 
expansion of CD8+ memory (Shedlock & Shen 2003).               
Figure 1.11 The role of CD4 T-cells in the immune response in cancer.  
Depending upon the nature of the immune stimulus, CD4+Th0 cells either produce IL-12 that 
stimulates a Th1 type response or IL-4 that stimulates a Th2 response. In a) Th1 cells activate 
CD8+ via antigen dendritic cells (DC) or via b) by the production of IL-2 and in c) by directly killing 
tumour cells. Th2 cells activate B cells to produce antibody and also stimulate eosinophil cell 
mediated immune responses (d) .Taken from: (Wang 2001)  
Naive CD4+ Th0 cells, on stimulation with antigen loaded APC, develop into either Th1 or 
Th2 subsets. These cells are characterised by the cytokines they secrete and their 
immune function. Th1 cells secrete IL-2, IFN and lymphotoxin and are important in 
amplifying the CD8+  cytotoxic response. Th2 cells secrete IL-4, IL-5, IL-10, and IL-13 and 
influence macrophage function and immunoglobulin responses (Figure 1.11). Cytokines 
produced by CD4+  and CD8+  cells cross regulate each other (Morel & Oriss 1998). In   
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haematopoietic stem cell transplants it has been shown that the transfusion of CD4+  
donor lymphocytes induces the expansion of CD8+ donor T-cells with enhanced cytolytic 
activity against recipient haemopoeitic cells (Zorn et al. 2002).  
A further subtype of CD4+ T-cells are regulatory cells (Treg) which can suppress host 
immune responses and induce self-tolerance (Sakaguchi et al. 1995b). These cells make 
up approximately 3-5% of CD4 + CD8 thymocytes expressing CD25 (IL-2 receptor) 
(Sakaguchi et al. 1995a). Expression of CD25 is not exclusive to Tregs as it is also 
expressed by activated, non regulatory effector lymphocytes (Vigouroux et al. 2004). 
There is evidence that Tregs are regulated by natural killer T-cells (NKT),  (Tamada et al. 
1997). Tregs may also have a role in the suppression of tumours and leukaemia (Terabe & 
Berzofsky 2004). They have also been implicated as having a role in  cGVHD (Clark et al. 
2004).  
CD8+ T-cells are important for the elimination of intracellular pathogens via HLA class I  
recognition. In the transplant setting there is a critical role for specific CD8+ T-cells in the 
elimination of tumour cells and there is evidence that T-cells are the cells primarily 
responsible for the GVL effect (Lowe et al. 2003). These cells are particularly important in 
the post transplant setting for the control of viral infections especially CMV (Cwynarski et 
al. 2001). In addition to the CD4 and CD8 molecules, mature T-cells express CD45 and 
CD3 molecules that associate with the TCR and are involved in transmission of activation 
signals.  
The Forkhead box P3 gene (FoxP3) has been identified as the marker for Treg 
development and has provided a  target for  interest in studying regulatory mechanisms in 
alloreactivity and autoimmune diseases. In autoimmune disease Treg  cells isolated from 
patients have been shown to exhibit reduced regulatory function compared to healthy 
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controls. More recently experimentation in mice has used chemical stimulants to induce 
naive T-cells (CD4+, CD25-) to express FoxP3 and the resultant T-cells were able to 
display T-cell suppression of immune responses and have the Treg phenotype (CD25+, 
CTLA4+, GITR+, CD127-) (Moon et al. 2009). This line of research may result in the 
induction  of specific immune tolerance in the future. 
1.9 Development of TH1 and TH2 subsets 
Naïve CD4+ T-cells (Th0) differentiate into either Th1 or Th2 depending upon the stimuli 
present early in an immune response. IL-12 is the major inducer of Th1 cells and IL-4 of 
Th2 cells. These cytokines may also act as growth factors on these subsets. The main 
function of Th1 cells is in phagocyte mediated defence against intracellular infections. Th1 
cells secrete IFN , lymphotoxin, TNF and IL-2. IFN acts on macrophages and on B cells 
to stimulate the production of IgG antibodies which opsonises pathogens for 
phagocytosis. The main function of Th2 cells is the stimulation of IgE production and 
eosinophil/mast-cell mediated immune responses. Th2 cells secrete IL-4 and IL-5, which 
stimulates B cells to produce antibody and activates eosinophils respectively.  
1.10 Apoptosis 
In the immune system, programmed cell death is the means by which unwanted cells are 
removed without the activation of the inflammatory cascade. This process is called 
apoptosis. It is characterised by DNA cleavage, nuclear condensation and fragmentation, 
changes in membrane lipids and detachment from extra cellular matrix. Apoptosis is 
particularly important in T-cell maturation in the thymus where self -reactive T-cells are 
removed (Ohashi 2003). 
The process is mediated through the activation of caspases which are enzymes present 
in cytoplasm. In lymphocytes caspase activation and apoptosis can occur in two ways. 
One involving mitochondrial permeability changes and the other through death receptors 
in the plasma membrane (Liou et al. 2003). If lymphocytes are deprived of essential 
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factors for survival, e.g. growth factors, this results in the increase in mitochondrial 
membrane permeability and the release of cytochrome C into the cytoplasm of the cell. 
The latter functions with apoptosis activating factor (Apaf-1) to activate caspase 9, which 
begins the apoptotic pathway. This is passive or programmed cell death.  
The second pathway is mediated by the binding of death receptors to death-inducing 
membrane receptors. The latter include receptors for tumour necrosis factor (TNF) and 
the family includes a large number of proteins including Fas and CD40. Fas are a 36kD 
protein expressed by lymphoid cell membranes. Cross-linking of these receptors induces 
apoptosis. FasL is a homotrimer expressed on T-cells after activation with antigen or IL-2. 
On maturity activated T-cells express both Fas and FasL. The latter binds to Fas on the 
same or adjacent cells forming a cluster of three or more Fas molecules. Clustered 
intracellular death domains bind FADD (Fas associated death domain) which in turn binds 
caspase 8, which ultimately triggers apoptosis.  
1.11 Cytotoxic killing 
The process of CTL mediated killing requires  antigen recognition followed by activation 
and delivery of the lethal hit that kills target  cells. CTLs kill targets in two ways; the first 
method is mediated by perforin and proteases called granzymes, which are stored in 
granules in CTL and NK cells. CTL recognise antigens on target cells using the TCR, and 
the granules are actively moved within the CTL to the plasma membrane engaged with 
the target cell. Perforin monomers assemble in a calcium dependent step into structures 
which can selectively disrupt cell plasma membranes. The second killing mechanism 
requires the binding of Fas ligand (FasL) which is expressed on activated CTL with Fas 
on the surface of the target cells, this initiates apoptosis. These mechanisms are the 
same for NK-mediated cell lysis. 
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1.12 T-cell activation and migration 
The production of effector cells requires both antigen recognition and co-stimulation. 
CD4+ and CD8+ T-cells recognise HLA/peptides complexes presented by antigen 
presenting cells in lymphoid organs. T-cells, either CTL or CD4+ Th cells, are stimulated, 
proliferate, mature and enter the peripheral blood circulation as effector cells. These and 
other cells have crossed through blood vessels by means of adhesive iterations using 
three families of cell surface molecules; integrins, adhesion molecules and selectins (e.g. 
LFA-1 to ICAM-1 or 2; CD2 to LFA-3) endothelial cell molecules that have been activated 
by cytokines (Springer 1990). These effector T-cells migrate and encounter antigens in 
the periphery and respond by secreting cytokines and activating inflammatory responses.   
Cytokines are the soluble mediators of innate and adaptive immunity and one way cells 
communicate with each other. Cytokines are produced in the innate immune system by 
macrophages and NK cells and mediate early inflammatory events. In the adaptive 
immune system, cytokines amplify responses through stimulating proliferation and 
differentiation of antigen-activated lymphocytes. They can activate specialised effector 
cells such as macrophage and dendritic cells. Cytokines also influence the synthesis and 
actions of other cytokines through feedback mechanisms (e.g. action of TNF is inhibited 
by IL10)  and may act locally or systemically by binding to specific membrane receptors 
on target cells (Karupiah 2003;Said et al. 2010).  
Tumor necrosis factor (TNF) is the primary mediator of the acute inflammatory response 
and is produced by mononuclear phagocytes, antigen stimulated T-cells, NK cells and 
mast cells. TNF can also induce apoptotic cell death (Micheau & Tschopp 2003). TNF is 
synthesised as a non-glycosylated type II membrane protein that has an amino terminus 
within the cell and a larger carboxyl end outside the cell. The membrane form is 
expressed as a homotrimer and is able to bind the TNF-RIII receptor. This form may be 
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cleaved to release a 17kD form. Three of these polymerise to form the circulating 51kD 
homotrimer these bind to the TNF-RI/p55 receptor or TNF RIII/p75 with low affinity.    
IL-1 and - are pro-inflammatory cytokines involved in immune defense against infection 
and have a similar role to TNF in inflammation and mediate host inflammatory response 
to infections and other stimuli. There is also an inhibitor to their action IL-1RA which 
competes for receptor binding with IL-1 and IL-1 , acting as a suppressor to immune 
activation. The same cells as TNF produce IL-1.   
1.13 The alloreactive paradox  
Antigenic specificity to immune T-cell responses is only known to be conferred by contact 
between HLA/peptide complexes and the T-cell receptor.  The T-cell receptor is the 
product of four rearranged genes A, B, C, and D and exist in two forms ( and ) which 
complex with CD3 polypeptides; it is the   form that predominantly interacts with both 
class I and class II  HLA molecules. The complex of T-cell receptor/peptide/MHC 
structure also interacts with co-receptors CD4 (class II) and CD8 (class I) which along 
with CD3 confer signal transduction properties to the molecular complex (Garboczi, 
Ghosh, Utz, Fan, Biddison, & Wiley 1996)  
Experimental evidence from the 1970s suggest that T-cell receptors are MHC restricted 
meaning that pathogenic antigens are only recognised if they are presented by self-HLA 
molecules and ignored if they are presented by foreign HLA molecules.  A problem with 
the theory of MHC restriction is that five to ten percent of T-cells react to HLA antigens 
from foreign haplotypes and this alloreactivity is not MHC restricted (Ashwell, Fox, & 
Schwartz 1986). Most of the evidence gathered supportive of MHC restriction theories is 
derived from measured reactivity against a limited repertoire of antigens with a limited 
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number of MHC haplotype combinations. (Detours & Perelson 2000) suggest that the 
early experiments of the 1970s should be repeated with large number of MHC haplotypes 
to see if theories on restriction levels are reliable. Because of the technical difficulties in 
performing such experiments they mathematically modelled affinities between the 
components of the  TcR/MHC/peptide complexes with the main assumption of the model 
being that affinities between TcR/MHC/peptide complexes drive T-cell maturation in the 
thymus. Using parameters for molecular shape, charge and hydrophobicity to describe 
the binding of proteins in the TcR/MHC/peptide complex the model construct tested for 
100,000 possible TcR/MHC/peptide complexes. In this model they found that there was a 
trade off between MHC restriction and alloreactivity in which both cannot be high and that 
self-restriction is not high on average.  
1.14 Alloreactive pathways  
Two pathways of alloreactivity are commonly described in textbooks, which can explain 
both HLA restricted and non-restricted allo-recognition, by the immune system.  The 
pathways are termed the direct and the indirect pathways. A third pathway has been 
described where pathogen driven immune responses result in T-cells that  cross-react 
with allogeneic antigen. Evidence of this has been shown where clones of T-cells specific 
for Epstein Bar derived peptide presented in context of HLA-B8 antigen also crossreact 
with the allogeneic molecules HLA-B14, B44 and B35 (Burrows et al. 1997).    
Studies on T-cell responses to viral infection has demonstrated that peptides with 
dissimilar sequences can still stimulate the same T-cell clone and that cross-reactivity 
probably depends more on the three dimensional structures than sequence homology.  
This makes the prediction of  what epitopes will cross react  very difficult (Koehn et al. 
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2006).  Figure 1.12 illustrates a model for direct indirect and crossreactive antigen 
presentation.  
Figure 1.12  Model of allo-reactivity - in graft versus host or graft versus leukaemia   
reactions. T-cell response to alloantigens on recipient cells is mediated via three 
pathways. In this model the indirect presentation of the recipient HLA peptide could 
alternatively be a minor histocompatibility peptide, leukaemia specific peptide or a 
pathogen derived peptide. Where a T-cell has specificity for a pathogen derived peptide 
and also reacts with allo-antigen then it is said to be crossreactive. 
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In a recently published paper on direct and indirect allo recognition with corneal and 
skin transplants in mice, the authors reported differing pathways being activated 
dependant upon the source of allo stimulation. In corneal grafts indirect allorecognition 
was by CD4+ T-cells  producing low levels of IL-2. However skin grafts were rejected by 
both direct and indirect alloreactive pathways with high levels of IL-2 produced by the 
CD4+ cells. CD8+ T-cells for both corneal and skin graft transplants produced high 
levels of  IFN. Only CD8+ T-cells from the skin grafts were able to elicit a cytotoxic 
response (Boisgerault et al. 2009). The ability to predict what will generate an 
alloreactive response in any individual is highly complex and influenced by the genetic 
make up of donor and recipient, environmental factors such as exposure to pathogens 
and the nature of the graft implanted. Differences in allorecognition between umbilical 
cord blood donations, peripheral blood stem cells and bone marrow cells in stem cell 
transplantation have also been reported. This is reviewed with recommendations on 
stem cell sources in Chapter four of this thesis.  
The relative contribution of the direct and indirect pathways of allo recognition has until 
recently not been elucidated. In a transgenic mice experimental model the involvement 
of CD4-direct (CD4-d), CD4-indirect (CD-4i), CD8-direct (CD8-d) and CD8-indirect 
(CD8-i) cells in post transplant alloreactivity  was described. It was found that in naive 
mice CD4-i and CD8-i cells were undetectable but that 10 days post skin grafting 10% 
of the CD4 response was CD4-i cells and that these cells were even further enriched 
within the graft during alloreactivity (Brennan et al. 2009). It was concluded that the 
indirect pathway was favoured in T-cell responses post transplant. 
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Figure 1.13  Direct, indirect and cross-reactive pathways for presentation of 
alloantigens in a stem cell transplant. CD4+ T-cells recognising alloantigens in intact or 
processed forms  (also including including cross-reactive pathogen derived peptide) 
contribute to the graft versus host or leukaemia activity by providing help to CD8+ 
cytotoxic T-cells and alloantibody producing B cells.  
The consequences of alloreactivity in stem cell transplantation are associated with the 
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(aGvHD), chronic graft versus host disease (cGvHD), graft versus leukaemia (GvL) 
effect and decreased leukaemia relapse. 
1.15 Graft versus Host Disease (GvHD) 
Conditioning regimes prior to stem cell transplantation typically involve cytotoxic 
radiation and/or chemotherapy. In the treatment of malignant disease the objective is 
first to destroy the malignant cells through cytotoxic attack (irradiation/chemotherapy) 
and then by immunologic attack in what is termed a graft versus leukaemia effect  
(GvL). Tissue damage due to the conditioning treatment causes the release of 
inflammatory cytokines. This triggers the activation of antigen presenter cells (APC) and 
donor T-cells leading to the differentiation and expansion of effector T-cells directed 
against recipient antigen. The presence of post mitotic CD44lo/CD62Lhi/CD8+ T-cells 
can generate and sustain all allogeneic T-cell subsets in GvHD reactions (Socie & 
Blazar 2009) CD4+ T-cells  induce GvHD against MHC class II antigens and CD8+ T-
cells against MHC class I antigens (Zhang et al. 2005). Damage to the gut can result in 
the release of endotoxins such as lipopolysaccharides (LPS) which further stimulates 
the inflammatory response.   
A complication of GvHD are bacterial, viral and fungal infections as the patient immune 
system is overwhelmed by the inflammatory response observed in severe GvHD. This 
has been described as the immune inflammatory response running amok (Antin 2001)  
1.16 Acute graft versus host disease (aGvHD) 
Where this happens within the first 100 days of transplant this is said to be acute Graft 
versus Host (aGvHD)disease although there are some reports beyond the 100-day limit. 
The severity of aGvHD is scored on a five point scoring system. Grade 0, is no GvHD; 
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Grade I is a mild form observed as a skin rash which may disappear without therapy. It 
may be easily confused with other complications of stem cell transplantation.  With 
Grade II aGvHD, the skin rash extensively covers the body and may be associated with 
gut or liver symptoms. In Grade III the aGvHD is more severe and involves the skin, gut 
and liver, Grade IV is very severe aGvHD and is life threatening.   
The presentation of aGvHD in the skin appears as a micropapillary rash, which often 
starts in the palm of the hands, soles of feet or face but in severe cases can cover the 
body (with necrosis in extreme cases).  Raised levels of the enzymes S-ALAT and S-
ASAT plus bilirubin will indicate liver involvement. This may also result in liver 
enlargement and ascites.  Gut involvement may involve abdominal pain and diarrhoea, 
in severe GvHD this may also result in haemorrhage (Ringden 2005). Figure 1.14 
presents a model illustrating the sequential phases and factors known to influence 
GvHD.
  
Figure 1.14   GvHD - Is shown to have three sequential phases of tissue damage, T-cell 
activation and inflammation (adapted from Hill and Ferrara, Blood, 2000 and Jacobson, Bone 
Marrow Transplantation, 2009).   
1.17 Chronic graft versus host disease (cGvHD) 
Chronic GvHD usually appears after the first 100 days up to the first year although it may 
appear much latter.  The symptoms are more complex but may also include the skin, liver 
and gut. The grading of cGvHD is classified as mild, moderate or severe based upon the 
opinion of the treating physician.    
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The symptoms that may be observed are: 
keratoconjunctivitis, sicca syndrome, oral mucositis, oesophageal and vaginal strictures, 
liver disease, wasting, malabsorbtion, pulmonary insufficiency, bronchiolitis obliterterans, 
myositis, neuropathy, and immunodeficiency.  
1.18 T-Cell depleted grafts and GvHD 
GvHD is associated with significant morbidity post stem cell transplant. If the patient/graft 
is depleted of T-cells using monoclonal antibodies such as Campath® -1H (alemtuzumab, 
Genzyme Corporation, Cambridge, MA) (0.9-1.0mg/kg body weight administered in 3-4 
doses) then GvHD can almost be eliminated.  However T-cell depletion does not convert 
directly into improved overall patient survival due to its association with an increased risk 
of graft failure, Epstein Bar virus activation and leukaemia relapse. The paediatric acute 
lymphoblastic leukaemia (ALL) study outlined in Chapter 3 shows that T-cell depleted 
grafts when compared with T-cell replete grafts have significantly less aGvHD and cGvHD 
and this is consistent with the literature (van der Straaten et al. 2001)  
1.19 Post transplant monitoring and the impact of Donor-Recipient genomic 
divergence on stem cell transplant outcomes   
DNA sequence short tandem repeats (STRs) are found throughout the human genome. 
STRs show sufficient variability from individual to individual that they have become 
important tools in genetic mapping, linkage analysis, and human identity testing. For STR 
alleles  to be useful in post transplant monitoring of chimerism, they have to discriminate 
one individual from another even among HLA matched sibling transplants. STRs are used 
routinely to monitor donor chimerism post transplant where it is a useful tool to 
demonstrate engraftment and a marker for adverse events such as aGvHD, graft failure 
or disease relapse. There are no accepted standards set for the choice of STR markers 
and their reliability as sensitive markers for the determination of donor chimerism. 
Appendix 1 of this thesis is the abstract from a research publication funded by the 
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European Union and was an international multi-laboratory collaborative study on a 
standardised approach to the determination of stem cell transplant chimerism 
(Eurochimerism - project QLG1-CT-2002-01485; www.eurochimerism.org/ginfo.html). The 
purpose of the study was to provide a  standardised genetic test system for quantitative 
chimerism analysis in patients after allogeneic stem cell transplantation (paper submitted 
to the international  journal Leukaemia for publication; impact factor 9).  
The association of ethnicity with the incidence of GvHD after HLA identical sibling bone 
marrow transplantation is well documented (Baker et al. 2005;Oh et al. 2005). GvHD is 
associated with post transplant complications and non-relapse mortality (NRM). 
International analysis of  ethnicity in stem cell transplantation from unrelated donors forms 
a part of the ongoing 16th International Workshop. The workshop is looking at the 
incidence of acute GVHD, chronic GVHD, transplant-related mortality, relapse and overall 
survival after HLA matched unrelated HCT according to donor/recipient ethnicity. The 
following is a release of preliminary data from the 16th International Histocompatibility 
workshop due to be held in Liverpool, U.K., 2012.  
A total of 5555 10/10 Asian/Pacific Islander, Caucasian, African, Hispanic, Native American or 
mismatched race pairs. Multivariate analysis (Asian pairs used as the reference) uncovered highly 
significantly increased risk of grades III-IV acute GVHD and mortality in each population. Among 
HLA-A, B, C, DRB1, DQB1, DPB1 matched pairs ( 12/12 ), survival among Asian patients was 
superior to any other group. These results suggest that although the transplant pairs are HLA 
matched, undetected haplotype-associated variation may differ depending on the race/ethnicity of 
the transplant pair, and that this variation might explain the difference in clinical outcome. For the 
16th WS, we plan to accumulate more data from other ethnic groups and to analyse based on 
more diverse ethnicities and ethnic specific HLA haplotypes. Analysis of HLA haplotype matching 
of the transplant pairs by race/ethnicity will be explored.             Downloaded 22/11/2010 from : 
http://www.16ihiw.org/pdf/ihwghct_201006_newsletter.pdf  
Although the workshop is focused in HLA haplotype variation and ethnicity this thesis will 
examine the role of  genome wide genetic markers as signals for genetic diversity rather 
than using  race or ethnic origin.   
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In Chapter 5, the role of non-HLA genome wide divergence between donor and recipient 
was investigated. Satellite tandem repeats (STR) known to be highly informative in 
discriminating one individual from another even among siblings were used as a proxy for 
other inheritable genomic differences outside  of chromosome 6p21.3.  The study makes 
the assumption that higher levels of STR diversity between donor and recipient will be 
indicative of increased ancestral divergence and genomic difference between donor and 
recipient. The use of satellite tandem repeats found upon differing chromosomes as 
markers for genetic differences between high-resolution donor/recipient pairs and any 
possible impact this may have upon patient survival. Figure 1.15 shows the frequency of 
THO1 alleles in differing ethnic groups in the North American population.  The study will 
look at 15 highly polymorphic STRs located on differing chromosomes and will be used as 
a proxy for genetic difference outside of the short arm of chromosome six. 
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Figure 1.15   STR THO1 in three North American ethnic groups. As is seen in this 
histogram the frequency of the differing THO1 alleles (Chromosome 11) shows significant  
variation between ethnic groups; however, individual alleles cannot identify a particular ethnic 
background.   
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1.20 Acute Lymphoblastic Leukaemia (ALL) 
The haematological malignancies that affect adults and children have significant 
differences including response to treatment. Childhood cancer is uncommon and 
leukaemia cases make up the majority of malignancies. ALL accounts for the majority 
acute leukaemia in childhood (Katzilakis et al. 2004). In adults ALL is rarer, 0.7-1.8 per 
100,000  compared with 3.8 cases per 100,000 in children. There is a peak incidence in 
children at 3-4 years and in adults half the cases are under age 50 (Bassan et al. 
2004;Hoelzer & Gokbuget 2000).   
In ALL there are several major genetic subtypes where categorisation is based upon the 
cell lineage and mutations found in the leukaemic cells. The frequencies with which these 
genetic mutations are seen in paediatric and adult patients with ALL differ (see Table 1.3). 
ALL has characteristic cytogenetic features which are also used to predict the risk of 
relapse (Mrozek, Heerema, & Bloomfield 2004b). Amongst these are chromosomal 
abnormalities including translocation of genes, leading to expression of fusion proteins, 
e.g. t(9;22)(q34:q11.2) which is the most common abnormality termed Philadelphia 
chromosome positive (Ph+). Genetic abnormalities such as reduced or increased 
chromosome number (ploidy) e.g. high hyerperploidy (>50 chromosomes) are also 
common. The frequencies of these chromosomal abnormalities differ between children 
and adults. Less than 6% of children with ALL have a t(9; 22)(q34: q11.2) whereas this is 
present at a much higher frequency in adults with ALL. The frequency of abnormal 
karyotypes is also higher in adults (Mrozek, Heerema, & Bloomfield 2004a).     
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Table 1.3  Acute Lymphoblastic Leukaemia 
-------------------------------------------------------------------------------------------------------------- 
Leukaemia subtype           Paediatric  Adult 
-------------------------------------------------------------------------------------------------------------- 
T-cell 
-------------------------------------------------------------------------------------------------------------- 
TAL1 lp32          6%   12% 
HOX11L2 5q35        2%   1% 
LYL1 19p13         1.5%   2% 
HOX11 10q24        0.5%   6% 
-------------------------------------------------------------------------------------------------------------- 
B-cell 
-------------------------------------------------------------------------------------------------------------- 
Hyperdiploidy > 50 chromosomes     25%   6% 
Hypodiploidy < 45 chromosomes      1%   1% 
TEL-AML1 t(12;21)        22%   2% 
MLL rearrangements (t[4;11], t[11;19], t[9;11], etc.)  8%   10% 
E2A-PBX1 t(1;19)        5%   3% 
BCR-ABL t(9;22)        3%   30% 
MYC t(8;14), t(2;8), t(8;22)      2%   4% 
Others         24%   23% 
-------------------------------------------------------------------------------------------------------------- 
Adapted from Downing, J.R., and Shannon, K.M., Acute Leukaemia; A paediatric perspective 
2002, Cancer Cell, p438  
Malignancies also vary in terms of cell lineage and the tissues from which they originate. 
They can be detailed in the following broad categories; acute and chronic leukaemia s, 
myeloproliferative and myelodysplastic syndromes, Hodgkin s disease and non-Hodgkin s 
lymphomas (Downing & Shannon 2002). Figure 1.16 illustrates the malignancies 
observed in adults and children. The range of  haematological neoplasms affecting adults 
is wider than seen in paediatrics and the frequency of individual malignancies varies 
strikingly. For example, ALL is the most common cancer seen in children forming over 
50% of all haematopoietic malignancies. However, ALL in adults is seen in only 3% of 
reported cases and presents with a different frequency of observed genetic mutations 
(see Table 1.3.).  
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Figure 1.16 Frequency of the major subtypes seen in paediatric and adult 
haematopoietic malignancies. These include chronic myelogenous leukaemia (CML), 
chronic lymphoblastic leukaemia (CLL), Hodgkins disease, non-Hodgkins lymphoma (NHL), 
multiple myeloma (MM), acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), 
myelodysplastic syndrome (MDS) and myelo-prolipherative disease (MPD). (Downing, J.R., and 
Shannon, K.M., Acute Leukaemia; A paediatric perspective, 2002, Cancer Cell, p438)  
The majority of paediatric cases of ALL are cured with chemotherapy (>80%) however a 
significant number of children still die from relapsed or refractory ALL. In high-risk ALL 
cases the only curative therapy available is stem cell transplantation.  In stem cell 
transplantation for paediatric ALL  as with other malignancies the earlier in the disease 
progress the transplant takes place the better the outcome. The dilemma is choosing 
which child will benefit from chemotherapy alone and which ones are high risk and should 
be put forward for immediate transplantation. Comparative therapy studies reveal  that 
children transplanted in first remission (CR1) have a higher non-relapse mortality 
(although relapse rate is reduced), than patients treated only with chemotherapy 
(Balduzzi et al. 2005). Thus it is only the high-risk group of patients that would benefit 
from early transplantation. There is no complete agreement in defining which patient 
should be identified as high risk and thus likely to benefit from transplantation in CR1. In 
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the USA only children with Philadelphia chromosome positive (Ph+) ALL, low 
hypodiploidy and primary induction failure are considered for transplantation in first 
remission (Schultz et al. 2007). In Chapter four the influence of HLA typing methods and 
donor matching in paediatric stem cell transplantation will be examined in detail as an 
observational study spanning twenty years of HLA typing and transplantation. The study 
will be for a single disease at a single transplant centre.  
1.21  Hypothesis, Aims and Objectives 
The principal aim of this thesis is to determine what is current best practice for 
Histocompatibility and Immunogenetics laboratories supporting haematopoietic stem cell 
transplantation (HSCT) and demonstrate the added benefits of their application to a busy 
transplant program such as the Bristol Royal Hospital for Children HSCT unit.  
This aim is supplemented with a series of further aims: 
1. Determine current H & I practice for HSCT donor selection as applied throughout 
the United Kingdom.  
2. Determine guidelines of best laboratory and clinical practice for H & I laboratories 
in support of HSCT donor selection. The guidelines are to be  based upon a 
detailed review of the current literature on clinical practice and opinions from 
recognised experts in this field.  
3. Determine whether the application of best practice within H & I department. 
NHSBT, Filton has improved  patient transplant outcomes.  
4. Determine degrees of  genomic DNA diversity outside of the HLA gene cluster in 
high resolution HLA matched donor/recipient pairs.   
Research objectives were identified to meet the aims set for the thesis. The objectives are 
as follows: 
1. Investigate the current support offered by H & I laboratories to stem cell transplant 
programs throughout the United Kingdom.  
2. Review the current literature on HLA typing for donor selection in SCT.  
3. Investigate best practice in HLA matching for SCT.  
4. Perform an analysis of patient outcomes following SCT before and after the 
application H &I  laboratory best practice. 
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5. Use the knowledge gained from objectives 1-4 to create a set of guidelines for H & 
I laboratory best practice in support of SCT.  
6. Investigate the range of genomic wide STR differences observed between high 
resolution HLA matched transplant pairs, for both related and unrelated SCT.  
7. Investigate if genome wide STR mismatches (as a proxy for genetic divergence in 
families and populations) have an observable influence on patient survival  in high 
resolution HLA matched transplants.  
All  H&I  laboratories supporting haematopoietic stem cell transplantation in Europe must 
be accredited with the European Federation for Immunogenetics (EFI) or the American 
Society for Histocompatibility and Immunogenetics (ASHI). This is needed  to meet the 
stem cell transplant Joint Accreditation Committee for the International Society for Cellular 
Therapy and European Group for Blood and Marrow Transplantation (JACIE) 
requirements. JACIE was established in 1998 to assess and accredit transplant centres in 
the field of HSCT. The main purpose of these accreditation bodies is to promote high 
quality patient care in transplantation through an internationally recognised system of 
accreditation.  However the standards set for accreditation provide minimum measures to 
be met and need reviewing as medical and scientific progress is made. Aims numbered 
two to six are designed to provide steps towards meeting the principal aim.   
Aim number two determines a base line of current practice throughout the United 
Kingdom and provides a view of how the contents of this thesis may influence improved 
professional standards of patient care within the United Kingdom. In Chapter two, a cross 
sectional study of current laboratory practice in matching haematopoietic stem cell 
donor/recipient pairs within the United Kingdom is analysed to fulfil aim number two  and 
objective number one.   
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 While laboratory protocols may meet the need for laboratory accreditation standards they 
do not necessarily meet best medical practice. In Chapter three, guidelines for donor 
selection in paediatric and adult HSCT are outlined based upon a review of current and 
historic literature. The guidelines also incorporate the views of recognised expert opinion 
in the field of HSCT. This Chapter should meet aim number three and contribute to 
objectives two, three and five.  
The 2008 European Bone Marrow Transplant Handbook states  "There are no reported 
studies that compare outcome of HLA identical sibling donors with unrelated donors 
matched to the allelic level" for paediatric ALL (Klingebiel & Bader 2008).  Chapter four of 
this thesis is the first detailed prospective study of the impact of high resolution HLA 
typing (allelic) in the largest  stem cell transplant program for paediatric ALL in the United 
Kingdom. The study analyses the HSCT outcome for patients receiving  HLA matched 
sibling donors and matched and mismatched unrelated donors in stem cell 
transplantation. The study examines transplant outcome data over a twenty year time 
period and contrasts HSCT patient survival outcome before and after the introduction of 
differing HLA typing methods including high resolution HLA typing. The analysis also tests 
for possible confounding influences on patient disease free survival. This analysis will 
meet aim four of the project and contributes to meeting to objectives three to five.  
In Chapter five, paediatric ALL patients transplanted with HLA matched sibling and high 
resolution HLA matched unrelated donors are analysed to determine the degree of 
genome wide diversity for STR allele genomic identification profiling is observed. A 
statistical method for detailing the degree of STR mismatch between donor and recipient 
is developed and transplant outcome in terms of patient survival is analysed for any 
possible influence observed. Chapter five will meet aim four and objectives six and seven 
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of the thesis. Chapter six  will be a reflective review of my progress through doctoral 
studies highlighting the personal and professional progress this has fashioned. 
*** 
Chapter two shows that donor selection for HSCT in the United Kingdom is poorly 
standardised and that there is considerable opportunity to influence improvements in 
clinical practice and stem cell donor selection.      
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Chapter Two 
2 Cross-sectional study of stem cell transplant matching strategies in the United 
Kingdom and the Republic of Ireland.  
2.1  Histocompatibility Laboratories in the United Kingdom and Ireland.  
There are twenty five Histocompatibility and Immunogenetic (H&I) laboratories in the UK 
and Ireland (http://www.bshi.org.uk/members/h_i_contacts.html.) providing H&I services 
to the transplant community. These laboratories provide H&I services for both solid organ 
and stem cell donor transplants although not all laboratories do both. Those performing 
stem cell transplant work are involved in the HLA typing of the patient, the search for an 
HLA matched donor, selection of potential matches, matching and final donor transplant 
work-up, for thirty nine allogeneic stem cell transplant units throughout the United 
Kingdom and Republic of Ireland  
(http://www.bsbmt.org/pages/42-Transplant_Centre_List).   
A descriptive cross-sectional study was performed examining current practice in the 
search and identification of HLA matched donors for allogeneic stem cell transplantation 
(SCT). This study was undertaken to establish if high resolution typing was prevalent 
practice in matching SCT patients and donors in the United Kingdom and Ireland. The 
cross-sectional study provides a snapshot of the characteristics describing the 
contemporaneous selection of allogeneic SCT donors. A questionnaire was designed to 
provide a baseline description of the decision making processes for the identification of 
SCT donors. The donors were from family members, volunteer unrelated bone marrow 
registry donors or umbilical cord blood donors. The use of HLA match criteria for SCT in 
the United Kingdom and Republic of Ireland was extensively investigated for the year 
2009.  
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2.2 Sampling  
The decision was taken early in the study to direct the questionnaire at H&I laboratory 
directors, rather than the transplant units. The rational for this can be summarised with 
the following points: 
1) No allogeneic stem cell transplant is performed without HLA typing. 
2) The probability of obtaining a reply from the H&I laboratories was judged 
to be higher than from the transplant units. 
3) The questions asked were designed to extract descriptive data relating to 
the interaction of the H&I laboratory and the transplant units for which they 
provided an HLA typing and advisory service. 
4) The directors of the H&I laboratory would be aware of the HLA selection 
criteria used in each SCT unit they serviced. 
5) The researcher has professional interaction with the directors of all H&I 
laboratories and would be able make one to one contact with the director 
of any laboratory for which there was missing or questionable data.  
2.3 Method - Questionnaire design  
Steps common to all transplant centres in the decision making process relating to donor 
selection using HLA match criteria were identified. Questions were designed to probe 
these activities and examine differences between transplant centres. The following 
operations were investigated; patient HLA typing, donor selection within families, 
unrelated stem cell donor registry searches, preliminary donor selection, confirmatory 
HLA typing and final donor work-up for transplantation. All questions were designed to be 
categorical or closed-ended thus permitting quantitative statistical analysis of the results. 
Because of the technical and complex nature of the data being sought,  a mail bases 
option for data collection was chosen. A questionnaire accompanied with a cover letter 
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explaining the purpose of the survey was circulated to all H&I laboratories in the United 
Kingdom and Republic of Ireland.  
Where a laboratory provides H&I services for more than one transplant unit it was 
requested to fill out a separate questionnaire for each transplant unit served. Questions 
were designed to define the selection practice used at each step process leading to final 
donor selection and transplantation. This permitted comparisons to be made between 
laboratories and by default the activity of the 39 transplant units they served.  
Question one solicited a response to establish whether the laboratory supported stem cell 
transplantation. If the laboratory was not involved in SCT then they had no need to 
answer any further questions. Where a laboratory supported SCT the question 
ascertained if the laboratory was involved in the work-up to paediatric or adult transplants 
or both paediatric and adult transplants.   
When a patient is referred to a transplant unit for assessment and the decision is made 
that the patient is suitable for stem cell transplant therapy, an early step in this process is 
to investigate within the patients family whether there is a suitable and willing HLA 
matched family donor. The patient, siblings and parents (where available) are HLA -A, -B, 
-C and -DRB1 typed to medium resolution as a minimum requirement. Where 
consanguinity exists within a family, additional relatives may also be typed as prospective 
donors.   
Questions two, three and four were designed to probe the process of identifying HLA 
identical related donors (mostly siblings). The questions examine criteria relating to H&I 
laboratory investigations in a family member transplant donor work-up. This included 
finding out if the laboratory determined that the donor and recipient shared parental HLA 
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haplotypes. Also, whether high resolution HLA typing was performed to confirm allelic 
identity between donor and recipient if parental haplotypes were not established.   
Where the patient does not have an HLA matched family donor the H&I laboratory is 
involved in a stepwise process to identify the best HLA matched unrelated donor 
available. The first step in this process is to search the bone marrow donor and cord 
blood registries to see whether possible HLA matched donors are available. Worldwide 
there are more than 16 x106 registered bone marrow donors and 450,000 umbilical cord 
units banked (Petersdorf 2010).  
In searching for a suitable unrelated HLA matched stem cell donor (URD), questions five, 
six, seven, eight and nine explore the following points: 
Are all patients high resolution HLA typed prior to performing an unrelated donor search? 
Who selects the potentially matched donors to be selected for confirmatory HLA typing? 
In the first phase of the donor search how many donors are commonly called in for 
confirmatory HLA typing? 
What resolution level of HLA typing is performed upon receipt of a sample for 
confirmatory HLA typing? 
Who selects the final unrelated donor for stem cell transplant? 
Question ten establishes the frequency with which a specialist from the H&I laboratory 
and the transplant unit team meet to discuss donor selection. Question eleven probes the 
resolution of  HLA typing performed at HLA class I and class II for matching final donor 
and recipient prior to transplant. The question ascertains which HLA loci are typed to 
low/medium or high resolution prior to transplantation. Question twelve determines in 
which year high resolution typing was introduced to the laboratory for donor recipient 
matching at each HLA loci.  
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Question thirteen asked  the H&I director to specify the HLA matching requirements of the 
transplant units they provide services to, specifying at each HLA loci the level of 
resolution required. Question fourteen is in three sections (a, b and c) and probes the 
strategies most commonly deployed to find an alternative stem cell donor by the 
transplant units where a fully HLA matched donor (family or unrelated) is not found, or is 
unlikely to be found in a suitable time frame. The question outlines strategies for selection 
of an HLA mismatched donor, a haplotypic donor or cord blood donor(s). The final 
question (fifteen) establishes the number of unrelated stem cell transplants which were 
worked up and transplanted in the year 2008 for each transplant unit.  
2.4 Data response verification  
Within the questionnaire certain queries were designed to act as partial verifiers for the 
answers to earlier questions. Question five asks if a high resolution type on the patient is 
performed prior to initiating a donor search and question eleven asks if high resolution 
typing is performed on all final matching. Question twelve  was designed to find out when 
high resolution typing was introduced to the laboratory for HLA class I and class II. The 
response to questions five and eleven have to be consistent with the reply to question 
twelve.   
In question nine the H&I director is asked if the laboratory selected the final donor or 
advised upon the selection of the final donor for transplantation. In question ten the 
frequency of H&I laboratory and transplant unit meetings to discuss donor selection was 
determined. If the frequency of meetings was less than fortnightly it would be unlikely that 
the director had a close advisory role with the transplant unit. Finally, by adding together 
the collective answers to question fifteen the results can be compared with published 
levels of activity for stem cell transplants in the U.K. and Republic of Ireland (Gratwohl et 
al. 2009).  
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2.5  Questionnaire Pilot  
The questionnaire was piloted at the H&I laboratories of the NHS Blood and Transplant 
Service, Filton, Bristol. The director of the laboratory and the section leader responsible 
for direct liaison with  the SCT Unit at the Bristol Hospital for Children reviewed the 
questionnaire looking for clarity of expression and questions that might introduce bias 
from the respondent. The questionnaire was adjusted to remove some ambiguity of 
meaning and distributed in March 2009 to all twenty five H&I laboratories in the UK and 
Ireland.   
2.6  Questionnaire returns  
Survey questionnaires were returned to the researcher from April to August 2009. The 
directors of three laboratories were contacted to encourage the return of the 
questionnaire during this period. One laboratory director was contacted to clarify an issue 
with regard to their selection HLA matching criteria. In order to assess how representative 
a sample the returns were, respondents were asked to state the number of transplants 
worked up by the laboratories going to transplantation in 2008. Replies were received 
from all laboratories surveyed and representing a total of 1164 allogeneic stem cell 
transplants performed in the UK and Ireland in 2008. These figures compare favourably 
with the published U.K. and Irish activity for 2007 of 1067 allogeneic stem cell transplants 
and reflect expected growth in stem cell transplant activity. This provides confidence that 
the returned questionnaires reflect current practice for allogeneic transplantation in the 
U.K. and Republic of Ireland in 2009.     
2.7 Cross-Sectional Study analysis  
The study and its analysis are for descriptive purposes only. The entire population of 
interest was surveyed and a 100% response rate was acquired. The data obtained is 
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more than inferential and provides an accurate picture of current practice in SCT donor 
selection.  As such, inferential statistical modelling has been judged as unnecessary and 
the statistics are presented as tallied frequencies among the respondent laboratories.  
2.8 Cross-Sectional Study Results  
Questionnaires were returned from all twenty five laboratories listed as providing H&I 
services on the British Society for Histocompatibility and Immunogenetics web site 
(http://www.bshi.org.uk/members/h_i_contacts.html.). Seven of the laboratories do not 
provide H&I services to stem cell transplant programmes. Four laboratories provide 
support for adult SCT only. Thirteen laboratories supply support for both adult and 
paediatric STC and one laboratory supports only adult sibling SCT (Table 2.1). Only 
laboratories providing support for SCT continued beyond question one of the survey.  
Table 2.1  H&I laboratory SCT service provision 
Laboratory provision of stem cell transplant H&I services in the UK and Ireland 
Do not provide stem 
cell transplants 
support 
Adult stem cell 
transplant support only
Both adult and paediatric 
stem cell transplant 
support  
Adult sibling stem 
cell transplant 
program only 
7 4 13 1 
Seven of the twenty five laboratories surveyed reported no involvement in stem cell transplantation. One 
laboratory provided services for adult sibling transplants only, four laboratories provided services for adult 
transplants only and thirteen provided services for adult and paediatric transplants.  
The gold standard donor SCT therapy of acute blood borne malignancies is an HLA 
matched sibling donor (Fielding & Goldstone 2008). Other HLA matched family members 
can be used if there is consanguinity in the family or an HLA matched parent may be 
used where the parents share an HLA haplotype. Table 2.2 details the HLA typing 
strategies followed at differing laboratories. Nine laboratories always try to establish 
parental haplotypes in families when identifying an HLA identical family donor. The same 
nine laboratories will high resolution type the matched donor and recipient where parental 
haplotypes are not established. None of the remaining nine laboratories routinely 
establish parental haplotypes and seven of them high resolution type the HLA matched 
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pair at HLA class II only. Two laboratories do not establish parental haplotypes and do not 
perform any high resolution HLA typing.  
Table 2.2  HLA typing for related donor transplant 
Laboratory practice for HLA typing of patient and related donors in the UK 
and Ireland 
Establish parental 
haplotypes for sibling 
transplant when 
possible 
Allelic HLA type 
recipient and related 
donor where parental 
haplotypes cannot be 
established 
Allelic type at HLA class 
II and low to medium 
resolution type at class I 
and do not establish 
parental haplotypes 
Provide only low to 
medium resolution HLA 
typing for sibling 
transplants and do not 
establish parental 
haplotypes 
9 9 7 2 
Nine laboratories routinely established parental haplotypes in siblings prior to transplant. Where 
establishment of haplotypes was not possible, nine laboratories typed the siblings to the allelic 
level to confirm compatibility. A further seven laboratories high resolution typed  for class II  but not 
class I. Two laboratories provided only low to medium resolution typing at both class I and class II 
for sibling transplants.   
HLA matched family donors are only available for approximately 30% of patients to be 
transplanted in the United Kingdom. Where no related donor is suitable, a computerised 
search through the HLA types of the >16 x 106 adult volunteer donors available on stem 
cell donor registries worldwide and the 450,00 donations available on cord blood 
registries must be made to find suitable unrelated donors.  Table 2.3 details the level of 
HLA typing used by the laboratories to perform this search. Five laboratories perform the 
search using a high resolution HLA class I and class II type while seven laboratories use 
a high resolution class II type but a low resolution class  I type.  Five laboratories use low 
resolution typing at this juncture of the process.  
       Table 2.3  HLA typing for unrelated donor searches 
Patient HLA typing prior to donor search 
Laboratories high resolution typing 
patient at HLA class I and II  prior to 
running an unrelated donor search 
Laboratories high resolution  typing 
at HLA class II but low to medium  
resolution type at class I prior to an 
unrelated donor search 
Laboratories low  resolution 
typing patient  at HLA class  
I and II prior to running an 
unrelated donor search 
5 7 5 
Five laboratories allelic type their patient at HLA class I and II prior to performing a donor search;  
seven allelic type at class II but medium to low resolution type at class I and five perform only low 
resolution typing prior to performing a donor search. 
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When the computerised searches are completed a selection is made from the best 
matched donors listed and a request for donor blood samples is made to the relevant 
stem cell donor registry. These samples are used to confirm the HLA type listed by the 
registry and perform additional typing in line with the local policies of the stem cell 
transplant unit. Table 2.4 identifies who makes the important choice selecting the most 
appropriate donors for additional blood samples and further HLA typing. 
Table 2.4   Who selects the matched donors requested for confirmatory HLA   
Typing? 
Who selects donors for confirmatory HLA typing? 
HLA laboratory selects the 
matched donors for CT sample 
Transplant consultant  selects the 
matched donors for CT sample 
Registry selects the matched 
donors for CT sample 
11 4 2 
In eleven instances the H&I laboratory was responsible for selecting donors for confirmatory HLA typing. In 
four centres it was the transplant consultant or the local transplant team that chose the donors for 
confirmatory typing. In two instances it was the registry that selected the donors.    
Table 2.5 lists the number of CT samples routinely requested per patient for further 
confirmatory HLA typing. This figure may vary from patient to patient dependant upon the 
likelihood of finding a match. The data submitted details the number of donors most 
commonly requested at each laboratory. 
Table 2.5  Number of CT samples requested per patient 
How many samples are routinely requested for CT samples per patient? 
Four donors or less Five or six donors Seven or eight donors 
10 4 3 
In ten laboratories four or less CT samples were routinely requested per patient and in four laboratories five or six samples were 
requested, three laboratories requested between six and seven samples.  
Table 2.6 details the number of H&I laboratories that are actively involved in the final 
selection of donors in collaboration with the transplant unit team.    
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Table 2.6  Who chooses the final donor for transplantation? 
Who makes the final donor choice? 
Transplant consultant with advice from H&I 
laboratory specialist jointly chose the final donor 
Transplant consultant without input from the H&I 
laboratory chose the final donor 
15 2 
Fifteen H&I laboratories were involved in the selection of the final donor and In two laboratories the 
transplant consultant chose the final donor without advice from the H&I laboratory.               
                                                                 
Table 2.7 shows that ten laboratories supply high resolution typing and matching services 
to the transplant units they serve and seven laboratories provide medium resolution class 
I typing and high resolution class II typing and matching (HLA DRB1). Fifteen laboratories 
additionally used DQB1 high resolution matching in their selection  and six use DPB1 . 
Table 2.7  HLA match criteria used. 
Level of resolution used to select final donor for each HLA locus 
Number of laboratories requiring high resolution 
match at HLA-A, B, C and DRB1  
Number of laboratories requiring medium resolution 
match at HLA-A, B,C and high resolution match at 
HLA-DRB1  
10 7 
Ten H&I  laboratories reported requiring to match at high resolution for HLA-A, B,C & DRB1. Seven 
laboratories required low resolution matching at HLA-A, B and C with high resolution matching at DRB1. 
The use of HLA DQB1 and DPB1 for matching was inconsistent between laboratories in both high 
resolution and low resolution match groups.  
In Table 2.8  the year that high resolution typing for HLA class I and II was introduced is 
identified and the number of laboratories providing this service from that year is tabulated.  
Table 2.8  Year for which HLA high resolution typing for both class I and      class II  
alleles was introduced.  
Number of laboratories introducing HR typing and  year of introduction 
1 in 1999 3 in 2001 3 in 2002 1 in 2003 
2 in 2004 2 in 2005 2 in 2006 1 in 2009 
2 laboratories have not yet introduced high resolution class I typing  
No laboratory introduced change in typing resolution in years  2000, 2007 or 2008.  
Table 2.9 details the high degree of variability seen in choosing an HLA mismatched 
PBSC or BM donor in the absence of an HLA matched unrelated donor.  Although not 
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tabulated the selection of cord blood donations showed an equally diverse and variable 
approach to cord selection. This level of variability highlights the need for donor selection 
guidelines in stem cell transplantation within the United Kingdom.   
Table 2.9  HLA mismatch criteria used where a matched donor is not an option 
13 Algorithms submitted from 17 laboratories for the selection of an HLA 
mismatch  donor when no HLA matched donor is available 
(A)>(B)>(DQB1) (A)>(C)>(DQB1) (C)>(A)>(B) (C)>(A)>(DRB1) 
(C)>(DQB1)>(DRB1) (DPB1)>(DQB1)>(DRB1) (DQB1)>(A)>(B) (DQB1)>(A) 
(DQB1)>(C)>(A) (DPB1)>(DRB3,4,5)>(C) (DQB1)>(A)>(DRB3,4,5) (DPB1,DRB3,4,5)>(DQB1)>(C)
(C,DRB3,4,5,DQB1,DPB1)>(A)>(B,DRB1) 
Seventeen H&I  laboratories returned thirteen differing algorithms(2009). They are listed as (first 
preference) > (second preference) >  (third preference). All loci within brackets are given equal weighting 
and (>) equates to being preferred before the preceding loci.  
2.9 Significance of cross-sectional study findings  
This study provides key indicators of what clinical and professional practice improvements 
are still to be realised in the United Kingdom regarding HLA matching of patients and 
donors for stem cell transplantation.  The lack of uniformity in practice is of concern as it 
is clear that a significant number of allogeneic HLA matched transplants are being 
performed sub-optimally with regards to HLA matching.   
In a National Bone Marrow Donor Panel (NMDP, USA) funded study, a total of 1784 cell 
donor/recipient pairs initially matched at low resolution for HLA - A, B, C and DRB1 at the 
time of SCT were retrospectively high resolution typed (Flomenberg et al. 2004).  They 
found that in 34% of cases allelic mismatches were present that were only detectable by 
high resolution typing and in a significant number of cases multiple allelic mismatches 
were present.  The study concluded that these mismatches were associated with post-
transplant adverse effects on patient survival and graft versus host disease.  
 66
Improvements in transplant outcomes in the UK require an alteration in HLA typing and 
matching strategies such that all final donor pair matching uses high resolution typing and 
allelic matching of donor and recipient.   
The outcomes of this analysis provide a key indicator of the extent clinical and 
professional practice improvements, may yet enhance patient care following allogeneic 
stem cell transplantation. The results of this analysis were presented at the British Society 
for Histocompatibility and Immunogenetics and the American Society for 
Histocompatibility and Immunogenetics annual conferences in September and November 
2009 respectively (Appendix 2 is a poster presentation of this work).  
********** 
In Chapter three the impact on transplant outcomes of prospectively introducing high 
resolution HLA matching to a transplant program is demonstrated.              
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Chapter Three  
3 Bone Marrow Transplant outcomes in paediatric acute lymphoblastic leukaemia 
over five distinct HLA typing epochs: significantly improved leukaemia free 
survival in the era of high resolution typing.  
3.1 Introduction  
Recently published retrospective studies indicate that matching at the high resolution 
level for HLA alleles between donors and recipients in unrelated haematopoietic stem cell 
transplants is associated with improved patient survival (Crocchiolo et al. 
2009a;Flomenberg et al. 2004;Lee et al. 2007;Macmillan et al. 2008;Petersdorf 
2004;Petersdorf et al. 2007b). These multi-centre studies looked at stem cell transplants 
for which donors were initially selected using low/medium resolution HLA typing. The 
donor/recipient pairs were then retyped retrospectively to the high resolution level for HLA 
and transplant outcomes were analysed. The overall impact of prospective high resolution 
matching for HLA upon an active paediatric transplant program has not been reported.   
The Bristol Royal Hospital for Children started selecting stem cell donors for 
transplantation on the basis of HLA high resolution matching with recipients in January 
2002. This is the first detailed study analysing leukaemia free survival (LFS) in paediatric 
ALL where HLA high resolution matching of donor and recipient was performed prior to 
transplant. A total of 356 paediatric ALL stem cell transplants, performed between 1988 
and 2007, were reviewed. Comparisons were made of transplant outcomes before and 
after the introduction of HLA high resolution matching. Changes in treatment and epoch 
dependent improvements in outcome were reviewed for possible confounders to the 
influence of high resolution typing. 
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3.2 Methods   
3.2.1 Patients  
Data was assessed on 356 consecutive ALL patients under the age of 18 years who 
received a stem cell transplant between 1988 and 2007. Pre- and post- transplant data 
was extracted from the University Hospitals Bristol NHS Foundation Trust patient 
records. The patient/donor HLA genotype and matching data was extracted from the 
Bristol NHS Blood and Transplant histocompatibility laboratory database. This research 
was approved to meet NHS Blood and Transplant research group governance 
requirements.   
3.2.2 HLA typing   
HLA genotyping of patient/donor pairs for HLA-A,-B,-DRB1 and -DQB1 loci were 
introduced at the onset of the transplant program in 1988. HLA-C typing was added in 
1994 and HLA-DRB3, 4 and 5 typing in 1998. A review of HLA typing over the duration of 
the transplant program reveals five distinct periods where typing methods changed. 
These were: 1) serology for HLA class I typing with restriction fragment length 
polymorphism for HLA class II, 2) introduction of polymerase chain reaction sequence 
specific typing (SSP) for HLA class II typing, 3) introduction of HLA class I SSP low 
resolution typing, 4) introduction of high resolution HLA class II typing by SSP, 5) 
introduction of high resolution HLA class I and class II typing by sequence based typing 
and SSP (Figure 3.1). In this study, all donors were selected on the basis of best 
available HLA match at the time of transplant. No retrospective HLA typing has been 
performed for analysis purposes.   
High resolution typing of matched sibling donor (MSD) transplants was performed where 
parental haplotypes could not be established in the family (2003 onwards). Matched and 
mismatched unrelated donor (MUD and MMUD) patient/donor pairs at HLA-A,-B,-C,-
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DRB1,-DRB3,-DRB4,-DRB5 and -DQB1 were high resolution typed for final donor 
selection from January 2002 onwards (high resolution matched unrelated donor, [HR-
MUD]).   
In a large muti-centre, multi-disease study of 1874 unrelated donor transplant pairs; 58% 
of the transplant pairs were matched at low resolution for HLA-A,B,C and DR loci at the 
time of transplant (Flomenberg et al., 2004). Following retrospective high resolution typing 
of the transplant pairs, 34% of the pairs matched at low resolution had one or more 
mismatches at high resolution. Similarly in a Cord Blood Transplantation Study (COBLT) 
where patients and cord blood donations were typed at high resolution for HLA-DRB1 but 
were low resolution typed for HLA-A,-B at the time of transplant; retrospective high 
resolution typing of the HLA-A and -B loci resulted in demoting 32% of the match grades 
for the transplant pairs (Kurtzberg et al. 2008). This study has not performed retrospective 
typing of the low resolution typed MUD transplant pairs (pre-2002 transplants) due to the 
high cost. It is assumed that like the Flomenberg study of 1874 transplant pairs, there will 
be a high percentage undetected mismatches (>30%) if HLA typed at high resolution for 
HLA-A,-B,-C,-DRB1 and -DQB1 in the MUD transplants performed prior to 2002.           
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Figure 3.1 Evolution of HLA typing methods over the twenty years of a paediatric 
ALL transplant program. n=number of transplant pairs for each epoch  LR=low 
resolution; HR=high resolution; RFLP=restriction fragment length polymorphism; 
SSP=sequence specific primer; SBT=sequence based typing.  
3.2.3 Conditioning regime   
All children were conditioned with cyclophosphamide (60 mg/kg days -6, -5) and total 
body irradiation (1440 cGy in eight fractions on days -3 to 0 at 20cGy/min). This was 
adjusted for children under 4 years of age as previously described (Oakhill et al. 1996). 
From 1988-1999 unrelated donors in addition received Campath® monoclonal antibody 
(5-20mg/d depending upon body weight) on days -9 to -5. In January 2000 the rat derived 
Campath®-1G antibody was replaced with a humanised version Campath® -1H 
(alemtuzumab, Genzyme Corporation, Cambridge, MA) (0.9-1.0mg/kg in 3-4 doses).   
3.3 Data Analysis  
Data was grouped into five time periods (1988-1992, 1993-1995, 1996-1999, 2000-2001, 
and 2002-2007) on the basis of HLA typing methods used for patient/donor matching. 
Probability for LFS was calculated using the Kaplan-Meier estimator where death from 
any cause plus leukaemic relapse was considered to be an event. Patients were 
censored if they underwent a second transplant or were alive at last follow-up. Mean 
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values and 95% confidence intervals (C.I.) were reported for continuous variables and 
percentages for categorical variables. Inter-epoch variability around the mean for 
continuous values and possible trends in categorical data were analysed independently 
(Table 3.1). Multivariate analysis to test covariate influence on 2 year LFS using logistic 
regression and the Cox proportional hazards model  (Bradburn et al. 2003a;Bradburn et 
al. 2003b) were performed using SPSS software (version 17). The following covariates 
were tested for possible confounding influence; disease status, patient/donor 
cytomegalovirus serology combinations, patient age, patient/donor relationship and HLA 
match grade, stem cell source, days to engraftment, patient/donor sex combinations, graft 
versus host disease and changes to pre-transplant conditioning protocol (Table 3.2).   
The disease status of the patients was categorised as follows for the purposes of 
statistical analysis: first complete clinical remission (CR1); second complete clinical 
remission (CR2); third and fourth complete clinical remission CR3.  
Patients were considered as evaluable for engraftment if they survived 28 days post-
transplant. Neutrophil engraftment was defined as absolute neutrophil count (ANC) >0.5 x 
109/L on 3 consecutive measurements. Primary graft failure was defined as failing to 
reach this value within the specified time.        
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Table 3.1 Patient and donor transplant characteristics. 
                                                                HLA typing epochs  
Variable 1988-07   1988-92  1993-95   1996-99  2000-01   2002-07   
No. patients transplanted    356
 (100%) 72 (20%) 72 (20%) 80 (23%) 52 (14%) 80 (23%) 
Patient age at time of transplant 
Mean(95% C.I.)                                                    9(5-13) 7.6(4-11) 9.2(5-13) 8.9(5-13) 10.4(6-14)   9.5(5-13)  
    p=0.04* 
Disease Status 
CR 1   67   (19%) 14 (19%) 16 (22%) 11 (14%) 10 (19%) 16 (20%)  P=0.4** 
CR2   228 (64%) 48 (67%) 38 (53%) 53 (66%) 36(69%) 53 (66%)   
CR3   61   (17%) 10 (14%) 18 (25%) 16 (20%) 6  (12%) 11 (14%)  
Patient/donor CMV serology match 
Negative/negative  (-/-) 190 (53%) 43 (60%) 41 (57%) 37 (46%) 25 (48%) 44 (56%)   p< 0.001** 
Negative/positive   (-/+) 60   (16%) 8   (11%) 16 (22%) 26 (32%) 4   (7%) 6   (7%)    
positive/negative   (+/-) 52   (14%) 12 (17%)  5    (7%) 10 (13%) 13 (25%) 12 (15%) 
positive/positive    (+/+) 
(missing CMV data) 
32     (9%) 
(22  [8%])    
5   (7%) 
(4 [5%])    
10  (14%) 
(0) 
2   (3%) 
(5  [6%] ) 
6   (12%) 
(4   [8%] ) 
9   (11%)  
(9 [11%] ) 
Stem Cell Source 
Bone marrow 332 (93%) 72 (100%) 
72 
(100%) 80 (100%) 45 (86%) 
63 (79%)  
 p< 0.001** 
Cord blood 7    (2%) 0 0 0 1 (2%) 6   (7%)    
PBSC 17  (5%) 0 0 0 6 (12%) 11 (14%) 
Patient/donor sex match 
Female/female 56   (16%) 12 (16%) 10 (15%) 7   (8%) 9   (18%) 18 (23%)   p= 0.09** 
Female/male 73   (20%) 14 (19%) 11 (18%) 15 (29%) 15 (28%) 18 (23%)  
Male/female 100   (28%) 24 (34%) 28 (35%) 28 (35%) 7   (14%) 13 (15%) 
Male/male 127 (36%) 22 (31%) 23 (32%) 30 (38%) 21 (40%) 31 (39%)  
HLA match grade 
MSD 80   (22%) 26 (36%) 6   (8%) 12 (15%) 10 (19%) 26 (33%)   p< 0.001** 
HR-MUD 33   (9%) 0 0 0 0 33 (41%) 
MUD 134 (38%) 28 (39%) 41 (57%) 41 (52%) 24 (47%) 0 
MMUD 91   (26%) 16 (22%) 25 (35%) 25 (31%) 9   (17%) 16 (20%) 
HAPLO 18   (5%) 2   (3%) 0 2   (2%) 9   (17%) 5   (6%) 
Days to engraftment 
Mean 
(95% C.I.) 
17.25 
(16.5-
17.9) 
18.7 
(16.9-
20.5) 
14.6 
(13.5-
15.7) 
17.1 
(15.8-
18.4) 
17.3 
(14.4-18.2) 
19.5           
(17.8-20.1) 
 p< 0.001* 
Time in days from diagnosis to 
transplant 
Mean (95% C.I.)                                  
1052  
(1012-
1205)   
 985 
 (815-
1177) 
999 
   (821-
1205) 
 1109 
      (967-
1341) 
    1166 
     (989-
1715) 
1031    
   (888-1306)  
   p=0.75*
Graft versus Host Disease 
aGvHD (grade II  IV) 53 (15%) 12 (17%) 9 (12%) 15 (18%) 10 (19%) 7(9%)    p= 0.4** 
cGvHD (grade II  IV)           11  (3%) 5 (7%)   2 (3%) 4    (5%)   0     0     p= 0.001** 
Relapse 103  (29%) 26  (36%)    20(28%) 32   (40%)   12 (23%) 
    13 (16%) 
p= 0.001** 
 *analysis using one way ANOVA to compare variance around the mean, between groups  **analysis 
using chi square test for trends 
 Patient characteristics and trends in each HLA typing epoch. 
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Table 3.2 Association between covariates and 2 year LFS.
Variable  No. Hazard ratio 95% C.I. p  
No. patients with 2 year 
follow-up 
   356 
Disease Status 
CR 3   67 1 - - 
CR2    228 0.71 0.46  0.98 0.09  
CR1   61 0.77 0.46  1.19 0.24 
 
Patient/donor CMV  
Serology match 
Positive/positive    (+/+) 32 1 
Positive/negative   (+/-)  52 0.92 0.39  2.17 0.85  
Negative/positive   (-/+) 60 0.54   0.22  1.31         0.17 
Negative/negative  (-/-) 
Missing CMV data  
190 
22 
0.73 
0.44 
  0.35  1.51 
  0.15  1.31 
        0.39 
0.44  
Stem Cell Source 
PBSC 17 1 
Bone marrow 332 0.6 0.24  1.64 0.35 
Cord blood 7 0.7 0.15  4.24 0.45 
Patient/donor sex match 
Male/male 127 1.4 0.85  2.34 0.17 
Male/female 100 1.3 0.79  2.27 0.27 
Female/male 56 1.1 0.67  2.08 0.56 
Female/female 73 1 - - 
Patient-donor relationship plus HLA match grade 
MMUD(+CB)* 91 (+7) * 1 - - 
MSD  80 0.4 0.16  0.59 0.006  
HR-MUD 33 0.33 0.16  0.91 0.007 
MUD 134 1.07 0.53  1.55 0.72 
HAPLO 18 1.23 0.48  3.78 0.57 
CB* (7)* *CB merged with MMUD due to low numbers for analysis 
Days to engraftment 356 - - 0.9 
Patient age at time  
of transplant 356 - - 0.7 
Time in days from 
diagnosis to transplant 356 - - 0.7 
Graft versus Host 
Disease 
aGvHD (grade II  IV)/total 53/356 - - 0.001 
cGvHD (grade II  IV)/total 11/356 - - 0.6 
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3.4 Results  
Analysis of HLA match groups revealed a 25% improved LFS for MUD transplants  that 
had been typed and matched at high resolution (HR-MUD; LFS 78.8%, 2002-2007, 
P=0.026) compared with low or intermediate resolution (LR or IR) MUD transplants for all 
other HLA typing epochs (MUD; LFS 41%-53%, 1988-2001,  see Figure 3.2).  
.
Log Rank (Mantel-Cox) 
Chi-Square=11.1; P=0.026   
Figure 3.2 Comparison of leukaemia free survival for matched unrelated donor transplants. 
The analysis is over five HLA typing epochs spanning 20 years at a single transplant centre for 
paediatric ALL  patients.  HR-MUD transplant LFS improved by greater than  25%, P=0.026 
From 2000 to 2001, HLA matching was performed at high resolution for HLA class II but 
low or intermediate resolution at HLA class I. No improved survival was observed for this 
HLA typing epoch (MUD, LFS=46%) when compared to earlier HLA typing epochs.   
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If  transplants from the differing donor sources since 2002 are compared (era of high 
resolution typing), it is found that HR-MUD transplants have the same LFS as HLA 
matched sibling transplants for paediatric ALL patients (Figure 3.3).  
Log Rank (Mantel Cox)
Chi square=6; P=0.11 
Log Rank (Mantel Cox)
Chi square=11.5; P=0.009 
months months 
(A) (B)
Figure 3.3 Two year leukaemic free survival.  (A) Two year LFS prior to the introduction of high 
resolution typing. (B) Two year LFS post the introduction of high resolution typing. MUD transplant 2 year 
LFS was inferior to HLA matched sibling transplants before 2002 but improved to be similar to matched 
sibling transplants in the HR-MUD transplants p=0.009 (2002-2007).  
In Table 3.2., the disease status at time of transplant was seen to significantly effect the 
hazard ratio observed for two year LFS. The majority of transplants were performed when 
the patient was in CR2 at the time of transplantation. Between 2002 and 2007 fourteen 
HLA matched siblings and fourteen HR-MUD transplants were transplanted in CR2 at 
time of transplant. An analysis of 2 year LFS for patients transplanted when in CR2 
between 2002 and 2007 shows  the matched sibling and the HR-MUD transplant two year 
LFS to be identical (LFS= 92.4%, P=0.008; Figure 3.4) 
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Figure 3.4   Two year LFS of patients in CR2  at time of transplant (2002-2007). 
Fourteen HLA matched sibling and fourteen HR-MUD transplants were performed during this period and 
had  identical LFS at 92.4% after two years (P=0.008).  
If the survival analysis is restricted to a period between the years 2002-2005 the influence 
of HR-MUD transplants on five year LFS can be analysed (Figure 3.5). Although the 
patient numbers are reduced, a highly significant improvement (P=0.005) in five year LFS 
is still observed. The improvement is comparable to matched sibling transplants 
performed during the same HLA typing epoch and this is not observed prior to 2002.     
Log Rank (Mantel Cox) 
Chi square=11; P=0.008 
months 
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Figure 3.5 Five year leukaemic free survival.  (A) Five year LFS prior to the introduction of high 
resolution typing. (B) Five year LFS post the introduction of high resolution typing. MUD transplant five year 
LFS was inferior to HLA matched sibling transplants before 2002 but improved to be equivalent to matched 
sibling transplants in the HR-MUD transplants P=0.005 (2002-2005).  
The development of acute graft versus host disease (aGvHD) was found to be associated 
with decreased two year survival (Table 3.2, p=0.001). High resolution matching for HLA 
was associated with a decreased hazard ratio for the development of aGvHD when 
compared with epochs where low or medium resolution HLA typing was used and 
reached statistical significance (HR=0.4, 95% C.I.= 0.28 0.6, p<0.001). Survival among 
patients who developed aGvHD was higher in the HR-MUD typing epoch when compared 
with all earlier epochs. From 2002 to 2007, seven patients developed aGvHD of whom 
one died. This compares with ten patients developing aGvHD between 2000-2001 of 
whom eight died, fifteen cases of aGvHD between 1996-1999 of whom ten died, nine 
cases of aGvHD between 1993-1995 of whom eight died and 12 cases of aGvHD 
between 1988-1992 of whom seven died. Of the patients who develop aGvHD in the high 
Log Rank (Mantel Cox)
Chi square=5; P=0.17 
Log Rank (Mantel Cox)
Chi square=13; P=0.005 
months months
(A) (B)
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resolution typing epoch 86% survive at year two compared with only 25% for all other 
epochs combined (n=53; p=0.001).  
Cytomegalovirus (CMV) serological status shows a decrease in CMV seronegative 
patients receiving seropositive donors (-/+) after the year 2000. Differences in 
patient/donor serological status reached significance when analysed between epochs 
(Table 3.1, p<0.001) but these differences had no significant impact on 2 year survival in 
both univariate and multivariate analysis (Table 3.2, p>0.1).  
The source of stem cells used for transplant varied over time. It changed from 100% BM 
between the years 1988-1999 to 73% BM between 2002 - 2007. The use of PBSC donors 
(18%) and CB donors (9%) from 2002 - 2007 explains this change. The hazard ratio for 
two-year survival following BM and CB was 0.63 and 0.8 respectively when compare with 
PBSC transplants but failed to reach significance (p>0.3) in both univariate and 
multivariate analysis.  
Analysis of variance from the mean age of patients in the five HLA typing epochs showed 
significant differences (p=0.013), although patient age did not significantly impact 2 year 
survival (p=0.75) in this study.  
The interval between diagnosis and transplantation shows little variance between epochs; 
there was no statistically significant difference between epochs (95% C.I. 1012 1205; 
p=0.25) or impact upon 2 year survival (p=0.7).   
The percentage of patients in each disease status category (CR1 3) at the time of 
transplantation was relatively unchanged over time. The distribution of cases between CR 
categories in the high resolution typing epoch (2002-2007) was close to the overall mean 
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percentages for all other epochs combined (CR1, 19% v 19%; CR2, 69% v 64% and 
CR3, 12% v 17%) and CR category differences between epochs did not reach 
significance when analysed for trends (p=0.4). Disease status at the time of transplant 
was shown to have a statistically significant impact on LFS. CR2 had a reduced hazard 
ratio (HR) of 0.71 when compared with CR3 (95% C.I.=0.46-0.98, p=0.09) and CR1 had a 
HR of 0.77 compared with CR3 but this did not reach statistical significance (95% 
C.I.=0.46  1.19, p=0.24).  
The incidence of disease relapse declined to 16% between 2002-2007 from 23% between 
2000-2001, 40% between 1996-1999, 28% between 1993-1995 and 36% between 1988-
1992 (n=103; p=0.001, [Tables 3.1 & 3.3]). Relapse rate had a highly significant impact 
on 2 and 5 year survival. However it was not possible to identify any statistically 
significant impact for grades of HLA matching on relapse rate that was independent of 
epoch.
Table 3.3 Incidence of relapse catagorised by epoch and HLA match group.
 
Variable 
1988-
2007 
1988-92 1993-95 1996-99 2000-01 2002-07
No. patients transplanted in each 
epoch 
356 
(100%) 72  72  80   52  80 
Incidence of                                          
Relapse/ HLA match  
                                                                         
                                             
MSD 21 9/26 (35%)* 1/6  (17%) 4 /12 (33%) 
3/10 
(30%) 
4/26 
(15%) 
HR-MUD 5 - - - - 5/33 (15%) 
MUD 47 10/28 (35%) 12/41(29%) 20/41(49%) 
5/24 
(21%) - 
MMUD 25 5/16 (31%) 7/25  (28%) 8/25  (32%) 2/9   (22%) 
3/16 
(20%) 
HAPLO 5 2/2   (100%) 0 0/2     (0%) 
2/9   
(22%) 
1/5   
(20%) 
Relapse totals for each epoch 103 26     20 32      12      13           p< 0.002** 
( %)*=percentage of transplant patients who relapsed  for HLA match category in each epoch 
**analysis using chi square test for trends 
Epoch dependent improvements in LFS were seen in MSD, but this did not reach 
statistical significance (Table 3.4., p=0.15) or match the MUD to HR-MUD improvement 
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observed with the introduction of high resolution matching (Figure 3.2 & Table 3.4, 
p=0.026). No statistically significant improvement in LFS over time was seen in MMUD or 
in MUD prior to the introduction of high resolution typing at HLA class I and class II loci.  
In the HLA typing epoch (1996-1999) immediately before the change in Campath 
conditioning (from Campath®-1G to Campath® -1H) the MMUD transplant LFS was 41%. 
This was similar to the MMUD LFS during the high resolution typing epoch (46%). When 
comparing the MMUD patients 2 year LFS for all epochs, no statistically significant 
difference in survival was observed between epochs (Table 3.4., p=0.59).  
Table 3.4. Summary of 2 year LFS listed by epoch and HLA match 
grade. 
Transplants  Censored 
HLA match Epoch 
Transplant 
total 
Event 
NRM   or  relapse LFS (n) 
overall 
LFS% 
1 (2002  2007) 26 1           /            4      21 80.8% 
2 (2000  2001) 10 0            /           3 7 70.0% 
3 (1996  1999) 12 1            /           4 7 58.3% 
4 (1993  1995) 6 0             /          1 5 83.3% 
5 (1988  1992) 26 1             /          9 16 61.5% 
MSD 
Overall 80 3             /         21 56 70.0% 
Test for equality of survival distributions between differing epochs for MSD transplants 
Log Rank (Mantel-Cox)         X2=6.8; p=0.15 
1 (2002  2007) 33 2            /            5 26 78.8% HR-MUD 
Overall 33 2            /            5 26 78.8% 
Test for equality of survival distributions between differing epochs for HR - MUD and MUD transplants 
Log Rank (Mantel-Cox)         X2=11.1;  p=0.026 
2 (2000  2001) 24 8            /           5 11 45.8% 
3 (1996  1999) 42 4            /           20 18 42.8% 
4 (1993  1995) 41 9            /           12 20 48.8% 
5 (1988  1992) 28 3            /           10 15 53.6% 
MUD 
Overall 135 24          /           47 64 47.4% 
Test for equality of survival distributions between differing epochs for MUD transplants 
Log Rank (Mantel-Cox)         X2=0.7;  p=0.85 
1 (2002  2007) 16 5            /            3 8 50.0% 
2 (2000  2001) 9 0            /            2 7 77.8% 
3 (1996  1999) 25 3            /            8 14 56.0% 
4 (1993  1995) 25 8            /            7 10 40.0% 
5 (1988  1992) 16 4            /            5 7 43.2% 
MMUD 
Overall 91 20          /           25 46 50.0% 
Test for equality of survival distributions between differing epochs for MMUD transplants 
Log Rank (Mantel-Cox)          X2=2.8;  p=0.59 
1 (2002  2007) 5 2            /            1 2 40% 
2 (2000  2001) 9 3            /            2 3 33.3% 
3 (1996  1999) 2 0            /            0 2 100.0% 
4 (1993  1995) 0 0            /            0 - - 
5 (1988  1992) 2 0            /            2 0 .0% 
Haplo 
Overall 17 5            /            5 7 41.1% 
Test for equality of survival distributions between differing epochs for Haplo transplants 
Log Rank (Mantel-Cox)         X2=2.3; p=0.51 
Overall Overall 356 54          /         103 199 55.8% 
LFS for each match grade stratified by the epoch. MUD transplants were replaced by HR-
MUD transplants in 2002 with a resultant >25%  LFS increase.  Although a degree of 
epoch dependant improvements are seen  in other HLA match catagories, they do not  
reach significance or reflect the MUD to HR-MUD improvement observed. Frequency of 
Non Relapse Mortality (NRM) is comparable between HLA matched sibling and HR-MUD 
transplants and is higher in all other categories. 
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3.5 Discussion 
In 1999 The Bristol Royal Hospital for Children reported HLA matched and mismatched 
unrelated donor transplants had similar LFS (Green et al. 1999). The current 
contemporaneous study confirms the earlier findings for MUD transplants, but reports 
significant improvements in LFS for matched unrelated donor transplants subsequently 
with the introduction of allelic typing (HR-MUD group). Further, for patients in CR2 at the 
time of transplant, HR-MUD LFS was the same as for MSD in the small cohort of patients 
in this category (p=0.008).  By contrast MMUD transplants show little improved LFS when 
compared to the 1999 study (50% v 40%).  MMUD transplants performed after 2002 were 
for HR typed single antigen or allele mismatches (n=16) and showed no significant 
improved LFS (50%) in comparison to previous HLA typing epochs (Table 3.4, p=0.59). 
This was contrary to expectations as the literature states that a single HLA antigen or 
allele mismatch is well tolerated and comparable to HR-MUD transplants (Bray et al. 
2008a;Lee et al. 2007). However these numbers are relatively low and therefore firm 
conclusions should not be made.  
The marked improvement in HR-MUD outcome has occurred at the same time as the 
switch to high resolution typing. It is therefore tempting to assume that this improvement 
is due to the change in typing methodology with the consequent reduction in unidentified 
mismatches (Flomenberg et al. 2004). However, potential confounding variables need to 
be excluded before this effect can be confirmed.  
Some variables, such as CMV status of donor/recipient pairs and time to transplant, 
which are known to affect transplant outcomes can be clearly shown to have no effect 
(Table 3.2). The change in Campath antibody is also unlikely to be responsible for the 
particular improvement in the HR-MUD cohort because a) there was no improvement in 
survival seen in the year 2000-2002 when the change to Campath-1H was made and b) 
the change to Campath-1H was applied to both MUD and MMUD transplants and if this 
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was causal a similar improvement in the outcome of MMUD transplants post-2002 would 
be expected.  
Changes in supportive care could be responsible for some of the improvements seen. 
There is some detectable time-dependent improvement seen between epochs though this 
did not reach statistical significance. This is most clearly seen in recipients of sibling 
transplants where other confounding variables such as change in typing strategy or 
conditioning are not present. An improved 2yr LFS is observed post-2002 in sibling 
transplants but does not reach significance when tested for equality of survival with other 
epochs (Table 3.4). If there were a general effect of improved supportive care then it 
would be expected to be seen across all subgroups. The lack of improvement in MMUD 
outcome since 2002 therefore argues against a significant supportive care effect. It is 
important to note that there has been no change in donor selection strategy. All patients 
transplanted were eligible for transplant from any donor, and a strict hierarchy of related 
sibling, MUD (or HR-MUD) and then MMUD applied to all recipients.  
The intrinsic risk of relapse due to leukaemic specific factors such as CR status and 
length of CR1 are well known to influence outcome from stem cell transplantation 
(Einsiedel et al. 2005). In this study there has been no change in the leukaemic risk 
profile (CR group or length of CR1 for CR2 patients) between epochs and between 
groups. Thus change in risk of relapse from the disease perspective do not explain the 
improved survival with high resolution matching compared to other HLA match groups.   
Therefore, the most likely reason for improved outcomes in the HR-MUD group is due to 
the change to high resolution typing. This change correlates with significantly reduced 
non relapse mortality (NRM) among the HR-MUD group. Table 3.4, shows NRM to be 
lower among the HR-MUD transplants and comparable to the levels seen in HLA 
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matched sibling transplants. Meanwhile the likely reason for reduced relapse rates across 
all donor groups since 2002 is the improved outcomes seen generally with modern 
relapse therapy.  
In comparing our data with the published literature, there are some notable differences. A 
collaborative study group of 450 transplant centres (CIBMTR, 2006) looked at long term 
survival following transplantation for acute leukaemia in children under the age of 18 
months (Eapen et al. 2006). In this study, the principal cause of treatment failure differed 
between MSD and MUD transplants. Relapse was reported as the most common cause 
of failure in MSD transplants. NRM was the most common cause of failure among MUD 
transplants and it was argued that this may be due to a higher proportion of patients in 
CR2 and CR3, plus more aGvHD and infections, than in MSD transplants. The CIBMTR 
study reported on infant AML and ALL and stratified their analysis by disease group. They 
reported overall survival outcome to be similar among MSD and MUD transplants. The 
current results differ significantly from the CIBMTR study as LFS of MSD and HR-MUD 
transplants was significantly better than MUD and MMUD transplants. This may be due to 
the CIBMTR study focusing on ALL in infants under 18 months (higher frequency of MLL 
gene rearrangements associated with poorer prognosis) and the mean age of our study 
patients being nine years of age. The CIBMTR study did not involve high resolution HLA 
matching.  
A more recent CIBMTR paediatric study compared transplant outcomes for transplants 
performed between 1993 2006 among MSD, mismatched related donors (mmRD) and 
MUD bone marrow transplants. High resolution typing of the MUD donors was performed 
retrospectively by the NMDP (Shaw et al. 2010). The patients in this study were from four 
disease groups, AML, ALL, CML, MDS and all transplants were T-cell replete. In the 
CIBMTR study, three year disease free survival was reported to be 54% for the MSD 
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transplants, 44% for the mismatched related donor group and 43% for the high resolution 
matched unrelated donor group. In these transplants, grade 2 - 4 acute GvHD at 100 
days was observed in 29% of the MSD transplants, 56% in the mmRD transplants and 
45% in the high resolution HLA matched unrelated transplants. The outcome data on the 
individual disease types for disease free survival and acute GvHD was not reported 
making comparisons difficult. However the results contrast  with 15% acute GvHD and 
two years LFS of 80.8% among MSD patients and 78.8% in HR-MUD patients for the T-
cell depleted bone marrow transplants reported in this paediatric ALL study.  
The National Marrow Donor Panel (NMDP, USA) published a report examining post-stem 
cell transplant survival in paediatric acute leukaemia s over a similar twenty year time 
span (Macmillan, 2008). They reported an approximate 30% survival advantage in the 
MMUD transplant cohort transplanted between 2003 and 2006 when compared to earlier 
periods studied. Our findings show no significant epoch dependent improvement in LFS 
among MMUD transplants. The NMDP study also reports on survival for paediatric ALL 
patients transplanted while in CR1, CR2 and CR3. The NMDP reported overall survival at 
62% for paediatric ALL patients transplanted in CR2 between the years 2003 and 2006 
(p<0.001). This contrasts with our findings where HR-MUD transplants in CR2 at the time 
of transplantation have the same two year LFS as MSD transplants of 92.4% (p=0.008). 
The NMDP report is a large multi-centre study (data from 102 transplant centres) and 
uses three categories of HLA match (well matched, partially matched and mismatched 
(Weisdorf et al. 2008)). Our data is from a single centre, with a well-defined patient cohort 
and has applied stringent categorisation of HLA match grades when matching at the high 
resolution level.  Both studies review transplant outcomes from similar 20-year time 
frames.  
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Other groups have reported comparable HR-MUD and MSD LFS in transplants for acute 
myeloid leukaemia (Moore et al. 2007) and chronic myeloid leukaemia (Arora et al. 2009) 
where high resolution HLA-A,-B,-C, and -DRB1 matching is performed. Our study, 
however, has shown significantly improved LFS when comparing HR-MUD transplants to 
MSD transplants for paediatric ALL patients. Transplant pairs HLA typed to low or 
medium resolution level and HLA mismatched pairs continued to show inferior LFS when 
compared with HR-MUD and MSD transplants.   
The data shows an improved LFS for the HR-MUD group compared to both previous 
typing strategies (MUD) and MMUD grafts. There is a statistically significant reduction in 
CH-NRM in the HR-MUD group compared to MUD and MMUD which represents the 
clearest explanation for this improved LFS.  
The current findings may impact ethical considerations where minors are selected as 
suitable sibling donors. If an adult HR-MUD donor offers a similar LFS outcome as an 
MSD from a minor, the ethics of donation are altered. Current recommendations from the 
committee on bioethics from the American Academy of Paediatrics has five criteria to fulfil 
for the use of minors as stem cell donors (Committee on Bioethics 2010). The first criteria 
to be met when considering a minor as a sibling donor requires that; there is no 
medically equivalent histocompatible adult relative who is able and willing to donate .  The 
question now posed is; should a medically equivalent histocompatible adult unrelated 
volunteer donor be selected in preference to the matched sibling donor when a minor? 
This may be an issue to be considered if subsequent studies corroborate these findings.  
LFS in unrelated donor paediatric ALL transplants improves significantly when 
prospective high resolution matching for HLA is performed. In a recent cross-sectional 
study it was reported that 100% of donors and recipients in allogeneic transplants 
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performed in the United Kingdom were high resolution typed at HLA-DRB1 and -DQB1 
(DPB1 matching was common at some centres) but only 40% were high resolution typed 
for HLA-A,-B, and -C. Intermediate resolution typing and matching is still performed for 
60% of allogeneic transplants at HLA-A, B, and C (Harvey & Green 2009).   
The data presented indicates that prospective typing and matching at the high resolution 
level for HLA-A,-B,-C,-DRB1 and -DQB1 correlates with a greater than 25% improvement 
in overall LFS making HR-MUD outcomes comparable to MSD transplants over a 2 and 5 
year follow up for paediatric ALL patients. This improvement is not seen in the epoch 
where HLA-DRB1 and -DQB1 were high resolution matched but were intermediate 
resolution matched for HLA-A,-B, and -C (2000-2001). The study findings are in 
agreement with earlier reports looking at retrospective HLA high resolution matching (Lee 
et al. 2007). The results in this study support the concept that donor selection guidelines 
for HLA matching in unrelated donor stem cell transplants for paediatric ALL transplants 
where an unrelated BM or PBSC transplant is to be performed should require high 
resolution HLA typing and matching of donor and recipient at HLA-A,-B,-C,-DRB1 and -
DQB1.  
This work was presented in open forum a the BSHI annual conference in Edinburgh 
2010 (appendix 3) 
*********  
3.6 Reflective comment  
In Chapter two it was established that not all United Kingdom transplant units have 
adopted high resolution HLA matching for donor and recipient in haematopoietic stem cell 
transplants. Published data from retrospective studies show that this level of matching is 
beneficial to overall patient survival. Chapter three shows that prospective selection of 
donors using high resolution matching methods, improves patient survival by more than 
25% at two and five year follow-up. Data has been converted into knowledge but not yet 
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converted to an accepted wisdom. In Chapter four the goal is to turn knowledge into 
accepted wisdom by preparing donor selection guidelines for the United Kingdom 
approved of and circulated by influential professional bodies. 
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4 Guidelines for selection and HLA matching of related, adult unrelated donors 
and umbilical cord units for haematopoietic stem cell transplantation. 
4.1 Introduction 
Strong evidence for significantly improved transplant outcome in unrelated donor 
haematopoietic stem cell transplants by matching for HLA using high resolution typing 
between patient and donor has been published over recent years (Flomenberg et al. 
2004;Lee et al. 2007;Petersdorf et al. 2007a;Petersdorf 2004;Petersdorf et al. 
2004;Petersdorf, Gooley et al. 2007b;Petersdorf 2008). Multi-centre studies have 
retrospectively high resolution typed HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 transplant 
pairs. They analysed the effect of HLA high resolution donor matching and mismatching 
on patient survival. Other studies have used an algorithm to define transplant pairs as 
well matched, partially matched and mismatched for HLA typing and retrospectively 
analysed transplant outcome showing an epoch dependent improvement in overall 
transplant survival (Macmillan et al. 2008).   
From these and earlier studies the National Marrow Donor Program (NMDP, USA) has 
issued HLA matching guidelines in 2003 (updated in 2008) of best practice for matched 
unrelated donor (MUD) stem cell transplants in adults (Bray et al. 2008b;Hurley et al. 
2003). They describe guidelines for the optimal HLA match positively impacting post 
transplant survival in adult transplants. The core component of the NMDP guidelines for 
optimal transplant outcome requires a high resolution HLA-A, -B, -C and -DRB1 loci 
matched unrelated donor to be used where a HLA matched sibling is not available. The 
guidelines further suggest that where a mismatch is unavoidable a single mismatched 
allele or antigen at HLA-A, -B, -C or -DRB1 donor should be selected. Similar guidelines 
are being used for HLA matching in a European prospective study (ALL-SCT-BFMi 
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consortium) in stem cell transplants for children with ALL (Peters et al. 2005;Schrauder et 
al. 2008). The European study also includes HLA-DQB1 as locus for matching, the results 
of which are yet to be published.  
4.1.1 Current status of unrelated donor HLA match criteria used in the UK  
A recent cross-sectional study (2009) of all Histocompatibility and Immunogenetic (H&I) 
laboratories in the UK and Ireland revealed that no uniform standards or guidelines are 
being followed for the HLA matching of unrelated recipient/donor pairs in stem cell 
transplantation(Harvey & Green 2009). The survey shows that high resolution typing at 
HLA class-I and class-II for recipient/donor matching is performed in the selection of 40% 
of final transplant pairs in the UK and 100% in Ireland. The remaining 60% pairs are 
matched at the high resolution level for HLA class-II and low to intermediate resolution 
level for HLA class-I.   
All laboratories surveyed matched at HLA-A, -B, and -DRB1 but there was no consensus 
on the use or need for matching at HLA-C, -DRB3, -DRB4, -DRB5, -DQB1 or -DPB1. 
Where a HLA matched donor was unavailable, 13 differing centre dependant criteria were 
in use to identify a suitable mismatched donor (see Table 2.9). This recent survey 
emphasised the wide variability in HLA matching and selection criteria used by stem cell 
transplant units in the UK.         
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4.1.2 The need for guidelines in the United Kingdom  
The use of clinical guidelines founded on evidence-based medicine to set standards is an 
important aspect of clinical medicine and patient care. Guidelines for the allocation of 
solid organ donors have been published in the UK. No guidelines have been issued for 
related and unrelated allogeneic stem cell donor selection based on UK  best practice. 
Some publications provide recommendations in this setting but deal mostly with single 
disease aspects of transplantation or stem cell source (Lanino et al. 2008;Rocha & 
Locatelli 2008). The guidelines presented in this document are intended to be applicable 
to clinical practice in UK transplant centres.  
4.1.3 Purpose of the guidelines  
The aim of this document is to offer haematopoietic stem cell donor selection guidelines 
to health care professionals involved in donor selection for patients undergoing allogeneic 
stem cell transplantation. The guidelines highlight the most relevant HLA factors to 
consider in the rapid provision of the best matched related and unrelated adult volunteer 
stem cell donors or umbilical cord blood unit. Clinical urgency as determined by the 
transplant team will remain the principal determinant that impacts the choices offered. It is 
hoped that the document will offer valuable guidance in a wide range of stem cell 
transplant scenario.        
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4.1.4 Preparation of the guidelines  
The first draft of this document was researched and prepared by the John Harvey who 
subsequently chaired a writing working party meeting. This constituted an estimated 90% 
contribution to the final document. The guidelines were reviewed by a working party of:  
Children s Cancer and Leukaemia Group 
British Society for Histocompatibility and Immunogenetics  
British Society for Blood and Marrow Transplantation  
British Transplant Society 
Royal College of Pathologists 
Institute of Biomedical Science 
The guidelines are based on review and consensus literature up to Feb 2011.  
All recommendations made in this document are bordered and 
highlighted thus. 
4.2 HLA Typing 
4.2.1  Definitions of low, intermediate and high resolution, allelic and confirmed allele 
high resolution HLA typing:   
The following definitions have been compiled by a joint working party from the following 
organisations: American Association of Blood Banks (AABB), American Society for 
Histocompatibility and Immunogenetics (ASHI), College of American Pathologists (CAP), 
European Federation for Immunogenetics (EFI), Foundation for the Accreditation of Cellular 
Therapy (FACT), National Marrow Donor Program (NMDP), World Marrow Donor Association 
(WMDA) (August 2010). 
4.2.2 Low resolution (LR):   
The DNA-based typing result is at the level of the digits comprising the first field in the DNA-
based nomenclature. Examples include: A*01; A*02. The exception is B*15 in which low 
resolution is defined as a subset of alleles that might be considered as sharing a broad 
serologic type, either B15 or B70.  
4.2.3 Intermediate resolution (IR):   
Intermediate resolution is defined as a DNA-based typing result that includes a subset of 
alleles sharing the digits in the first field of their allele name and that excludes some alleles 
sharing those digits. Examples include: A*02:01 or A*02:02 or A*02:07 or A*02:20 but not 
other A*02 alleles. There may be cases in which the subset of alleles includes one or more 
alleles with a name beginning with different digits but these alleles should be the exception 
i.e., the majority of the alleles should share the same first digits e.g., A*01:01 or A*01:02 or 
A*01:14 or A*36:04. 
4.2.4 High resolution (HR):   
A high resolution typing result is defined as a set of alleles that specify and encode the same 
protein sequence for the peptide binding region of a HLA molecule and that excludes alleles 
that are not expressed as cell-surface proteins. Examples are typings with the following 
characteristics: (1) includes only alleles within a P group designation eg., A*02:01P, 
DPB1*04:02P or (2) includes alleles within a G group designation (eg., A*02:01:01G, 
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DRB1*12:01:01G) with the exception that it does not include non-expressed alleles with the 
same nucleotide sequence (e.g., A*02:01:01G without A*02:43N and A*02:83N). A list of P 
and G groups can be found at  http://hla.alleles.org. 
4.2.5 Allelic resolution (AR):   
The DNA-based typing result is consistent with a single allele as defined in a given version of 
the WHO HLA Nomenclature Report as described on the reference web site, 
http://hla.allele.org. An allele is defined as a unique nucleotide sequence for a gene as 
defined by the use of all of the digits in a current allele name. Examples include 
A*01:01:01:01; A*02:07.  
4.2.6 Confirmed allele high resolution (CAHR):   
A confirmed allele is one that has been identified in two or more unrelated individuals and is 
designated as confirmed in the IMGT/HLA database (http://www.ebi.ac.uk/imgt/hla). A 
confirmed allele high resolution typing result is defined as a set of alleles that specify and 
encode the same protein sequence for the peptide binding region of a HLA molecule, and 
exclude confirmed alleles that are not expressed as cell-surface proteins and include 
alternative genotypes with two unconfirmed alleles that specify different protein sequences, 
when applicable. An example of confirmed allele high resolution typing is: A*02:01:01G in 
which the non-expressed alleles, A*02:43N and A*02:83N, are not excluded because both 
 are unconfirmed. 
 4.3 Stage of disease, time to transplant and HLA matching 
One of the earliest steps in choosing a suitable stem cell donor for transplantation is to 
consider the disease and the potential progression of the patient. Patients with a slowly 
progressing disease such as myelodysplastic syndrome in low and intermediate-1 
international prognostic score groups (IPSS), can be considered to have ample time to 
search for the best matched unrelated donor. In these cases delayed transplantation to 
source the best possible donor is associated with maximising overall survival. However for 
patients with myelodysplasia in intermediate-2 and high risk IPSS, immediate transplantation 
is associated with maximal life expectancy (Cutler et al. 2004).  
This contrasts with acute leukaemia s where the patient s condition can rapidly deteriorate 
and a limited window of opportunity in terms of clinical remission may limit the time available 
for an unrelated donor search. The transplant physician must advise the H&I laboratory on 
the stage of the patient s disease (early, intermediate or advanced) giving an indication of 
clinical urgency. A patient progressing to advanced disease has a higher mortality risk from 
the disease than the added risk from a single HLA allele/antigen mismatch or alternative 
donor therapy such as umbilical cord blood (UCB) transplantation. The progress of the 
patients disease and the likelihood of finding a HLA high resolution matched donor will 
determine the choice of stem cell source selected for treatment (Weisdorf 2008). 
The H&I specialist must advise on the likelihood of finding a high resolution matched donor 
within the time frame set by the transplant consultant. The likelihood of finding a high-
resolution matched donor should be based upon the frequency of the HLA alleles and 
haplotypes in the population. The ethnic origin of the patient and the frequency of potential 
matches must be identified as early as possible (Cano et al. 2007;Hurley et al. 2004;Kollman 
et al. 2007;Spellman et al. 2008).    
  
Guidance and tools to assist in donor selection and allele frequencies are freely available. 
http://www.marrow.org
http://www.bmdw.org
http://hla.alleles.org
http://www.ebi.ac.uk/imgt/hla/
Extended donor searches for uncommon HLA haplotypes usually fail to find a high resolution 
matched donor and sacrifice time to the progression of disease(Weisdorf 2008). Alternative 
stem cell sources or acceptance of a limited HLA mismatch with an unrelated panel donor 
should be explored early in the planning of the transplant where time to transplant is 
restricted by the progress of the patient s disease. 
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4.4 Related stem cell donor selection.  
4.4.1 Recommendations for HLA matched related donor  
The patient, siblings and parents (where available) should be HLA-A, -B, -C, -
DRB1 and -DQB1 typed at low resolution as a minimum requirement. Where 
consanguinity exists within a family, additional relatives may also be typed as 
prospective donors. 
Where possible, familial haplotypes should be assigned to establish 
presumptive high resolution identity between donor and recipient. 
Where familial haplotypes cannot be established, recipient and selected donor 
should be high resolution typed at HLA-A, -B, -C, -DRB1 and -DQB1. 
Laboratories not able to perform HLA class-I or class-II high resolution typing 
must arrange for an EFI or ASHI accredited laboratory to perform these tests at the 
required level of resolution. 
Where there are ambiguities in a HLA type all alternative alleles must be listed in 
the typing report. 
For the patient and all selected matched siblings, a repeat sample for 
confirmatory HLA typing must be obtained and the patient and donor retyped.  
If a sibling is a HLA identical twin and is selected as a donor there is likely to be 
less of a graft versus leukaemic effect in the transplant. Further testing for zygosity 
should be performed. 
   
4.4.2 HLA mismatched related donors  
If there are no HLA matched siblings, and the time to transplant is short, then mismatched 
related donors can be considered. These transplants historically constitute an increased risk 
of graft failure, severe graft versus host disease and related morbidity. 
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Where parents share a HLA haplotype or a parent is homozygous for HLA loci 
then a pheno-identical transplant can be considered. It is recommended that patient 
and donor are high resolution typed to determine the exact degree of HLA mismatch 
between donor and patient.  
Where a related donor differs from the patient for a single antigen (i.e. sibling 
with crossover) then a one antigen/allele mismatch transplant can be considered. The 
patient and donor should be high resolution typed to determine the full extent of 
mismatch. 
Parents and siblings sharing a single haplotype with the patient can be 
considered for a haploidentical related transplant. 
Where there is consanguinity within the family, a comprehensive family tree 
should be sketched and selected extended family testing can be considered where 
appropriate. 
4.5 Unrelated donor selection  
4.5.1 Genetic factors impacting the availability of a HLA matched unrelated stem cell 
donor.   
The number of HLA-A, -B and -DRB1 low resolution matched donors available for a patient 
following a BMDW search often reflects the likelihood of finding a high resolution matched 
unrelated donor. It has been reported that Caucasoid patients have a 40-50% chance of 
having a high resolution matched donor at HLA-A, -B, -C, -DRB1 and -DQB1 (10/10 match) 
and that the probability of finding a 10/10 high resolution match is highly predictable (Tiercy 
et al. 2000;Tiercy et al. 2007). The chance of a 10/10 match in other ethnic groupings is 
lower (Schmidt et al. 2009a). The following factors should be considered when searching for 
a high resolution matched unrelated donor.  
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Patients with commonly found HLA-B and HLA-C or HLA-DRB1 and -DQB1 associations 
have a positive impact on the likelihood of finding a donor.  
Patients with uncommon HLA-B and HLA-C or HLA-DRB1 and -DQB1 associations have 
a negative impact on likely donor availability. 
The frequencies of HLA-B and HLA-C or HLA-DRB1 and -DQB1 associations in donor 
registries for differing ethnic groups are available for comparison with the HLA type of the 
patient (Cano et al., 2007) (see 2.2, tools to assist in donor selection). 
The following will negatively impact the availability of a matched donor. The presence of a 
patient allele with a frequency of <5% within the low resolution matched possible donors (e.g. 
B*4405). The presence of an allele in the patient that is a possible match for low resolution 
donor types where other alleles having frequencies >10% are the alternative possible 
mismatches (e.g. B*35, B*44, DR*04, DRB1*11, DRB1*13). 
The presence of alleles from the low resolution typing groups HLA-B51 and B18 or the 
presence of alleles HLA-B*2705, B*4402 and B*4403 in the patient, have a raised risk of a 
HLA-C mismatch. 
Patients are less likely to find a matched donor from an ethnic group differing from their 
own (Schmidt et al. 2009) 
Patients with parents coming from differing ethnic groups (mixed race) have a raised risk 
of not finding a high resolution match. 
Where the maternal HLA type of the cord donation is known, non inherited maternal 
antigens (NIMA) when selected as a mismatch have been shown to reduce transplant related 
mortality and relapse rates.  
Where known, non inherited maternal antigens should be selected as the preferred 
mismatch in related/unrelated  and umbilical cord SCT where possible (van Rood et al. 
2009).   
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4.5.2 Recommendations for unrelated donor selection  
The benefits of high resolution matching for HLA decreases as the disease progresses from 
early to intermediate to advanced disease states. Disease progression and stated time to 
transplant, must be considered when deciding if a search for a high resolution matched donor 
should be pursued or an alternative more quickly available stem cell source such as umbilical 
stem cells or HLA non-identical related transplant should be investigated (Bachanova & 
Weisdorf 2008). Patients with unusual HLA types can consider other stem cell sources early. 
EFI standards recommend minimum requirements for HLA typing in unrelated stem cell 
transplantation but do not specify a standard for matching which is determined by local 
transplant policies.   
NMDP guidelines for adults recommend that high resolution HLA matching for HLA-A, -B, -C 
and -DRB1 is used for the recipient and final stem cell transplant donor (high resolution 
typing defined in section 2.1.3 of this document). Contemporaneous studies show this level 
of resolution and matching (8/8 match) to be the minimum level favourably influencing 
leukaemia free survival (LFS) in unrelated donor transplants (Bray et al., 2008).  
Matching for HLA-DRB3, -DRB4, -DRB5 has not yet been shown to significantly improve 
LFS. HLA-DQB1 mismatches are thought to have an additive negative impact where there is 
already a mismatch at HLA-A, -B, -C or -DRB1(Lee et al.,  2007).               
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In these guidelines we recommend a 10/10 high resolution match at HLA-A, -B, -C,-
DRB1 and DQB1 loci to be used where possible with an unrelated donor.  
Where a 10/10 match is unavailable a single mismatch at HLA-A, -B, -C, -DRB1 or 
DQB1 is acceptable. A single allele or antigen mismatch at HLA-DQB1 should be 
selected in preference to HLA-B or -C which in turn should be selected in 
preference to HLA-A or -DRB1 as these mismatches have been reported to be 
better tolerated (Lee et al. 2007).  
Mismatching at two or more loci compound the survival risk to the patient. The 
transplant strategy must minimise the number of HLA allele mismatches between 
donor and recipient (Lee et al.  2007). 
Alternative stem cell sources should be considered early in the donor search 
where a patient is unlikely to have an HLA matched unrelated donor. 
Mismatches at HLA-DPB1 have been shown to offer a graft versus leukaemic advantage but 
also increased graft versus host disease and associated morbidity. There was no significant 
influence on overall survival associated with matching at this locus (Shaw et al. 2007). 
Matching/mismatching at the DPB1 locus should be considered on an individual basis 
following the transplant physicians evaluation of the patients transplant related risks. 
Emerging literature refers to permissible and non-permissible mismatches (Crocchiolo et al. 
2009b). 
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4.6 HSC source  
4.6.1 Peripheral Blood Stem Cell (PBSC), Bone Marrow (BM) or Umbilical Cord Blood 
(UCB).  
The choice of haematopoietic stem cell source is influenced by several factors; the urgency 
of the patients condition, age, weight, disease status and the availability of a suitable HLA 
matched donor will determine the choice. Each stem cell source has distinct advantages and 
disadvantages requiring assessment in the best interest of the patient. They differ in needs 
concerning cell dose, HLA match requirements, and risks of acute and chronic GvHD, time to 
engraftment and speed of availability of cells for harvest and transplant (see Table 4.2).   
In recent studies of paediatric transplants for acute leukaemia, UCB transplants with up to 2 
HLA antigen mismatches had similar 5 year leukaemia free survival (LFS) as 8/8 high 
resolution matches at HLA-A, -B, -C or -DRB1 using unrelated BM and PBSC transplants. In 
adult BM and PBSC transplants, 8/8 high resolution matches at HLA-A, -B, -C or -DRB1 have 
lower TRM and higher leukaemic free survival LFS than UCB transplants(Eapen et al. 2007). 
UCB transplants with an adequate cell dose have a similar transplant outcome as single 
allele mismatched unrelated PBSC or BM transplant. 
It is recommended that UCB units are matched by high resolution typing for HLA-
DRB1 and intermediate resolution for HLA-A and B (Gluckman, Koegler, & Rocha 
2005;Hurley et al. 2006;Rocha & Locatelli 2008).  Every effort should be made to 
minimise mismatching at these loci but where there is no choice a 5/6 or a 4/6 match 
may be accepted. A higher level of mismatch is not recommended.
 4.6.2 Stem cell source and engraftment  
PBSC transplants offer the fastest neutrophil engraftment followed by BM with UCB 
transplants the slowest to engraft. Slow engraftment in UCB transplants is associated with 
higher post transplant morbidity. In a recent UCB transplant study HLA match and total 
nucleated cell dose were shown to independently influence the rate of neutrophil engraftment 
(Kurtzber et al., 2008). In UCB transplants, engraftment can be enhanced by using more than 
one cord blood unit.  
The use of more than one UCB unit is recommended for those patients for whom a 
single cord unit would offer an inadequate cell dose. In choosing a second UCB unit it 
is recommended that the UCB unit  is HLA matched to the patient and the other UCB 
unit  using criteria recommended in 4.6.1 (Barker et al. 2005)*. 
*Note recent publication indicating that unit  unit matching is less important than unit TNC(Barker, Byam, & 
Scaradavou 2011) 
 
4.6.3 UCB - HLA match, cell dose and engraftment  
When selecting a cord blood unit, it is important to match the cell dose to the size of the 
patient being transplanted. A consensus has evolved that 2.5 x 107 nucleated cells per 
kilogram body weight is the minimum cell dose required to reliably achieve engraftment in 
unrelated cord blood transplants (Laughlin et al. 2004). UCB units have on average 1/10th the 
number of lymphoid derived cells of an average BM collection (Gluckman 2006). The cell 
dose from the cord blood unit and the degree of HLA matching affect engraftment. In general, 
the greater the level of mismatch the higher the cell dose needed for engraftment. Doses 
>5.1 x 107 nucleated cells per kilogram body weight are recommended to overcome the 
effect of HLA mismatch (Hurley et al., 2006) .  
The University of Minnesota recommends the following adjustments to cell dose depending 
upon the HLA match category of the donor/recipient pair where matching is at high resolution 
level for HLA-DRB1 and low resolution level for HLA-A and B loci (Gluckman 2006). 
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Recommendations on cell dose with HLA mismatch UBC transplants:  
6/6 HLA match >3 x 107 nucleated cells per kilogram body weight 
5/6 HLA match >4 x 107 nucleated cells per kilogram body weight 
4/6 HLA match >5 x 107 nucleated cells per kilogram body weight 
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4.7 CD34+ve cells and engraftment  
It is important to transplant sufficient CD34+ve cells for engraftment to take place. As a stem 
cell source, PBSCs offer the highest yield of CD34+ve cells. Bone marrow harvests on very 
rare occasions fail to yield a sufficient CD34+ve cell dose. With cord blood donations the 
CD34+ve cell yield varies significantly form one unit to another and total nucleated cell yield is 
more commonly used to assess UCB unit selection for transplantation.  
Higher CD34+ve cell doses (>2 x 106/kg body weight) result in better neutrophil and platelet 
engraftment and are associated with improved survival especially in unrelated transplants. 
CD34+ve cell doses >8 x106 /kg of body weight are associated with increased chronic graft 
versus host disease where G-CSF stimulated peripheral blood stem cells are used(Heimfeld 
2003). 
Table 4.1  Selection criteria differences to be considered between BM, PBSC and CB 
stem cell sources.  
Stem cell selection 
criteria 
BM PBSC UCB 
HLA matching Minimum 9\10 
HLA-A,B,C,DRB1,DQB1 
Minimum 9/10 
HLA-A,B,C,DRB1,DQB1
Minimum 4/6 
HLA-A,B,DRB1 
Minimal recommended CD34+ 
cell requirements 
2.8 x 106/kg 4.5 x 106/kg 0.2x 106/kg 
Average time to neutrophil 
engraftment  
15-23 days 12-19 days 22-32 days 
Time to identify, HLA retype 
and harvest donor cells 
2 months 2 months 1 month 
Acute and chronic GvHD risk Lower than PBSC Higher than BM Lower than BM 
and PBSC 
Availability of second 
donation and donor 
lymphocyte infusions 
Yes Yes No 
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4.8  HLA antibodies and engraftment  
Until recently the impact of HLA antibodies on engraftment was unclear and opinion was 
formed from contradictory case study reports in the literature with few cases available for 
analysis due to the matching criteria inherent in HLA matched related and unrelated donor 
transplants. The use of mismatched cord blood donors has led to more transplants being 
performed where the patient has HLA antibodies directed against cognate specificity s 
present in the donor. Two recent studies indicate that the presence of HLA antibodies in the 
recipient becomes a significant risk factor of transplant non-engraftment where the HLA 
antigen specificity recognised by the antibody is present in the donor.   
In a Japanese study of 374 cord blood transplants, 16.4% (41/250) of the patients aged 
between 16 and 74 years transplanted for malignancies had HLA antibodies. Of those 
patients 8 had antibodies against cognate antigen present in the transplanted cord blood. 
Engraftment for patients with HLA antibodies but no cognate antigen in the transplanted cord 
was 93.6% with a median time to engraftment of 21 days. Where the cognate antigen was 
present in the donor engraftment fell to 58% (p=0.017), a median time to engraftment of 46 
days(Takanashi et al. 2008). A more recent NMDP study looking at failed BM transplants, 
found that the presence of donor specific HLA antibodies (HLA-DSA) in the recipient directed 
against cognate HLA antigens in the donor is associated with an increased risk of non-
engraftment (OR 22.8, p=0.0002)(Spellman et al. 2010). From these studies the following 
can be considered best practice in HLA mismatched stem cell transplants. HLA-DSA in the 
recipient is a significant risk factor for non-engraftment.     
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Recipients who may require a HLA mismatched transplant should be tested early 
for HLA antibodies. The specificities of HLA antibodies detected in the recipient must 
be determined before the final donor is selected. 
In selecting HLA mismatched donors (CB, PBSC or BM) it is advisable to avoid 
selecting donors with HLA antigens for which the recipient has HLA-DSA. The 
transplant team must be made aware of any antibody incompatibility detected. 
 
Stem cell dose (megadose) is used in mismatch transplants to overcome immune barriers to 
transplantation(Gur et al. 2002;Handgretinger et al. 2001). The effectiveness of this strategy 
in the presence of HLA-DSA in the recipient is unknown.  
4.9 Acute graft versus host disease (aGvHD) and HLA mismatching 
Acute GvHD is a major hazard in stem cell transplantation and  a significant cause of death. 
HLA mismatches between donor and recipient are reported as major risk factors for aGvHD 
(Bacigalupo et al. 2004).Other possible risk factors are sero-positivity for herpes viruses and 
female donor to male recipient transplants (Ringden et al. 2009).   
The main targets for aGvHD attack are skin, liver and gut. This occurs within the first 3 
months (100 days) after transplantation. The severity of the disease is graded on a 5 point 
scale from 0 to IV, where 0 represents no detectable disease and IV is life 
threatening(Glucksberg et al. 1974). The clinical course of aGvHD involves cytokine up-
regulation and T-cell activation leading to tissue damage and increased susceptibility to 
infection (Antin 2001). Donor T-cells can trigger aGvHD following activation by recipient 
antigens in the form of HLA associated presentation of viral derived peptides, minor antigenic 
peptides including epithelial cell associated antigens(Bacigalupo et al. 1992). PBSC derived 
stem cells have the highest risk of causing aGvHD complications and associated morbidity 
when compared with BM transplants. Lymphoid cells from cord blood have decreased 
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reactivity and are described as being naive and immature cells. The aGvHD risks associated 
with umbilical cord blood transplants are lower than those of PBSC and BM (Bacigalupo et 
al., 2009). Grade I and II aGvHD has been reported as a favourable factor contributing to 
disease free survival(Chim et al. 2007;Esperou et al. 2003) in malignancies.   
4.10 Chronic graft versus host disease (cGvHD) and HLA mismatching 
Chronic GvHD is a more diverse syndrome than aGvHD and the grading of this disease is 
more complex (Akpek et al. 2001;Akpek et al. 2003;Horwitz & Sullivan 2006). The recognised 
independent variables seen to influence susceptibility to cGvHD are HLA mismatch, stem cell 
source, prior aGvHD and increasing age of patient.   
In homogeneous ethnic populations the sharing of minor histocompatibility antigens is 
reported to lower the incidence of cGvHD(Remberger et al. 2001). PBSC derived stem cells 
have the highest risk of causing cGvHD complications and associated morbidity. BM grafts 
are lower risk and UCB transplants have the lowest risk of cGvHD as a stem cell source. 
cGvHD risks associated with HLA mismatches in UCB transplants are lower than 
mismatches in PBSC and BM transplants due to the immature nature of the lymphoid cells 
present in cord blood.  
4.11 Non-HLA factors to be considered for selection  
4.11.1 Cytomegalovirus (CMV)  
Even with recent improvements in anti-viral and GvHD prophylactic therapies, CMV remains 
a major cause of morbidity and mortality in allogeneic SCT.  CMV can cause disease in 
different organs after SCT including hepatitis, gastro-enteritis, retinitis, encephalitis, and 
pneumonia and remains a major risk factor in SCT.    
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CMV seropositive patients having CMV seropositive donors have been shown to have better 
survival and reduced TRM than seropositive patients receiving seronegative stem cell 
donations. Seronegative patients with seropositive donors develop primary CMV infection in 
30% of cases and have an increased mortality (Boeckh et al. 2003;Ljungman, Hakki, & 
Boeckh 2010). 
It is recommended that CMV seropositive patients receive seropositive donors and 
seronegative patients receive seronegative donors wherever possible. Strategies 
should be adopted to avoid blood product-associated CMV infections in seronegative 
recipients by either leucodepleted products or CMV negative products. 
 
4.11.2  ABO blood group  
ABO incompatibility between patient and donor is a common feature of stem cell 
transplantation and does not constitute a major contra indication to donor selection.  
However strategies designed to reduce transplant-related toxicity such as low intensity 
conditioning and graft versus host prophylactics is associated with extended host 
isohaemaglutinin production. This can result in delayed donor erythropoiesis post transplant. 
Patients with pre-existing erythropoiesis problems have been shown to require prolonged red 
blood cell transfusion therapy post transplant. These complications can be reduced where 
major ABO mismatches are avoided in donor selection (Bolan et al. 2001).  
It is recommended that where a patient has multiple HLA and CMV matched donors, 
major ABO incompatibilities should be avoided where possible. 
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4.11.3 Gender  
The impact of matching for gender on SCT has been reported (Csete 2010). For most 
conditions treated by SCT it has been reported that a male donor has a positive effect on 
long term survival regardless of the sex of the recipient (Pond, Lipton, & Messner 2006).  
However in multiple myeloma patients the best outcome has been reported with patients 
receiving a female donor and the pairing of female patient with female donor has the best 
outcome for this diagnosis (Gahrton et al. 2005). Female recipients are at a greater risk of 
experiencing other complications such as thrombotic thrombocytopenia purpura post 
transplant, regardless of donor gender (Fuge et al. 2001).  
It is recommended for most patients undergoing SCT that a male donor is the 
preferred option, with the reported exception of multiple myeloma where female donor 
is the preferred option.  
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4.12 Algorithm for a donor search  
The following algorithm outlines the process for identifying HLA matched stem cell donors or 
umbilical cord units for a UK patient. Individual transplant units and/or HLA laboratories must 
have their own operating procedures outlining each step of the process and must be a 
registered user with Bone Marrow Donors Worldwide.  A comprehensive user guide is 
available from http://www.bmdw.org and further advice is available from individual registries. 
Initial request  
Transplant consultant requests 
a search for  an unrelated 
donor  and/or cord blood unit 
Patients diagnosis, 
demographics, HR-HLA  type, 
sex, age, weight, CMV status, 
blood group and urgency of 
transplant are detailed 
Preliminary search: 
Log on to: 
http://www.bmdw.org  
Enter on-line match 
programs using username  
and password. 
Add new recipient details, 
add user preferences, add 
match preferences. 
Run unrelated donor and 
cord match programs 
Review search    
results  
Where multiple matches are 
available on BMDW,  search 
UK  registries directly (BBMR, 
WBMDR, AN) for  an HLA  
matched  donor  
Where there are few or no 
matched donors consider most 
suitable ethnic group for 
extended registry search and/or  
single allele mismatch and/or 
cord blood transplant options 
Figure 4.1 Outline of donor search process
Chose matched donors for 
further investigation from 
UK registries. Where 
multiple donors are 
available CMV, sex, age, 
weight, status, blood group 
can be used as further 
selection criteria 
BMDW 
Individual unrelated donor 
and cord blood registries 
If a patients HLA alleles are 
more prevalent in an ethnic 
grouping outside the UK, 
request an extended registry 
search in the most suitable 
registry. Also, consider a 
single allele/antigen 
mismatch  donor or a cord 
blood  transplant 
Request samples for  
verification HLA  typing 
(confirmatory). Upon   receipt 
perform  high resolution 
extended  typing and select  
final donor plus a back-up 
donor. Reserve donor(s) or 
cord(s).  
Set date for transplant with 
transplant consultant and  
advise registrysending 
prescribed documentation 
Donor harvest and shipment 
or cord shipment and 
recovery. 
Transplant
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4.13 H&I Laboratory - Operational Recommendations  
The H&I laboratory must be directed by a consultant or equivalent trained and 
qualified in Histocompatibility and Immunogenetics. 
There must be close liaison between the H&I laboratory and the transplant unit. 
An experienced member of the H&I laboratory staff should attend regular 
transplant co-ordination meetings providing advice on donor selection and noting the 
clinical urgency attached to each patient by the transplant team and treating 
consultant. 
The H&I laboratory must provide a named person who is responsible for the co-
ordination of the search progress with cover support for absences. 
Each case must be reviewed on an individual basis establishing urgency and 
suitability of the donor search strategy. 
The laboratory must have a written strategy designed to minimise the time from 
unrelated donor search to final donor selection. 
The laboratory must be accredited with the European Federation for 
Immunogenetics or The American Society for Histocompatibility and Immunogenetics 
to meet the transplant unit JACIE requirements. 
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4.14     Clinical Notes for Scientists  
In these guidelines, clinical notes for scientists were written by consultant HSCT 
haematologists actively working in stem cell transplantation and are included in the 
appendices (appendix 4). 
***** 
4.15 Reflective comment  
These guidelines will be published and distributed this year (2011). They reflect a 
considerable body of collective knowledge which when turned into guidelines for  evidence 
based best clinical practice can be considered a form of wisdom. It gives the United Kingdom 
haematopoietic stem cell transplant community the ability to effectively and efficiently apply 
accumulated knowledge and so produces the desired optimal results in patient treatment.  
However all is not known and further research is needed. In Chapter five additional genetic 
factors impacting transplant outcome are explored.              
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Chapter Five  
Ex Africa semper aliquid novi
(Out of Africa always something new)  
Gaius Plinius Secundus (23  79AD)  
5 Ethnicity and Haematopoietic Stem Cell Transplantation 
The 16th international histocompatibility workshop is to be held in Liverpool, UK in 2012. A 
research group aim of this workshop is to look at the influence of ethnic differences between 
donors and recipients on stem cell transplant outcomes. The research hypothesis of the 
group is Donor-recipient ethnicity may affect the risk of acute GvHD and other transplant 
associated outcomes after HLA matched unrelated HCT . In data already previewed for this 
group, a total of 5555 Asian/Pacific Islander, Caucasian, African, Hispanic, Native American 
or mismatched race pairs were analysed for differences in transplant outcome. This ongoing 
HLA workshop will examine the role of ethnic specific HLA haplotype differences and stem 
cell transplant outcomes, matching the pairs by race and ethnicity where the donor recipient 
pairs are already 10/10 HLA matches.   
However, perceived ethnicity may not be a reliable marker of genomic divergence between 
stem cell donor and recipient (unless from a specified geographic area identified as an 
ancestral homeland for a population grouping). This Chapter will examine the role of multi-
chromosomal Short Tandem Repeats (STRs) as markers for genetic differences that may 
influence transplant outcomes in high resolution HLA matched related and unrelated 
transplants.    
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5.1 Worldwide human settlement and ethnic differentiation  
The relationship between geographic origin, race and genetics is very complex and is a 
subject over which anthropologists continue to debate. Notions of race and ethnicity are as 
much related to social and cultural identity as genetic ancestry. Where race correlates with 
geographic origin then it is seen as a proxy for relative genetic homology (Sarata A.K. 2008)  
Several models have been put forward to explain worldwide human settlement. The out of 
Africa model where all Homo sapiens had common ancestors who migrated from East Africa 
is the current most popular theory of a human founder effect (Ramachandran et al. 2005). An 
alternative hypothesis puts forward the concept that humans have evolved worldwide on a 
multiregional basis. However, a near consensus has developed supported by available 
evidence in favour of the hypothesis that modern human beings have common ancestry from 
East Africa (Liu et al. 2006). Figure 5.1 shows a map of the shortest routes through which 
colonisers would travel from an origin in East Africa. Lui and colleagues estimate that an 
initial expansion of the human race from a founding population of approximately 1000 about 
56,000 years ago was accompanied by high population growth rates. Using DNA samples 
from a collection of >1000 individuals from 52 differing populations, 783 autosomal 
microsatellite markers were analysed for population related polymorphism. Lui et al (2006) 
showed that genetic differentiation between populations increases linearly along the land 
masses detailed in Figure 5.1 from East Africa (DNA diversity panel supplied by Centre 
d'Etude du Polymorphisme Humain [CEPH] founded by Prof. Jean Dausset).       
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Ancestral Colonisation Routes 
 
Figure 5.1. Shortest colonisation routes from East Africa (Addis Ababa) along landmasses and 
high mountain ranges (areas with average elevation 12,000 m) to the populations from the CEPH 
human genetic diversity panel. Small blue dots represent populations, the hypothetical origin of 
modern humans is represented as a large red dot, colonisation routes are shown in red, and 
uncrossable areas with average altitude 12,000 m are brown. (Liu et al 2006)  
5.2 Race, visible traits and concepts of ethnicity 
Skin pigmentation is a central theme in most discussions concerning race. The genetics of 
human skin pigmentation in differing populations has proved highly variable. A large scale 
study looked at the relationship between skin pigmentation and ancestry in five distinct 
populations (Parra, Kittles, & Shriver 2004). They found the relationship between skin colour 
and ancestry was highly variable and stated that great caution has to be used when using 
skin pigmentation as a proxy for ancestry as both dark and light skinned individuals are found 
on most continents.   
The largest known genetic distance is between Africa and Oceania (Table 5.1). However 
based upon physical appearance and skin pigmentation this might be counterintuitive as 
indigenous Australians and New Guineans resemble Africans in terms of dark skin and hair 
texture (Cavalli-Sforza 1997;Cavalli-Sforza & Minch 1997).  
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This comparatively large figure for genetic distance probably reflects the isolation of Oceania 
since the end of the last glacial maximum (subsequent rising sea levels 20,000 years ago). 
The similar phenotype of dark skin pigmentation and similar hair texture for African and 
Oceania populations are probably the result of convergent evolution in response to 
environmental factors. 
Table 5.1 Genetic distances among major continents; based on 120 classical 
polymorphisms (calculated from frequency differences of polymorphic alleles in differing 
populations from Cavalli-Sforza L.L., 1997). 
Africa Oceania East Asia Europe 
Oceania 0.247 
East Asia 0.206        0.1 
Europe 0.166 0.135 0.097 
America 0.226 0.146 0.089 0.095 
If other phenotypes are examined then those commonly used in determining race, such as 
the epicanthal fold seen in the eyelids of East Asians, it is found that other populations in the 
world share this phenotype (the Khoisan of South Africa, the Saami of Northern Sweden, 
Native Americans and Andamanese of the Indian Ocean). The blonde hair commonly 
associated with Europeans can be found in a small number of dark skinned populations of 
the South Pacific Solomon Islands and Vanuatu.   
Where social or ethnic identities correspond to distinct, disparate and identifiable geographic 
localities then these identifiers can act as a proxy for human genetic variation. However, in 
many western societies where there has been significant migration of populations and 
interbreeding between ethnic groupings, the use of social identities as a proxy for genetic 
identity does not work and are at best naive biological characterisations (Foster & Sharp 
2002) 
5.3 Intrapopulation variation (admixed ancestry) 
The assignment of race or ethnic origin is often a measure of perception of one individual by 
another. This can be useful in studies of health disparities where resource allocation and 
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social interactions can impact health (Cho 2006). However it is likely to lead to confusion in 
an evaluation of post stem cell transplant morbidities due to genetic disparity.  
In the USA the fastest growing ethnic minority are the Latinos (Hispanics). As a group they 
represent a heterogeneous mix of European, African and Native American ancestries. Most 
Latinos are unsure of their precise ancestry and tend to base their self reported ancestry on 
their national origin and their physical appearance. If ancestry estimates of four Latino 
populations are examined (Table 5.2) a wide variability in genetic composition is found  
reflective of country of origin (Price et al. 2007).  
Table 5.2 Ancestry estimates of four Latino Populations expressed as % ancestry by 
population (Price et al. 2007) 
Ancestry LA* Latino Mexican Brazilian Columbian 
European 48 52 71 71 
Native North American 40 43 10 7 
Native South American 4 2 8 12 
African 8 4 1 10 
*Los Angeles, USA 
If ancestry in Latino individuals from the same geographic area (Puerto Rica) rather than 
populations is looked at, the genetic variability from the same limited geographic area in this 
ethnic group is remarkable (see Figure 5.2)           
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96 healthy Puerto Ricans clustered by genetic admixture levels 
Figure 5.2 Individual ancestry estimates in Puerto Ricans 
Population specific genotype data for 116,204 single nucleotide polymorphisms (SNPs). Each bar 
represents the estimated genetic ancestry of an individual (Gonzalez et al. 2005).  
From Figure 5.2 it can be seen that individual Puerto Ricans can have their European genetic 
ancestry vary in a range from 79% to 30% and African ancestry vary from 50% down to 7%, 
with the native American component relatively constant. From this genetic admixture an 
individual classified as a Latino or Hispanic on the basis of ethnic identity, does not 
necessarily predict the likely population specific allelic profiles of their genes.  
For African Americans the average European component of the genetic admixture in differing 
regions of the USA varies from 10% to 20% within the population (Parra et al. 1998). The 
admixture process in the African Americans began with the arrival of the first African slaves 
to British colonies approximately 300 years ago. The process continued with new impetus 
after World War I (following the great migration of African Americans from the rural southern 
states to the urban north in search of economic advantage). The African component of the 
admixture is derived from six distinct African ancestries. The principal African populations 
identified in the African American admixture are the Mandenka from West Africa, the Yoruba 
of Central West Africa, the Bantu from Kenya and South-western Africa and the Bakia, Mbuti 
and San from Southern Africa (Zakharia et al. 2009).In Figure 5.3  the individual admixtures 
identified in 128 individual African Americans are shown. 
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From both Figures 5.2 and 5.3 it is seen that specific individuals identified as Latino or 
African American may converge more in terms of genetic background with Europeans or 
Africans (dependant upon their genetic admixture) than with another individual within the 
same ethnic grouping.  Their genetic architecture remains distinct from Africans, Europeans 
and Native Americans but their genetic stratification remains highly complex.  The use of 
genome wide SNPs and/or STR polymorphism studies is likely to offer more information 
concerning likely ancestral genome divergence and convergence than concepts of race and 
ethnic origin.  Social classification on the basis of race and ethnicity may not correspond to 
the biological variation that may impact stem cell transplant outcomes.  
                
European (0 to 72%)                                              Mankenda African (3% to 29%)                                              
               
Yoruba African (18% to 64%)                                  Bantu African (3% to 28%) 
               
Figure 5.3 Analyses of African American ancestry. Bar plot displays 128 individual ancestry estimates for African Americans from a 
supervised structure analysis of six African and one U.S. Caucasian populations using 450,000 single nucleotide polymorphisms (adapted from 
Zakharia et al. Genome Biology 2009). 
Three additional African groups contributed modest levels to the genetic admixture (Biaca 1.7%, 
Mbuti 0.5%, San 0.3% on average)  
In Chapter 3 the relationship between HLA identity and transplant outcome in donors and 
recipients who may share ancestral haplotypes for one gene cluster (HLA) is examined. In 
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this Chapter the STR profiles of high resolution matched HLA donor-recipient pairs shall be 
used to develop a model testing for likely ancestral genetic divergence between the donor 
and recipient in a multi chromosomal basis. I shall use the STR profiles as proxies for 
genomic ancestral divergence between the high resolution HLA matched transplant pairs and 
test for any possible impact on transplant outcome and survival.   
5.4   Model for genetic divergence  
(Lowe et al. 2001) reported the use of six STR loci to infer the ethnic origin of a crime stain in 
a British population using a forensic science database of five ethnic groups that represent 
99.7% of the UK population (Caucasians, Afro-Caribbeans, Indian sub-continentals, South 
East Asians and Middle Easterners).  More recently an online calculator for individual 
affiliations to a major population has become available but is limited by the lack of available 
full individual STR profiles within populations. Although individual allelic frequencies are 
published, complete profiles which would form the basis of population affiliation data is not 
freely available for analysis.  The online calculator (http://cracs.fc.up.pt/popaffiliator/) for 
individual affiliation to major population groups has data on Eurasian, sub-Saharan African, 
East Asian,  Near Eastern, North African, Central-South American and North American 
populations (Pereira et al. 2010). The tool does not have data on Western Europeans which 
is the population of interest in this study.   
Another constraint on available methods for calculating population affinity or genetic distance 
is that existing methods compare an individual STR profile to a population profile. For this 
study the analysis will compare one individual with another.  The transplant pairs are 
composed of two groups, sibling donors and unrelated donors. All donors and recipients 
were high resolution matched at HLA -A, -B, -C, -DRB1 and -DQB1 loci.   
Genetic distance can be measured in several ways. Two examples are minimal genetic 
distance (Dm) or standard genetic distance (Ds) as described by Nei (Nei 1973;Nei, 
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Chakraborty, & Fuerst 1976). Nei used non-linear measurements designed to analyse 
electropheretic and blood group polymorphism. In this thesis STRs which are tandem DNA 
motifs repeated a number of times (Figure 5.4) will be used and analysed. 
Figure 5.4 Two STR alleles for comparison for the MYCL1 locus. 
These two alleles differ in length by 9 bases indicated by the presence of differing numbers of repeat units 
shown in green.  
The STR constellations will either be four base unit repeats or five base unit repeats. STR 
loci have relatively high mutation rates compared to the rest of the genome. The mechanism 
for generating mutations favours replicating or deleting single motifs at each mutation step. 
The generation of STR allelic polymorphism is described as having a stepwise mutation 
mechanism. This is a useful characteristic for measuring genetic distance as it has the 
advantage of increased observable mutations (alleles) linked by mutation rate and allele size 
as a measure of passing generations. This was used to  devise a formula to measure  
genetic distance suitable for the analysis of loci such as STRs (Shriver et al. 1995). 
Calculations of genetic distance are favoured where the polymorphism observed conforms to 
the linearity of the mutation rate after population divergence and STR mutations conform to 
this concept.       
[GAAA]2[TAAA]1[GGAA]1[GA]3[GAAA]1[GA]1[GAAA]14[GAAAA]2[GAAAAAAAA]1[GAAAA]3GAAAAAA]1[GAAAA]2[GAAA]1 A
B [GAAA]2[TAAA]1[GGAA]1[GA]3[GAAA]1[GA]1[GAAA]15[GAAAA]2[GAAAAAAAA]1[GAAAA]4[GAAAAAA]1[GAAAA]2[GAAA]1
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Figure 5.5 relationship between time and two measures of genetic distance in 
generations since population divergence for 2 mutation rates A and B.   
Filled circles are genetic distance measure Dsw and open circles are Ds with time measured in generations. A 
is a mutation rate of v = 0.0003 and B is a mutation rate of v = 0.001. The measure Ds, does not maintain a 
linear relationship. ( Schriver et al, 1995)  
The mutation rates used by Shriver et al in Figure 5.5 show the effect of average and lower 
limits of mutation rates for STRs upon calculations for genetic distance. A later study 
revealed an average mutation rate of 0.0005 (1/2000 generations) for 377 human STR loci 
with an average number of STR alleles present per constellation of 10.8 with a standard 
deviation of 3.6 in the population tested (Ramakrishnan & Mountain 2004)).       
Mutation rate =0.0003 
Mutation rate =0.0001 
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Figure 5.6 Step wise mutation model.   
In Figure 5.6 STR polymorphism is seen to exhibit homoplasty wherein two alleles may be 
identical by DNA fragment size but not by direct ancestral descent. An increased level of 
polymorphism in the population is observed with the passage of time in thousands of 
generations. The model assumes symmetry at each mutation step in terms of addition or 
subtraction of a single tandem repeat unit. If 0.0005 is used as the mutation rate for Figure 
5.6  then it would have taken between 6000 to 8000 generations to produce the additional six 
alleles present at time M4. The process in terms of a mathematical model is an example of a 
Markov Chain in which the next step is dependent upon the current state but is part of a 
random process.  Unlike other forms of genomic polymorphism, STR loci have the 
characteristic of variable repeat unit number and that this difference in length observed is 
M0 
M1 
M2 
M3 
-   + 
-    +
- + 
-   + 
-    + -   + 
-   + 
Common Ancestor 
5 repeats 
5 repeats 5 repeats 
4 repeats 
4 repeats 
4 repeats 
4 repeats 
6 repeats 
6 repeats 
6 repeats 
6 repeats 
7 repeats 
8 repeats 
2 repeats 
In this diagram we depict the effect of stepwise mutation over time. At mutation MO there is only 
one ancestral allele consisting of five repeat DNA motifs. At each mutation step a repeat unit may 
be added or removed such that at mutation step M3 the possible number of alleles present in the 
population ranges from 2 repeat units to 8 repeat units. Six additional alleles could have been 
introduced by step wise mutation in this model population.  
Tim
e
3 repeats
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time related to ancestral origin. Slatkin used the differences in allele length observed in 
differing populations to derive a measure for genetic distance termed RST , defined as : 
                                           Sbar   -  Sw         
                                                  Sbar   
(Slatkin 1995) 
: Sbar is the DNA motif repeat number difference squared for alleles between populations at each locus.  
: Sw is the DNA motif repeat number difference squared between alleles within populations at each locus.   
Slatkin suggests using the weighted average value across loci in the calculation and this 
metric was used to measure genetic distance between populations  as shown above (Slatkin 
1995). This calculation proved less useful in comparing two individuals and the Weighted 
Average Allelic Size Difference (WAASD) between donor and recipient was devised  in this 
thesis as a metric for ancestral divergence( see Table 5.5).  
It can be assumed that over thousands of generations there will be a continuous growth in 
the genetic mutations observed between divergent populations. With STR mutations this 
increase would be measurable as increasing differences in the length of the STR alleles 
observed between individuals within the population groups. Homoplasty in the mutation 
process will lead to a degree of inaccuracy in the model but the work of Slatkin indicates that 
when weighted average values are used then STR length remains an accurate tool to 
measure genetic distance. The hypothesis of this study is that individuals with shared 
ancestry will have fewer differences in STR lengths than those with highly divergent ancestry. 
In this thesis Weighted Average Allele Size Difference (WAASD) for STR alleles between 
stem cell donors and recipients will be used as a metric for genomic divergence between the 
donor and recipient ancestries.       
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5.5 Materials and Methods  
In Chapter 3 of this thesis, eighty paediatric ALL transplants were analysed for factors 
affecting two year survival following the introduction of high resolution HLA typing (2002 to 
2007). Post transplant monitoring of chimerism using STR markers to identify donor and 
recipient DNA in the post transplant peripheral blood of the recipient has been performed on 
patients within this cohort since 2004. From this there are 38 high resolution HLA matched 
transplants for which donor and recipient STR profiles are available for analysis.   
In Chapter 3 the factors found to impact survival in these patients were:  
- resolution and HLA match of the transplant pair 
- clinical remission status at time of transplant 
- use of a sibling or unrelated donor  
The analysis performed will look at the distribution of WAASD in the 38 transplants for which 
STR profiles are available and examine whether these differences impact patient survival for 
both related and unrelated transplants. Binary regression and Cox proportional hazards 
analysis will be used to examine the effect of possible confounders on patient survival. A 
Kaplan Meier estimate of survival will be performed relating to the WAASD in the transplant 
pairs.  
  Sample size - Power and Precision 
Statistical power can be considered as the probability of obtaining a positive result for a given 
test which should produce a positive result. Increasing the sample size for a given study will 
increase the power. One goal of this study is to test the null hypothesis that there is no 
correlation between the WAASD values and survival in haematopoietic stem cell transplants  
Using power and precision analysis software (Power and Precision, Biostat, USA) it was 
calculated that, for a sample size of 38 with a mean WAASD value of 1.407 having a 
 126
standard deviation of 0.465, a power of 80% was calculated to yield a statistically significant 
result in logistic regression analysis. The analysis took into account that the event rate at the 
mean WAASD value was 5% and the event rate at a maximum WAASD value (2.16) was 
21%.  The analysis gave power approaching 100% to yield a statistically significant value in 
Kaplan Meier estimates of survival with these input parameters. 
5.6 Data  
In transplants between syngeneic twins, there are no observable differences in STR allelic 
size between donor and recipient (Table 5.3).  
Table 5.3 An example of STR allele sizes observed in a syngeneic twin transplant  
STR loci    
Recipient
allele 
size  
Donor 
allele 
size 
D3S1358   124 124 
 
145 145 
TH01   162 162 
177 177 
D21S11   227 227 
231 231 
D18S51   302 302 
313 313 
Penta E   387 387 
387 387 
D5S818   131 131 
135 135 
D13S317   184 184 
188 188 
D7S820   232 232 
236 236 
D16S539   291 291 
295 295 
CSF1PO   333 333 
341 341 
Penta D   398 398 
416 416 
vWA   142  142 
154 154 
D8S1179   226 226 
234 234 
TPOX    268 268 
280 280 
FGA   341 341 
358 358 
WAASD = 0 
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In Table 5.4 the STR profile for an allogeneic HLA matched sibling transplant pair is shown.     
Table 5.4 An example of allele sizes observed in an HLA matched sibling transplant 
pair for fifteen STR loci.   
STR loci   Recipient 
allele size  
Donor 
allele 
size  
Allele size 
difference 
in base 
pairs  
Allele size 
difference 
in STR 
repeat 
units 
D3S1358 122 122 0 0 
126 126 0 0 
TH01 174 174 0 0 
174 174 0 0 
D21S11 216 232 16 4 
222 222 0 0 
D18S51 307 307 0 0 
311 303 8 2 
Penta E 410 410 0 0 
440 410 30 6 
D5S818 129 129 0 0 
133 133 0 0 
D13S317 183 183 0 0 
195 195 0 0 
D7S820 220 220 0 0 
236 236 0 0 
D16S539 285 293 8 2 
293 293 0 0 
CSF1PO 341 341 0 0 
353 353 0 0 
Penta D 414 414 0 0 
420 400 20 4 
vWA 146 146 0 0 
154 150 4 1 
D8S1179 213 213 0 0 
225 221 4 1 
TPOX  269 269 0 0 
269 281 12 3 
FGA 344 344 0 0 
348 348 0 0 
   
In Table 5.5 an example of the STR profile for an HLA matched unrelated donor transplant 
pair is shown .     
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Table 5.5 An example of allele sizes observed in an HLA matched unrelated transplant 
pair for fifteen STR loci.  
STR loci   
Recipient
allele 
size  
Donor 
allele 
size  
Allele 
size 
difference 
in base 
pairs  
Allele 
size 
difference 
in STR 
repeat 
units 
D3S1358 117 117 0 0 
126 122 4 1 
TH01 174 162 12 3 
174 166 8 2 
D21S11 222 214 8 2 
226 218 8 2 
D18S51 311 299 12 3 
310 322 12 3 
Penta E 385 415 30 6 
400 420 20 4 
D5S818 129 129 0 0 
137 133 4 1 
D13S317 195 187 8 2 
199 191 8 2 
D7S820 219 219 0 0 
227 224 3 1 
D16S539 277 289 12 3 
293 289 4 1 
CSF1PO 337 333 4 1 
337 333 4 1 
Penta D 414 406 8 2 
414 406 8 2 
vWA 138 146 8 2 
146 150 4 1 
D8S1179 229 225 4 1 
229 225 4 1 
TPOX 269 273 4 1 
269 285 16 4 
FGA 344 328 16 4 
352 356 4 1 
If allelic size difference and frequency are tabulated, the WAASD between the donor and 
recipient can be derived from the sum product of the size difference multiplied by frequency 
divided by the sum of the frequencies tabulated (Table 5.6).  
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Table 5.6 An example of the WAASD for (A) an HLA matched sibling pair and (B) an 
HLA matched unrelated transplant.  
(A) Derived from Table 5.3 HLA matched sibling transplant 
Repeat unit differences 
observed in Table 5.3a 
(a) 
Frequency of observed 
differences for Table 5.3a 
(b) 
Weighted average allele size difference 
for 15 STR loci listed in Table 5.4 
0 22 
1 2 
2 2 
3 1 
4 2 
6 1 
The sum product of column (a) and (b) 
divided by the sum of column (b). 
0.76 
(B) Derived from Table 5.4 HLA matched unrelated transplant 
Repeat unit differences 
observed in Table 5.4a 
(a) 
Frequency of observed 
differences for Table 5.4a 
(b) 
Weighted average allele size difference 
for 15 STR loci listed in Table 5.5 
0 3 
1 11 
2 8 
3 4 
4 2 
6 1 
The sum product of column (a) and (b) 
divided by the sum of column (b). 
1.83 
The STR allele sizes were tabulated for all 38 transplant pairs and the size differences in 
terms of repeat units were listed. The WAASD for fifteen STR loci in each transplant pair was 
derived and tabulated in Table 5.7.    
All transplants in this study are high resolution HLA matched.  Factors included for analysis in 
this study are listed in Table 5.7. These are; related or unrelated; the remission status at time 
of transplant;  the number of STR allelic mismatches observed per transplant pair;  WAASD 
values.    
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Table 5.7 Tabulated WAASD calculated using 15 STR loci. Clinical remission status at 
time of transplant and post transplant two year follow up is also listed.    
Transplant 
pair 
Total STR 
allele 
differences 
between donor 
and recipient 
Weighted 
average STR 
allelic size 
difference 
between donor 
and recipient 
Related or 
unrelated 
HLA 
matched 
transplant 
Status 
at year 2
Two year 
survival in 
months 
Clinical 
remission 
at time of 
transplant
1 9.00 0.56  Msib alive 24 1 
2 10.00 0.66 Msib alive 24 2 
3 9.00 0.73 Msib alive 24 2 
4 8.00 0.76 Msib alive 24 2 
5 10.00 0.77 Msib alive 24 2 
6 13.00 0.83 Msib alive 24 1 
7 20.00 0.86  HR-MUD alive 24 2 
8 11.00 0.86 Msib dead 19 2 
9 14.00 0.9 Msib alive 24 2 
10 15.00 1 Msib alive 24 2 
11 14.00 1 Msib alive 24 1 
12 18.00 1.13 HR-MUD alive 24 3 
13 18.00 1.2 HR-MUD alive 24 2 
14 24.00 1.2 HR-MUD alive 24 2 
15 21.00 1.26 HR-MUD alive 24 2 
16 23.00 1.36 HR-MUD alive 24 2 
17 23.00 1.4 HR-MUD alive 24 1 
18 23.00 1.4 HR-MUD alive 24 2 
19 19.00 1.4 Msib alive 24 3 
20 23.00 1.41 HR-MUD* alive 24 3 
21 22.00 1.5 HR-MUD alive 24 2 
22 21.00 1.53 HR-MUD dead 11 1 
23 23.00 1.6 HR-MUD alive 24 2 
24 24.00 1.63 HR-MUD dead 16 3 
25 19.00 1.7 HR-MUD alive 24 2 
26 26.00 1.7 HR-MUD alive 24 2 
27 20.00 1.75 HR-MUD alive 24 2 
28 26.00 1.8 HR-MUD alive 24 2 
29 27.00 1.82 HR-MUD alive 24 1 
30 18.00 1.82 Msib dead 11 2 
31 22.00 1.82 HR-MUD alive 24 2 
32 22.00 1.83 HR-MUD dead 18 3 
33 23.00 1.93 HR-MUD alive 24 2 
34 22.00 1.96 HR-MUD dead 3 2 
35 23.00 2.06 HR-MUD alive 24 2 
36 22.00 2.06 HR-MUD dead 7 3 
37 22.00 2.11 HR-MUD alive 24 2 
38 23.00 2.16 HR-MUD dead 4 2 
  HR-MUD is high resolution HLA matched unrelated transplant 
 Msib is HLA matched sibling transplant 
All patients are censored at 24 months for analysis.        
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5.7 Data Analysis  
In Figure 5.7  the distribution of the WAASD values in Msib transplants are shown. The mean 
WAASD for Msib transplants is 0.94 with a standard deviation of 0.35 for twelve cases with a 
minimum value of 0.56 and a maximum of 1.82 although this maximum value is an outlier. 
The mean WAASD for HR-MUD transplants is 1.62 with a standard deviation of 0.34 for 
twenty six cases with a minimum value of 0.86 and a maximum value of 2.16.   
Figure 5.7  These histograms detail the distribution of WAASD observed in  Msib and 
HR-MUD transplants.  
If these values are entered into a box plot (Figure 5.8) then the Msibs and the HR-MUD 
transplants separate into two  populations in terms of their WAASD values.       
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Figure 5.8 Box plot of WAASD  seen in Msib and HR-MUD transplants.   
The box plot indicates the mean values of 1.66 for HR-MUD pairs and 0.84 for Msib pairs. 
The box represents the  95% confidence interval around the mean with an upper limit of 1.76 
and a lower limit of 1.48 for HR-MUD transplants and an upper limit of 1.16 and a lower limit 
of 0.72 for the Msib grouping. The arm terminators indicate the maximum and minimum  
values observed for these groups with a dot indicating an outlier seen in the Msib grouping.     
Dividing the groupings into those that are alive or dead over two years of patient follow up,  
shows the following distribution of WAASD values (Figure 5.9).        
n = 26 
n = 12 
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Patients dead at two years follow up
Patients alive at two years follow up 
Figure 5.9  These histograms detail the distribution of WAASD  observed in  patients 
alive or dead after  24 months.  
In the patients alive at 24 months the mean WAASD  is 1.32 with a standard deviation of 0.45 
in thirty transplant pairs. For patients dead after 24 months the mean WAASD  is 1.73 with a 
standard deviation of 0.41 in eight  transplant pairs although this includes an outlier (Msib, 
patient died of disease relapse).   
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Presenting this data as a box plot shows two overlapping populations of patients with the 
patients who died having higher WAASD values than the surviving patients (Figure 5.10).  
Figure 5.10 Box plot of WAASD s seen in  patients alive or dead after  24 months.  
The cause of death in terms of transplant related mortality or disease relapse is an important 
consideration. Figure 5.11 illustrates in a box plot the causes of  post transplant death 
(relapse or transplant related mortality) plotted against  WAASD values at 24 months.   
n = 30 
n = 8 
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Figure 5.11 Box plot of WAASD  seen in  patients alive or dead through relapse or TRM 
at  24 months.  
In this box plot there are three cases of relapse, two of them were with the Msib group and 
one with the HR-MUD group. No Msib transplants died of TRM.    
The data for variables WAASD, the number of STR allelic mismatches, Msib or HR-MUD 
transplant and the remission status of the patient at the time of transplant plus survival data 
were data inputted for analysis using binary logistic regression and by Cox proportional 
hazards for survival.  Tables 5.8 to 5.11 show the output obtained from the analysis.       
n=30 n=3 n = 5 
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Table 5.8 Hosmer and Lemeshow test for model goodness of fit for the four co-variants  
WAASD, STR allele mismatch, related or unrelated, and clinical remission.  
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 10.407 8 .238 
The Hosmer and Lemeshow test is indicative that the binary logistic regression model is a 
reasonable fit for data analysis as indicated by the high p value (Sig.).   
Table 5.9    Model summary with Cox & Snell R2 and Nagelkerke R2  values. 
Model Summary 
Step -2 Log likelihood Cox & Snell R2 Nagelkerke R2 
1 24.902a .312 .485 
a. Estimation terminated at iteration number 7 because 
parameter estimates changed by less than .001. 
The model summary approximates how much variance is accounted for within the model. In 
this analysis between 31.2% and 48.5% of variance is accounted for within the binary 
regression model.         
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Table 5.10  Variables in logistic regression  model and their predictor values. 
Variables in the Equation 
B S.E. Wald df Sig. Exp(B) 
No. of Allele MMatch -.555 .364 2.329 1 .127 .574
WAASD 7.639 3.399 5.050 1 .025 2078.678
Msib or HR-MUD .092 1.890 .002 1 .961 1.096
CR 3.278 2 .194
CR(1) -.943 1.612 .342 1 .559 .390
CR(2) -3.354 1.863 3.242 1 .072 .035
Step 1a
Constant -.049 3.400 .000 1 .989 .952
a. Variable(s) entered on step 1: Allele_MM, WtAvInterSizeDiff, relat, CR. 
Table 5.10 gives WALD values for each variable indicating its influence as a predictor 
variable  for survival within the model. It also estimates the level of significance for each 
value and  gives an indication of changes to the predicted odds [Exp(B)] for survival if there is 
a single unit change any of the predictor variables. Only the WAASD variable significantly 
affects the survival odds.   
Table 5.11 Variables in Cox proportional hazards model and their predictor values. 
Variables in the Equation 
B SE Wald df Sig. Exp(B) 
Allele Mismatch -.346 .220 2.478 1 .115 .707
Related/unrelated -.333 1.345 .061 1 .805 .717
CR(3) 4.612 2 .100
CR(1) -.116 1.327 .008 1 .930 .891
CR(2) -1.816 .861 4.447 1 .035 .163
WAASD 5.525 1.999 7.641 1 .006 250.867
A Cox proportional hazard model was ran as an additional analysis to confirm the results 
yielded in the binary regression model. The Cox proportional hazard model uses the hazard 
function in survival data to calculate values that can be interpreted similarly to the binary 
logistic regression.  Both models yield  slightly differing values but  indicate the same trends.   
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Data was also analysed in a Kaplan Meier estimate of survival. The data was  divided into 
two groups for survival analysis using a WAASD value of 1.8. This value represents the 
mean for all WAASD values plus one standard deviation taken to a single decimal point. The 
two groups are: 
transplant pairs with  WAASD values above 1.8 
transplant pairs with  WAASD values of 1.8 or  below   
A Kaplan Meier survival estimate for these two groups revealed the lower WAASD values 
have significantly better survival rates (Figure 5.12)    
Figure  5.12 Kaplan-Meier survival estimates of two groups with values above or 
below 1.8 WAASD units for all transplants.  
Figure 5.13 depicts the survival of HR-MUD transplants only. As with Figure 5.12,  higher 
WAASD values result in a lower survival rate and the difference in the survival of transplant 
pairs with WAASD values above and below 1.8 still reaches significance even in the absence 
of Msib transplants. 
Log Rank (Mantel - Cox) 
Chi Square = 6.7, p = 0.009
WAASD < 1.8; n = 27; survival = 90% 
WAASD > 1.8; n = 11; survival = 54% 
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Log Rank (Mantel - Cox)
Chi Square = 5.8, p = 0.015
WAASD < 1.8; n = 16; survival = 87%
WAASD >1.8; n = 10; survival = 60%  
Figure  5.13 Kaplan-Meier survival estimates for HR-MUD transplants only for two 
groups greater or less than 1.8  WAASD units            
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5.8 Results   
Table 5.3 shows that there are no allelic size differences detectable between syngeneic 
twins. Tables 5.4  and  5.5 illustrate the differences observed between donor and recipients 
for 15 STR loci in both Msib and HR-MUD transplants. Table 5.6 (A) and (B) tabulates the 
STR size differences observed in numbers of repeat motifs present for each allele. The 
frequency observed for each size difference in the transplant pair is also listed and these 
values are used to calculate the WAASD values. Table 5.7 outlines key variables for the 
transplant pairs studied. These variables are Msib or HR-MUD transplant, the number of STR 
allelic mismatches observed, the WAASD values from each transplant, their status at 24 
months, their survival post transplant in months and their disease state in terms of remission 
at time of transplant.   
Figure 5.7 illustrates the differing spread of WAASD values observed in HR-MUD transplants 
compared to Msib transplants. Figure 5.8 shows with box charts that these values form 
groups of transplant pairs with different means and 95% confidence intervals.  Figures 5.9 
and 5.10 similarly show that if the transplant pairs are grouped as alive or dead,  they form 
two distinct groups. If the patients are further differentiated in terms of cause of death, the 
patients who died due to transplant related mortality form a group distinct from the patients 
alive in terms of variance from their mean WAASD values. There were only 3 patients who 
suffered disease relapse two of whom were Msib transplants and one was a HR-MUD 
transplant.   
This descriptive analysis shows differing groupings, but does not offer information concerning 
the possible influence of co-variables in predicting post transplant survival. To test the 
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influence of the covariates on survival, the data were analysed using three differing statistical 
models: 
Binary logistic regression 
Cox proportional hazards 
Kaplan Meier estimate of survival  
The WALD values for the binary logistic analysis listed in Table 5.10 shows the variable 
WAASD has the greatest effect on transplant survival and is the only variable to reach 
significance. The analysis  shows a significant change in the predicted odds for survival as 
the WAASD values increase. It can be concluded from this that WAASD values have an 
independent prediction value for survival in high resolution HLA matched haematopoietic 
stem cell transplants.  These results are corroborated in the Cox proportional hazards 
analysis (Table 5.11) where the WALD test for influence was slightly higher than found in the 
logistic regression but the change in odds for survival are lower than in the binary regression 
model yet remain highly significant. Both the Cox proportional hazard and binary logistic 
regression models indicate that WAASD values independently and significantly influence 
survival. The Cox proportional hazard model for survival found remission status at time of 
transplant and WAASD values independently influence two year survival.  The WAASD 
values had by far the highest level of influence as determined in the WALD test.   
The Kaplan Meier  estimates for survival shown in Figures 5.12 and 5.13 illustrate a highly 
significant difference in overall survival for transplant pairs with WAASD values above and 
below  a value of 1.8. In Figure 5.12 transplant pairs with WAASD values of 1.8 or below 
have a 90% survival  and those that are above 1.8 have a survival rate of 54% (Log Rank; 
Chi square = 6.7, p = 0.009).  Figure 5.13 shows that this effect is independent of whether 
the donor recipient  pair is an Msib or a HR-MUD transplant as all Msibs are removed from 
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this analysis. HR-MUD transplants with WAASD values below 1.8 have an 87% survival  and 
those that are 1.8 or above have a survival rate of 60% (Log Rank; Chi square = 5.8,  
p = 0.015)   
5.9 Discussion  
The ongoing 16th International Histocompatibility Workshop investigation into influence of 
ethnicity in haematopoietic stem cell transplantation outcomes stimulated the development of 
the concepts in this study. Research into the use of STR allelic size in anthropology, forensic 
science and post transplant chimerism testing led to the question; would multi-chromosomal 
differences in STR profiles not be a better proxy for genomic difference than concepts of 
ethnicity? Concepts of race and ethnicity were reviewed by Foster & Sharpe (Foster & Sharp 
2002) and found to be a flawed methodology for determining genetic difference between 
individuals. This was seen to be particularly important in genetic admixture populations such 
as North American Hispanics (Gonzalez et al. 2005) and African Americans (Zakharia et al. 
2009)   
In Figure 5.6, the stepwise mutation of STRs is illustrated. In this illustration, assuming a 
mutation rate of 0.0005 and a generation to represent 16 years (time to birth of first child for 
females), a time line from Mo to M3 would have spanned 95,000 years of human evolution. 
This would track to before current ethnicities and races emerged. A timeline covering this 
period would include huge population migrations, wars, famine, and the last glacial maximum 
during which six alleles were added for this single STR constellation. At time M0 in Figure 5.6 
the United Kingdom was still attached to mainland Europe with no sea divide.  The timeline 
would cover the evolutionary emergence of blue eyes, blond hair, red hair, changes in skin 
pigmentation, the epicanthal fold in eyelids and all other phenotypes associated with race 
and ethnicity. The study assumes that STR allele length differences may act as a marker for 
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the co-evolution of a multitude of other mutations seen in human proteins that are not visible 
traits. The study used fifteen STR loci located upon differing chromosomes, each having a 
differing mutation rate and each locus with more than ten alleles identified per STR 
constellation making them highly informative for this study.   
In a publication on developing genomic and proteomic analysis for use in haematopoietic 
stem cell transplantation, Prof. John Hansen (Hansen 2009) states Despite complete 
matching for all variation spanning 4Mb of DNA across the MHC, acute GvHD and transplant 
related mortality (TRM) occurs in a significant number of HLA identical donor transplants. 
Hansen goes on to review genetic polymorphism in other genes reported to be associated 
with stem cell transplant outcomes (IL2A, IL1B,IL 1RN, IL6, IL10, INFG, TGFB, TNF, CTLA4, 
ESR1, IL2, IL7, IL8, IL 10RB, IL18,NOD2 and VDR). He states that the results of these single 
centre studies have not been independently validated by others in separate patient 
populations and that the original results lack statistical power due to the small number of 
cases. Other workers have similarly extensively reviewed many of the factors reviewed by 
Hansen but also included known minor histocompatibility factors such as HA-1, CD31 and 
NK cell reactivity and the KIR gene locus and ligands (Mullighan & Bardy 2007). Mulligan and 
Brady suggest that none of these non-HLA markers are ready for routine use as clinical tools 
without further studies to address their limitations. They further state that studies of these 
factors have failed to produce a clinically useful model for risk and the published studies have 
at times been conflicting. Mulligan and Brady also state that it is conceptually attractive to 
have a single genetic variant assist in clinical decision making in the HLA matched stem cell 
transplant setting, but that this is likely to be over simplistic. They state that what is required 
is a risk index of clinical and genetic variables that distinguishes between multiple potential 
donors for patients, highlighting potential transplant pairs at highest risk of complications. In 
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this study WAASD values offer a possible index able to assess multiple genetic differences 
between donor and recipient coming from differing ancestries.   
5.10 Reflection on usefulness of  results  
The study postulates that a multiplicity of genetic differences in non-HLA genes are a 
significant cause of post transplant related complications in HR-HLA matched transplant 
pairs. Using WAASD values as predictors for two year transplant survival in the small cohort 
of patients that form this study yielded highly significant statistical values when modelling 
transplant survival. This work could be ultimately be used to develop a simple clinical tool for 
the selection of related and unrelated HR-HLA matched stem cell donors. It offers the 
possibility of minimising risks of transplant complications by possibly reducing the multiple 
genetic differences existing between non-syngeneic donors and recipients.   
An additional advantage of using STR markers is that transplant centres already use STR 
profiles as markers for post transplant monitoring of chimerism and have access to the 
required expertise and equipment for this test. STR profiling pre-transplant DNA for final 
donor and recipient is already a routine part of most haematopoietic stem cell transplant 
programmes. Additional costs to a transplant programme will therefore be minimal. The 
process would  require the profiling of both the donor and recipient at the donor selection 
stage in the transplant. The data collected could then be used to calculate WAASD values. 
This offers a simple and inexpensive index for non-HLA genetic divergence between donor 
and recipient. The difference in WAASD values seen between Msib transplant pairs and HR-
MUD transplant pairs (Table 5.6, Figure 5.8) and the extensive use of these values in 
anthropological studies indicates that its use as an index for genetic variation is a robust 
possibility. The use of WAASD values as a tool has the added advantage of using existing 
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staff, equipment and laboratory reagents. This study needs to be expanded to greatly 
increase the sample size prior to further dissemination of thesis.                                                   
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Chapter Six   
6 Reflection on educational experience 
Prior to commencing the professional doctorate (PD), it never occurred to me that I would 
benefit from reflecting over my past learning experiences. Schon (1987) points out that to 
not reflect upon past learning was an unprofessional characteristic as technical rationality  
would not be gained from past experiences. In my reflective practice I am able to see that I 
had permitted historic experiences become barriers to professional development. My 
attitude to academic compromise prior to commencing the course was to block it from the 
view of others and bury it in my memory. I have reflected on how my view of academic 
learning became so narrow. As a dyslexic student, I conclude that early negative and 
unpleasant experiences as a child in an era where dyslexia was not recognised as a  
learning barrier, blocked my ability to rationalise and learn from academic experience. This 
barrier was a blight to my traditional learning through school followed by university. In 
moving into the world of work I found that I was able hide my weakness from others through 
a barrage of tactics As part of my professional doctorate I have reflected extensively on how 
this has affected me.   
Claxton G. (2003) states that more than we might think our minds are constituted out of the 
habits and values that permeate our social milieu . He explains that teachers transmit 
values to children not by what they say to them explicitly, but by how they act and talk 
around them. My early educational humiliations left me unable to think rationally about my 
strengths and weaknesses in learning. The journalist Jullie Burchall broadcast to the nation 
dyslexic is just another name for stupid (BBC radio 4, Today Programme, 26/5/07). This  
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statement by a prominent journalist and writer encapsulates everything about my early 
educational experience and the prejudice I faced as a child, adolescent and young adult.         
Concrete experiences: 
(Reinforcement of feelings of 
embarrassment and failure)     
Repeatedly being classed                  Observed that strengths 
with poor performers                           were not recognised by  
because of a narrow view of    teachers.  
educational achievement.                
Formed low expectations of self. 
(This carried into university 
education and adulthood. 
         Developed strategies to hide  
weaknesses wherever possible.) 
Figure 6.1 Kolb s learning cycle representing my early learning experiences as a 
dyslexic pupil in the 1960s and 1970s. (adapted from  Boud D. 1985) 
Boud D., K. R. &. W. D. 1985, "Promoting Reflection in Learning: a model.," in 
Reflection: Turning Experience into Learning, 1 edn, Routledge Falmer, London.   
School 
Education  
Experience of a 
dyslexic pupil in 
the 1960s & 
1970s             
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Within education, a revolution in cognitive science has taken place and fewer children have 
to endure these ill informed attitudes. Educators are now probably the most enlightened 
group of professionals when dealing with dyslexics. As part of my PD studies and my 
personal reflection on past learning, I sought help and advice from an educational 
psychologist. I have found the advice and description of my own learning strengths and 
weaknesses invaluable in assisting me gain confidence in my own abilities to complete this 
body of work. It has given me the freedom of thought  that permits me to follow my interest 
in haematopoietic stem cell transplantation without fear of what others think. This is a newly 
found liberty and I can thank the structured learning component of the PD for my 
emancipation.               
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6.1 Reflection upon self confidence   
The confidence to appreciate the contribution one is able to make to a research project and 
interact with health professionals at consultant level has been an important  factor in 
developing the research component of the PD.  The structured Part 1 of the PD has proved 
invaluable in giving me the skills to analyse quantitative and qualitative data and the 
confidence to project my analysis for dissemination to fellow professionals.   
6.2 Reflection on NHS consultant level communication  
Between my fingers and my thumb 
The squat pen rests 
I ll dig with it.          
 Seamus Heaney  
In science and medicine best practice and research output has to find a pathway from one 
interested party to another. In Heaney s poem Digging he discusses the output of his father 
and grandfather in terms of how they expertly wield a shovel in the turf and compares his 
output to theirs through the use of his pen. No one would know about the digging of Heaney s 
father without Heaney s writing. Similarly the best researcher or laboratory practice in the 
world is of very limited benefit if only a few individuals are aware of it.  If it is not projected to 
others through a form of recording, analysing and dissemination, it will be the light that shines 
hidden under a bush. No one will ever know it was there. It is essential to go out and 
convince other professionals of the worthiness of your findings.   
Reflecting upon the skills I obtained from the advanced research technique study module, it 
is clear that knowledge gained assisted me greatly with consultant level communications. 
The first step taken in developing the research component of the PD was to discuss a 
relatively crude statistical analysis on survival rates among paediatric ALL haematopoietic 
stem cell transplant patients (HSCT) with five consultant bone marrow transplant 
haematologists at the Bristol Children s Hospital. I had to convince the consultants that my 
early findings were worthy of their time, co-operation and more extensive access to patient 
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outcome data. The results of  this co-operation between me and the Bristol Children s 
Hospital consultants constitute Chapter 3 of this thesis and a paper is in preparation for 
publication. The data was presented at the British Society for Histocompatibility and 
Immunogenetics annual conference, Edinburgh, 2010 (appendix 3).  Prior to commencing the 
PD, I would have required the assistance of a statistician or another scientist to perform the 
statistical analysis used at every stage of  this study.  
In Chapter 2 the cross-sectional analysis performed, required the co-operation of  consultant 
clinical scientists from twenty one H& I laboratories supporting HSCT in the United Kingdom 
and Ireland. The study was 100% successful in obtaining head of laboratory feedback which 
meant the study was truly representative of current UK and Irish practice in HSCT. The 
qualitative analysis component the PD, Part 1 provided me with the skill set required to 
successfully perform this cross-sectional study of Chapter 2. The cross sectional study was 
presented at the British Society for Histocompatibility and Immunogenetics annual 
conference in Leeds, 2008 and at the American Society for Histocompatibility and 
Immunogenetics in San Francisco, 2009 (Appendix 2)  
6.3 Reflection on the conversion of data to wisdom  
data           information          knowledge            wisdom  
Data is not information, information is not knowledge and knowledge is not wisdom.  
Professor Henry Nix expressed this dictum at a seminar in 1992.  The dictum can be used as 
a framework for the reporting of results as proposed by Evans, D., (1995, p89). In this 
proposal data may be recorded by the researcher or it may be recorded by an 
organisation/person on the premise that it may be useful sometime. Transplant follow-up 
data collected falls into this latter category. In this thesis pre and post stem cell transplant 
data has been taken and analysed to generate information. The information has been 
interpreted to generate added knowledge in the discussion components of Chapters two, 
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three and five of the thesis. Through presentations and publications this knowledge is being 
disseminated to other professionals and if it is adopted as best clinical practice this could be 
a form of wisdom.  
              
Experience               reflective process    Outcome 
Figure 6.2  Model of reflective process for Publication and Dissemination 
Model of the reflective processes involved in preparing articles for publication and 
presentations (adapted from Boud D. 1985).   
-  Decide what 
presentation tool 
is to be used  
publication  
/media/scientific 
journal/presentati
on 
-  Decide target 
audience 
-  Prepare 
document 
/presentation with 
target audience 
in focus
- Present or publish data 
to co-workers / editors 
etc. 
-  Note and discuss 
critical comments 
-  Read critical review of 
work presented if 
available 
-  Reflect on what has 
been criticised  (its not 
personal) 
- Prepare final 
draft  
-Try and view 
document from 
perspective of 
target audience  
- Re-edit and 
present 
Reflect, analyse 
re-write, update 
Develop and 
refine 
document / 
presentation  
Read assignment, read relevant literature and 
prepare presentation/paper etc.  
Figure 6.2  illustrates moving from an idea to developing a manuscript or presentation. The 
model does not map out individual tasks, but illustrates that the process of reflection is 
circular and adaptive. Developing ideas is not simply the thought processes in your head but 
is interactive with the culture around and involves responding to others. Presenting data and 
complex concepts is an important part of any professional s role and is an activity where you 
stand up and are vulnerable to being shot down if your message is poorly researched or 
presented.    
The Guidelines for selection and HLA matching of related donors, adult unrelated donors, 
umbilical cord units for haematopoietic stem cell transplantation  as a model of best practice 
outlined in Chapter 4, was manifest in only 40% of transplants performed in the United 
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Kingdom at the time of the cross-sectional study outlined in Chapter 2. Following the future 
dissemination of the guidelines through the professional bodies represented in the guidelines 
writing workgroup, it is hoped the uptake of its recommendations on best practice will convert 
to 100% throughout the United Kingdom. This would constitute the conversion of data to 
information to knowledge to  wisdom and constitutes the principal professional aim of this 
thesis.  
6.4 Conclusion  
Some experiences in life are truly enhancing. The self confidence I have gained by 
completing the professional doctorate course falls into this category. It is not the qualification 
and professional opportunities it may bring that I value most but the deeper understanding of 
my own learning needs and weaknesses that I have gained by using the reflective practice 
the PD demands. It has assisted me gain the confidence to take yet further professional 
qualifications and lift my career aspirations from being content to work as a principal clinical 
scientist and aspire to obtain consultant clinical scientist status; a position I had always 
considered out of my reach. 
If  I couple my improved self awareness, to the research work presented from Chapters two 
to five; it is my hope that this thesis may play a small part in improving haematopoietic 
transplant outcomes for the vulnerable patients placed by circumstance and disease, into the 
care of the professional team of which I am proud to be part.         
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7 Appendices 
7.1 Appendix 1   
The EuroChimerism concept for a standardized approach to chimerism 
analysis after allogeneic stem cell transplantation   
T.Lion., F.Watzinger, S. Preuner, H. Kreyenberg, M.Tilanus, R. de Weger, J van Loon, L. de Vries, 
H.Cavé, C.Acquaviva, M.Lawler, M.Crampe, A.Serra, B. Saglio, F.Colnaghi, A.Biondi, J.van Dongen, 
M. van der Burg, M.Gonzalez, M. Alcoceba, G.Barbany, M.Hermanson, E.Roosnek, C.Steward, 
J.Harvey, F.Frommlet, P.Bader  
Abstract   
Hematopoietic stem cell transplantation is becoming an increasingly important approach to treatment 
of different malignant and non-malignant disorders. There is therefore growing demand for diagnostic 
assays permitting the surveillance of donor/recipient chimerism post transplant. Current techniques 
are heterogeneous, rendering uniform evaluation and comparison of diagnostic results between 
centers difficult. Leading laboratories from ten European countries have therefore performed a 
collaborative study supported by a European grant, the EuroChimerism Concerted Action, with the 
aim to develop a standardized diagnostic methodology for the detection and monitoring of chimerism 
in patients undergoing allogeneic stem cell transplantation. Following extensive analysis of a large set 
of microsatellite/short tandem repeat (STR) loci, the EuroChimerism (EUC) panel comprising 13 STR 
markers was established with the aim to optimally meet the specific requirements of quantitative 
chimerism analysis. Based on highly stringent selection criteria, the EUC panel provides multiple 
informative markers in any transplant setting. The standardized STR-PCR tests permit detection of 
donor- or recipient-derived cells at a sensitivity ranging between 0.8-1.6%. Moreover, the 
EuroChimerism assay facilitates accurate and reproducible quantification of donor and recipient 
hematopoietic cells. Wide use of the European-harmonized protocol for chimerism analysis presented 
will provide a basis for optimal diagnostic support and timely treatment decisions.   
Paper submitted to the journal Leukaemia for publication April 2011; Journal Impact Factor 9      
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7.2 Appendix 2                                                    
Survey of Human Leukocyte Antigen matching criteria used in donor 
selection for haematopoietic stem cell transplantation in the United 
Kingdom and Ireland.  
Harvey, John and Green, Ann F.  
Histocompatibility and Immunogenetics Department, NHSBT, Bristol, Filton, United Kingdom, BS34 7QH 
Method
In 2003 and 2008 the National Marrow Donor Program (NMDP, USA) issued HLA matching guidelines for matched unrelated donor (MUD) stem cell transplants. In the latest NMDP 
guidelines, it is recommended that patients and donors are matched at the allelic level for four HLA loci HLA-A, HLA-B, HLA-C and DRB1. However the existing WMDA guidelines on 
stem cell transplantation only recommend that patients and donors be phenotypically identical . Our aim is to investigate the variability in current HLA match selection practice for 
unrelated stem cell donor transplantation in the United Kingdom and Republic of Ireland. 
Discussion
The Results
Introduction
We have issued a survey questionnaire to all Histocompatibility and Immunogenetics Laboratories (n=25) listed on the British Society for Histocompatibility and Immunogenetics WEB 
pages (http://www.bshi.org.uk/). The questionnaire is designed to extract HLA match criteria details used for unrelated stem cell final donor selection in each of the transplant centres 
served by the H & I laboratory. Replies were received from all laboratories approached representing an approximate  total of 1164 allogeneic stem cell transplants performed in the UK 
and Ireland in 2008. This compares with the published UK and Ireland activity for 2007 of 1067 allogeneic stem cell transplants (Gratwohl et. al.,  2007, 2009) and gives the authors 
confidence that the returned questionnaires reflect current practice. 
Evidence for significantly improved transplant outcome in MUD transplants by allelic matching 
for HLA between patient and donor is strengthening (Flomenberg et al. 2004;Lee et al. 
2007;Petersdorf et al. 2004;Petersdorf et al. 2007). These contemporary studies have involved 
retrospective HLA high resolution typing of patient/donor pairs analysing transplant data for 
matched and mismatched transplants. Other studies have used an algorithm to define donor 
recipient pairs as well matched for HLA typing and again was applied to retrospectively 
analyse donor outcome (Macmillan et al. 2008). Recent research in this field has mostly been 
multicentre studies reviewing transplant outcomes from up to 110 transplant centres in the USA. 
From these and earlier studies, the National Marrow Donor Program [NMDP] has issued HLA 
matching guidelines of best practice for unrelated stem cell transplants (Bray et al. 2008;Hurley 
et al. 2003)  
Figure 1. across, depicts an epoch dependant significant improvement in overall leukaemia free 
survival in patients suffering from acute leukaemia treated with matched unrelated donor 
transplants. This improvement correlates with improved HLA typing methods, registry panel size 
and better quality matching. 
Table 1. Seven of the twenty five laboratories surveyed reported no involvement in stem cell transplantation. One 
laboratory provided services for adult sibling transplants only, four laboratories provided services for adult 
transplants only and thirteen provided services for adult and paediatric transplants. 
Figure 1.  2 year survival in paediatric ALL and AML UD 
transplants for differing epochs at multiple transplant 
centres (n=102)
MacMillan et al.,  NMDP data  2008 
 p<0.001  
1 laboratory provides 
service to  adult 
sibling stem cell 
transplant program 
only 
13 laboratories 
provide service to  
both adult and 
paediatric stem 
cell transplant 
program  
4 laboratories 
provide service  to 
adult stem cell 
transplant 
program only 
7 laboratories 
provide no support 
for stem cell 
transplants  
The number of laboratories providing stem cell HLA typing services in the UK and Ireland 
Table 1. Laboratory Service Provision: Table 2. HLA typing for sibling 
transplants: 
2 laboratories 
provide only low 
to medium 
resolution HLA 
typing for sibling 
transplants 
7 laboratories allelic 
type at HLA class II 
and low to medium 
resolution type at 
class I but do not 
establish haplotypes 
9 laboratories 
routinely allelic HLA 
type sibling pair 
where parental 
haplotypes cannot be 
established 
9 laboratories 
routinely establish 
parental haplotypes 
for sibling transplant 
HLA typing of patient and sibling donors 
Table 2. Nine laboratories routinely established parental haplotypes in siblings prior to transplant. Where establishment of 
haplotypes was not possible, nine laboratories typed the siblings to the allelic level to confirm compatibility. A further seven 
laboratories high resolution typed  for class II  but not class I. Two laboratories provided only low to medium resolution typing at 
both class I and class II for sibling transplants. 
Table 3. Unrelated donor searches:   
(DQB1)>(C)>(A) (DQB1)>(A) then no 
preference
(DQB1)>(A)> 
(DRB3,4,5)
(DQB1)>(A)> 
(B)
(DPB1)>(DRB3,4,5)>(C) (DPB1)>(DQB1)>(DRB1
)
(C)>DQB1)> 
(DRB1)
(C)>(A)>(DRB1) (C)>(A)>(B) (A)>(C) 
>(DQB1)
(A)>(B) 
>(DQB1)
(DPB1,DRB3, 
4,5)>(DQB1)>(C)
(C,DRB3,4,5,DQB1,DPB
1)>(A)>(B,DRB1)
f.) 13 differing preferred mismatch criteria were reported from 17 laboratories  where fully matched donor cannot be found 
 They are listed below as (first preference) > (second preference) > (third preference)
7 laboratories - reported requiring allelic matching at class II but low to medium resolution matching at class I 10 laboratories - reported requiring allelic matches at HLA class I and II (some variation 
with HLA-DQB1 and DPB1 matching)
e.) Patient and final donor match criteria
2 laboratories - Transplant consultant without input from the HLA laboratory choose the final donor. 15 laboratories - Transplant consultant with the HLA laboratory  advice, jointly choose the final 
donor.
d.) Who chooses the final donor for the transplant?
3 laboratories < 8 donors/patient4 laboratories < 6 donors/patient10 laboratories  < 4 donors/patient
c.) Number of donors routinely called in per patient for CT sample following first search
2 laboratories - Registry selects the donors for CT sample 4 laboratories - Transplant consultant selects the donors for CT 
sample
11 laboratories - HLA laboratory selects the matched donors for 
CT sample
b.) Who selects matched donors requested  for confirmatory HLA typing (CT sample)?
5 laboratories low resolution type patient  at HLA class I and II 
prior to running a search
7 laboratories allelic type at HLA class II but low to medium resolution 
type at class I prior to running a search
5 laboratories  allelic type patient at HLA class I and II  
prior to running a search
a.) Patient HLA typing prior to donor search
Table 3. - Unrelated Donor Transplants: Five laboratories allelic type their patient at HLA class I and II prior to performing a donor search;  eight allelic type at class II but medium to low resolution type at class I and 
five perform only low resolution typing prior to performing a donor search. Searches: Twelve laboratories select donors for confirmatory typing on the basis of their HLA match grade. In four centres it is the transplant 
consultant or the local transplant team that chose the donors for confirmatory typing. In two instances it was the registry that selected the donors. Donors selected: Ten laboratories routinely call in < four donors at a 
time for confirmatory typing per patient, four laboratories call < six donors and three laboratories call < eight donors at a time. Upon receipt of confirmatory sample one laboratory routinely performs allelic typing upon  
the samples, nine perform allelic class II typing but medium resolution class I and seven laboratories perform only low resolution typing on receipt of confirmatory samples. Final Donor: In fifteen laboratories the 
selection of the final donor from the search is made jointly between the H & I Laboratory and the transplant team however for two laboratories the selection is made by the transplant centre without advice from the H & 
I laboratory.  Final Donor HLA typing: Patient and final donor are typed to the allelic level for HLA- A, B, C, and DRB1 by eleven laboratories, seven of these laboratories also type and match for HLA-DQB1 and two 
of them also include DPB1. Six laboratories type to the allelic level for class II but low to medium resolution type at class I; one of these laboratories will high resolution type the donor at class I if the donor comes from 
the NMDP registry but not for other donors. Final Donor Match criteria: Nine laboratories report requiring allelic matches at HLA A,B,C, and DRB1 of which eight also match at DQB1 and two at DPB1. One 
laboratory requires allelic matches at HLA- A,B and DRB1 while seven laboratories require allelic match at HLA-DRB1and DQB1 four of which include DPB1 with low to medium resolution required at class I loci. 
Acceptable mismatches: The reported acceptable mismatch criteria used to select a donor  where a fully matched donor was not available was a  kaleidoscope of varying practice throughout the UK and Ireland. 
Seventeen laboratories reported thirteen differing criteria for donor selection. 
References: 
It is clear from this survey that a significant cohort of transplant centres have yet to adopt the recommendations issued by the NMDP (2008) for MUD HLA matching (see Table 3. a., 3.e. 
and 3.f.). Also some transplant centres do not directly consult their HLA laboratory for the selection of the potential best matched donors for stem cell transplantation (see Table 3.b. and 
3.d.).  
Currently 10 laboratories in the UK and 1in the Republic of Ireland are compliant with the  NMDP recommendations. From the returns detailing transplant activity, approximately 40% of 
transplants performed in the UK and Ireland apply allelic level matching criteria for final donor selection. From the data presented by MacMillan et. al. (see figure 1) this can result in up to 
a 20% improvement in overall disease free survival in patients. The authors conclude that the profile and role of allelic matching within the U.K. stem cell transplant community and its 
impact on transplant outcomes needs greater emphasis and publicity.  
Petersdorf, E. W. 2004, "HLA matching in allogeneic stem cell transplantation", Curr.Opin.Hematol., vol. 11, no. 6, pp. 386-391. 
Flomenberg, N.,  , et al., 2004, "Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome", Blood, vol. 104, no. 
7, pp. 1923-1930. 
Lee, S. J., et al., 2007, "High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation", Blood, vol. 110, no. 13, pp. 4576-4583. 
Macmillan, M. L., et al.,  2008, "Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program", Biol.Blood Marrow Transplant., vol. 14, no. 9 Suppl, pp. 16-22. 
Bray, R. A., et al.,2008, "National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants", Biol.Blood Marrow Transplant., vol. 14, no. 9 Suppl, pp. 45-53. 
Gratwohl, A., et al.,  2008, "Why are there regional differences in stem cell transplantation activity? An EBMT analysis", Bone Marrow Transplant., vol. 42 Suppl 1, p. S7-S10.  
The authors thank all who filled and returned the survey questionnaire, space prevents us from offering individual recognition to all who assisted. 
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7.3 Appendix 3  
Prospective unrelated donor matching for HLA A, B, C, DRB1 and DQB1 at the allelic level 
correlates with a greater than 20% improved leukemic free survival in stem cell transplantation 
for paediatric ALL.  
John Harvey1, John Moppet2, Jacqueline Cornish2, Colin Steward2, Michelle Cummings2, Leigh Keen1, Steven Culliford1, 
Anthony Poles1, Patricia Breslin2, Ying Li1, Ann Green1. 
1 NHS Blood and Transplant, 500 North Bristol Park, Filton, Bristol, BS34 7QH 
2 Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol BS2 8BJ   
Abstract  
The overall effect of prospective allelic matching for human Leucocyte antigens (HLA) upon 
an active stem cell transplant program remains unknown. In contrast to published 
retrospective studies, the Bristol Royal Hospital for Children started prospectively selecting 
haematopoietic stem cell donors for transplantation on the basis of HLA allelic matching with 
recipients in January 2002. We present the first detailed study analysing leukemic free 
survival (LFS) in paediatric ALL where HLA allelic matching of donor and recipient was 
performed prior to transplant.  
Data
The data is from an established transplant centre and is for a well defined cohort of patients. 
A total of 356 paediatric ALL stem cell transplants performed between 1988 and 2007 were 
reviewed. Comparisons were made of transplant outcomes before and after the introduction 
of HLA allelic matching. Changes in treatment and epoch dependent improvements in 
outcome were reviewed for possible confounders to the influence of allelic typing using single 
and multivariate analysis. 
Conclusion
LFS in unrelated donor paediatric ALL transplants improves significantly when prospective 
allelic matching for HLA is performed. The study indicates that matching at the allelic level for 
HLA-A,B,C and DRB1 correlates with a >20% improvement in overall LFS (p<0.001). The 
study findings are in agreement with earlier reports which looked at retrospective HLA allelic 
matching.    
This data was presented at the BSHI 2010 annual conference in Edinburgh and is in preparation 
for publication       
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7.4 Appendix 4 Clinical notes for scientists.  
7.4.1 Adult Lymphoma 
Introduction 
Lymphoma represents a heterogeneous group of malignant disorders of the lymphoid 
system that may be broadly classified into two major groups: non-Hodgkin s 
lymphoma and Hodgkin s lymphoma. Non-Hodgkin s lymphoma may be further 
classified into more than 40 different clinicopathological entities that differ in their 
histological features and clinical behaviour. Non-Hodgkin s lymphoma may also be 
broadly divided into aggressive (high grade) or indolent (low grade) disease 
according to the clinical behaviour of the disease. In contrast Hodgkin s lymphoma 
consists of a classic form and the newly identified nodular lymphocyte predominant 
form. The sub-type of lymphoma is the principal determinant of the choice of therapy 
although treatment may be subsequently adapted according to the patient s 
individual disease characteristics and performance status. Malignant lymphoma 
typically presents as progressive enlargement of lymph nodes and may be 
accompanied by systemic symptoms of weight loss and drenching sweats. There 
may in addition be evidence of bone marrow failure and other organ dysfunction. 
Patients presenting with suspected lymphoma will be managed by a haemato-
oncology team. The diagnostic assessment requires a full medical assessment 
combined with CT scanning of the chest, abdomen and pelvis, bone marrow 
morphology assessment and lymph node biopsy to confirm the diagnosis. 
Therapies 
The treatment of lymphoma is complex with a wide variety of treatment options 
available ranging from expectant management (observation only) through to 
allogeneic stem cell transplantation. The majority of patients with lymphoma may be 
cured with conventional dose chemotherapy and radiotherapy and therefore are not 
candidates for stem cell transplant strategies. High dose therapy and stem cell 
transplantation is generally reserved for patients who are refractory to or relapse after 
first line therapy. Autologous stem cell transplantation has become established as the 
treatment of choice in patients with relapsed high grade non-Hodgkin and Hodgkin s 
lymphoma and may also used in patients with relapsed low grade non-Hodgkin s 
lymphoma. The role of allogeneic stem cell transplantation in the management of 
malignant lymphoma is more complex and requires evaluation of the individual 
patient, their disease characteristics and the allogeneic donor options in a tertiary 
referral centre. The British Society of Bone Marrow Transplantation and the EBMT 
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have both produced indications for stem cell transplantation in malignant lymphoma 
(see below). However the decision to proceed to allogeneic stem cell transplantation 
is taken on an individual case basis.  
Current HSCT  practice  
The urgency of an allogeneic stem cell transplant for lymphoma is also dependent on 
the individual case and it is recommended that H&I laboratories liaise directly with 
transplant physicians regarding the timing of a proposed transplant. Both sibling and 
matched volunteer unrelated donor (VUD) transplants may be considered for 
transplantation in most types of lymphoma. The role of mismatched VUD and cord 
blood transplants in lymphoma are less well established but may be required in 
certain circumstances as advised by the referring transplant physician. 
Donor selection in Hodgkin Disease:  
BSBMT Indications for BMT 
http://www.bsbmt.org/pages/64-Indications_Table  
National Protocols, e.g. UKALL (N) :  
Clinical advice for HLA laboratories: It is important to check with the transplant unit 
that they are prepared to consider a MUD donor and find out the likely time before 
HSCT is likely. 
Evidence based studies or reviews, indicative of optimal regime: 
(Peggs et al. 2005;Schmitz et al. 2002;Sureda et al. 2008) 
Donor selection in Mantle Cell Lymphoma:  
BSBMT Indications for BMT 
http://www.bsbmt.org/pages/64-Indications_Table  
Evidence based studies or reviews, indicative of optimal regime: 
(Dreyling et al. 2005;Faulkner et al. 2004;Khouri et al. 2003;Maris et al. 
2004;Robinson et al. 2002) 
 
Donor selection in Follicular Lymphoma:  
BSBMT Indications for BMT 
http://www.bsbmt.org/pages/64-Indications_Table 
Evidence based studies or reviews, indicative of optimal regime: 
(Faulkneret al.  2004;Lenz et al. 2004;Morris et al. 2004;Robinson, Goldstone, 
Mackinnon, Carella, Russell, de Elvira, Taghipour, & Schmitz 2002;Schouten et 
al. 2003;van Besien et al. 1998b;van Besien et al. 1998a) 
Donor selection in Diffuse Large B-cell Lymphoma (DLBCL):  
BSBMT Indications for BMT 
http://www.bsbmt.org/pages/64-Indications_Table 
Evidence based studies or reviews, indicative of optimal regime: 
(Bierman et al. 2003;Morris et al. 2004) 
Donor selection in Peripheral T cell Lymphoma:  
BSBMT Indications for BMT 
http://www.bsbmt.org/pages/64-Indications_Table 
Evidence based studies or reviews, indicative of optimal regime: 
(Corradini et al. 2004a;Corradini et al. 2004b;Wulf et al. 2005) 
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7.4.2 Adult Multiple Myeloma  
Introduction 
Multiple myeloma (MM) is a malignant disorder of plasma cells characterised by the 
progressive accumulation of malignant plasma cells in the bone marrow leading to 
progressive bone marrow failure. The malignant plasma cells typically produce a 
monoclonal antibody that may be detected in the blood as a paraprotein and which 
may lead to increases in the plasma viscosity and the syndrome of hyperviscosity. 
The malignant infiltrate is also responsible for profound changes in bone metabolism 
leading to thinning of the bones and the development of pathological fractures. Renal 
failure is also a common complication of MM which may require renal replacement 
therapy and compromise the delivery of effective therapy. Deposits of malignant 
plasma cells (plasmacytomas) outside of the bone marrow cavity may occur leading 
to localised tissue destruction and symptoms. MM is uncommon in patients under the 
age of 40 but shows a steady increase in incidence after the fifth decade. The 
diagnosis of MM is dependent on the demonstration of monoclonal plasma cells 
in the bone marrow and the presence of a paraprotein either in the blood or urine. 
Uncommonly the malignant plasma cells may not produce a paraprotein a 
conditioned referred to as non-secretory myeloma. The prognosis of MM has 
traditionally been reported as a median survival from disgnosis of 3-5 years. 
However, the development of new treatments (see below) in recent years  may have 
improved this prognosis. 
Therapies 
The treatment of multiple myeloma is complex and has evolved rapidly in recent 
years with the introduction of novel agents such as thalidomide and bortezomib. 
Patients with asymptomatic myeloma may not require any immediate therapy and 
can be closely observed in the outpatient setting. However the majority of patients 
will require therapy, the choice of which will depend on whether the patient is a 
candidate for high dose chemotherapy (HDT). Younger patients deemed to be fit 
enough for HDT receive induction combination chemotherapy typically with 
cyclophosphamide, thalidomide and dexamethasone. Once an adequate disease 
response is achieved autologous peripheral blood stems are harvested and then the 
patient will proceed to high dose melphalan followed by an autologous stem cell 
transplant. However this treatment approach is not considered as curative and most 
patients will ultimately relapse and require second line therapy. The choice of second 
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line therapy is again complex and will depend upon the duration of the patients first 
response, their performance status and whether a second autologous stem cell 
transplant is possible.  
Current HSCT  practice  
Allogeneic stem cell transplantation is only considered in a minority of younger 
patients where a matched sibling or volunteer unrelated donor is available. However, 
allogeneic stem cell transplantation for MM has been associated with significant 
toxicity and consequently is infrequently used. 
Donor selection in Multiple Myeloma 
BSBMT Indications for BMT 
http://www.bsbmt.org/pages/64-Indications_Table 
Clinical advice for HLA laboratories: Allogeneic stem cell transplantation is only 
considered in a minority of younger patients where a matched sibling or volunteer 
unrelated donor is available. Suitability for myeloblative versus reduced intensity is 
based on biological suitability (age, co morbidity, advanced disease stage etc.) 
Evidence based studies or reviews, indicative of optimal regime: 
(Alvares et al. 2006;Efebera et al. 2010;Gahrton et al. 2007;Kroger et al. 
2010;Levenga et al. 2010;Perfetti et al. 2006;Rotta et al. 2009) 
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7.4.3 Acute Lymphoblastic Leukaemia (ALL) in Adults 
Introduction 
Acute leukemia involves the uncontrolled proliferation of immature malignant cells 
(blasts) in the hematopoietic cell lineages. Leukaemia develops when the regulatory 
controls of cellular development fail. Acute leukemia evolves rapidly (in weeks) with 
the early appearance of symptoms. In cases of ALL the cells of the lymphocyte cell 
lineage (lymphoblasts) multiply uncontrollably. The uncontrolled multiplication of 
lymphoblasts results in imbalances with the other cells of the hematopoietic system 
and leads to hemorrhage, anemia and recurrent infections. Lymphoblasts infiltrate 
other organs altering their function and size; this is particularly seen with lymph 
nodes, spleen and liver. 
ALL can be grouped into:  
Pre (precursor) B cell ALL is the most common type in adults, with 7 out of 10 cases  
Mature B cell ALL - this type is identified by particular genetic changes  
Pre (precursor) T cell ALL is more likely to affect young adults and is more common in          
males 
Therapies 
The use of HSCT as a therapy has gained an increasing role in the treatment of adult 
ALL. However, the advantages (short duration of treatment, improved LFS in some 
trials) must be balanced against mortality, morbidity and complications of HSCT 
compared with alternate chemotherapy regimes. Long term survival for adults with 
ALL is currently about 40% and death is mostly due to high relapse rates. For a 
favourable outcome, clinical remission (CR) must be achieved following induction 
therapy. Determining the optimal post-remission therapy while the patient is in CR1 
offers the best opportunity for LFS in ALL. The optimal strategies remain undefined, 
with the following clinical options available: Alternative donor transplantation has an 
increasing role in the management of adult ALL.  
prolonged intensification consolidation and maintenance chemotherapy  
allogeneic HSCT 
There is no routine indication for autografting in CR1 ALL 
Current HSCT  practice for Adult ALL 
The British Society for Blood and Marrow Transplantation (BSBMT) publishes reports 
reflecting the prevailing clinical practice at the time of publication for the treatment of 
hematological diseases by HSCT.  
 
Donor selection in Adult  ALL: 
BSBMT Indications for BMT 
http://www.bsbmt.org/pages/64-Indications_Table 
Clinical advice for HLA laboratories: If the patient has no HLA matched sibling 
donor it is likely that an HLA high resolution matched unrelated donor will be first 
choice of treatment. The chances of finding this donor should be assessed as a 
matter of urgency using the tools previously described. 
Evidence based studies or reviews, indicative of optimal regime: 
(Bachanova & Weisdorf 2008;Fielding et al. 2007;Goldstone et al. 2008;Hahn et 
al. 2006a;Hahn et al. 2006b;Rowe & Goldstone 2007) 
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7.4.4 Acute Myeloblastic Leukaemia (AML)  and Acute Promyelocytic 
Leukemia (APL) in Adults 
Introduction 
Acute leukemia involves the uncontrolled proliferation of immature malignant cells 
(blasts) in the hematopoietic cell lineages. AML is responsible for approximately 80% 
of adult leukaemias and the median age of onset is 60-65 years of age. There are 
various sub-types of AML, depending on exactly what cell type becomes cancerous 
and at what stage in the maturing process. There are eight main sub-types M0, M1, 
M2, to M7. They also have other descriptive names such as acute myelomonocytic 
leukaemia (M4) or acute myeloid leukaemia (MO). The WHO nomenclature classifies 
AML into three main prognostic groups Good, Standard (Intermediary) and Poor 
risk groups. The therapy offered must take into account the risk group of the patient. 
Molecular studies are able to identify risk groups in AML however not all AML have 
molecular markers however  knowing if the patient is  PCR+ or PCR- is a useful 
indicator of likely relapse. 
Therapies 
AML is treated with chemotherapy to induce remission followed by a post induction 
phase to eliminate residual disease. Stem cell transplantation probably remains the 
best option for patients with standard or poor risk AML. Reduced intensity 
conditioning is an accepted treatment modality 
Patients who have a type of AML called acute promyelocytic leukaemia (APL) are 
usually treated with ATRA (All Trans-Retinoic Acid). 
Current HSCT  practice for Adult AML 
Autologous and allogeneic transplants are used in treatment of AML depending upon 
various risk factors (see Table on donor selection). 
 Donor selection in Adult AML :
 
BSBMT Indications for BMT 
http://www.bsbmt.org/pages/64-Indications_Table 
Clinical advice for HLA laboratories:  
The HLA laboratory should be aware of the disease risk of newly diagnosed AML  
patients and a donor search performed. 
Evidence based studies or reviews, indicative of optimal regime: 
(Cook et al. 2006;de Botton et al. 2005;Fung et al. 2003b;Fung et al. 
2003a;Kamimura et al. 2010;Moore, Nivison-Smith, Goh, Ma, Bradstock, Szer, 
Durrant, Schwarer, Bardy, Herrmann, & Dodds 2007) 
 7.4.5 Adult Chronic Myeloid Leukaemia 
Introduction 
CML is a rare disease where 90% of individuals have the Philadelphia chromosomal 
abnormality t(9;22) creating the BCR-ABL fusion gene and the production of 
deregulated tyrosine kinase.  
HSCT remains the only curative treatment for CML and with patients for whom 
chemotherapy fails it is an option where risk factors to the patient such as  donor 
type, disease stage, age of recipient, gender of donor and recipient and time from 
diagnosis to HSCT must be considered. Patients with post transplant relapse are 
supported with donor lymphocyte infusions to establish a GvL effect (has risk of 
severe GvHD). 
Therapies 
The introduction of Iminitab as a tyrosine kinase inhibitor (TKI) has become the first 
line long term treatment of choice for most patients. Second generation TKI s have 
been developed such that the majority of mutated kinases can be inhibited. In 
patients intolerant of TKI s or patients who lose there response to TKI treatment, 
stem cell transplantation remains a second line option with donor lymphocyte 
infusions the treatment of choice for patients who relapse after stem cell transplants. 
Current HSCT  practice for Adult CML 
In patients intolerant of TKI s or patients who lose there response to TKI treatment, 
stem cell transplantation remains a second line option with donor lymphocyte 
infusions the treatment of choice for patients who relapse after stem cell transplants. 
Donor selection in Adult CML:  
BSBMT Indications for BMT 
http://www.bsbmt.org/pages/64-Indications_Table 
Clinical advice for HLA laboratories 
As soon as the physician indicates the patient is being considered a for stem cell 
transplant a donor search should be performed. 
Evidence based studies or reviews, indicative of optimal regime:  (Baccarani et 
al. 2006;Cortes et al. 2007;Crawley et al. 2005;Hughes et al. 2006;Kebriaei et al. 
2007;Milojkovic & Apperley 2008) 
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7.4.6 Adult Chronic Lymphocytic Leukaemia 
Introduction 
CLL is more common in older men than women with an average age of 70yrs. It  
ussually develops very slowly. CLL causes a slow increase in the number of  B 
lymphocytes seen in the bone marrow. These cells migrate from the bone marrow via 
the blood and affect the lymph nodes and other organs such as the spleen and liver. 
With time CLL causes the bone marrow failure, resulting in low blood counts 
weakening the immune system. For most patients with early stage CLL, no treatment 
is started. However, the patient must be closely followed by their doctor. 
If chromosome tests indicate a more high risk type of leukemia, treatment may be 
started earlier. 
Therapies 
The following chemotherapy s are commonly used to treat CLL: 
Fludarabine, chlorambucil, cyclophosphamide (Cytoxan), and rituximab (Rituxan) 
may be used alone or in combination. Alemtuzumab (Campath) is approved for 
treatment of patients with CLL that have not responded to fludarabine. Bendamustine 
is a newer drug recently approved for use in patients with CLL that has come back 
after initial treatment. Stem cell transplantation may be used in younger patients with 
advanced CLL. Right now, transplant is the only therapy that offers a potential cure 
for CLL. 
Current HSCT  practice for Adult CLL 
Offers only long-term cure for CLL, offered to suitable patients with poor risk 
prognosis. For most CLL patients reduced intensity conditioning (RIC) is 
recommended but for some patients <45years with high risk disease standard 
conditioning may be preferred as an option. Very high risk CLL (>20% cells with del. 
17p or purine analogue refractoriness) should be treated with p53 independent 
therapy and then stem cell transplant with an allograft in CR1. High risk CLL is 
defined by EBMT criteria as relapse within 6 months of PA therapy or within 2 years 
of intensive therapy. Other indications  are patients in >CR2 in subsequent relapse 
with one other adverse feature such as marrow failure, unmutated Vh genes, 
ZAP70+, CD38+, Del 11q or trisomy12. 
 Donor selection in Adult CLL:  
BSBMT Indications for BMT 
http://www.bsbmt.org/pages/64-Indications_Table 
Clinical advice for HLA laboratories 
In most instances there is adequate time for donor searches to be performed 
however advice on likety time to transplant should be sought. 
Evidence based studies or reviews, indicative of optimal regime: (Brown et al. 
2006;Grever M, Andritsos LA, & Lozanski G 2008;Kantarjian H & O'Brien S. 
2007) 
                       
7.4.7 Aplastic anaemia (AA) in Adults 
Introduction 
Aquired AA is life threatening characterised by pancytopenia or bicytopenia in 
peripheral blood. It is classed as severe if more than two cell lines are involved and 
very severe when the neutophil count is bellow 0.2 x 109/L due to infection risks. The 
disease profile is heterogeneous and can involve a reduced pool of progenitor cells, 
immune suppression of haematopoiesis and accelerated apoptosis in the marrow 
progenitor cells. Patients require blood and blood product support. The aim of 
treatment  is to improve peripheral blood counts and transfusion free survival with 
minimal risk of infections.  
EBMT studies have revealed three groups of patients in terms of outcome following 
therapy.  Patients for whom bone marrow transplantation (BMT) offered best 
outcome, patients for whom immunosupresive therapy offered best outcome and 
patients for whom no difference in outcome was found between treatments. 
Therapies 
The treatments available for AA are BMT or immunosuppresive therapy (IST). 
Current HSCT  practice for Adult AA| 
BMT offers best outcome in patients aged under 40 years including children. 
Immunosupresive therapy is superior in adults aged above 40 years. 
Donor selection in Adult  AA:  
BSBMT Indications for BMT 
http://www.bsbmt.org/pages/64-Indications_Table 
Clinical advice for HLA laboratories 
In most instances there is adequate time for donor searches to be performed 
however advice on likely time to transplant should be sought. 
Evidence based studies or reviews, indicative of optimal regime: (Bacigalupo 
et al. 2009;Bacigalupo et al. 2010;Maury et al. 2009;Pulsipher et al. 2010;Young, 
Bacigalupo, & Marsh 2010) 
   
7.4.8 Hodgkin disease in Paediatrics 
Introduction 
Hodgkin disease comprises about a third of paediatric lymphoma, with a peak 
incidence in adolescence. It presents with lymphadenopathy with or without systemic 
symptoms (eg fever, weight loss) and its extent is staged by the number and site of 
lymph node regions and / or  extralymphatic tissues involved and whether systemic 
symptoms are present. 
Therapies 
Initial treatment comprises 2-6 courses of combination chemotherapy depending on 
the disease stage. Radiotherapy to all sites of initial disease (ie at presentation) is 
given to those patients in whom a PET scan performed after 2 courses is positive. 
Current HSCT  practice for Hodgkin disease in Paediatrics 
Most patients with relapsed Hodgkin disease undergo second-line chemotherapy with 
or without local radiotherapy (indicated when bulky disease remains after reinduction 
treatment), followed by autologous HSCT. Allogeneic HSCT may be considered after 
a second relapse after a previous autologous transplant, or in primary progressive 
disease. 
Donor selection in Paediatric Hodgkin disease:  
CCLG  Indications for BMT 
http://www link to be established 
Clinical advice for HLA laboratories 
It is important to check with the transplant unit that they are prepared to consider a 
MUD donor and find out the likely time to transplant. 
Evidence based studies or reviews, indicative of optimal regime: (Claviez et al. 
2009;Schmitz et al. 2009) 
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7.4.9 Myelodysplasia in Paediatrics 
Introduction  
Myelodysplasia (MDS) incorporates a group of clonal haematopoietic stem cell 
disorders involving one or more cell lineage(s), characterized by ineffective 
haematopoiesis leading to one or more cytopenia(s), disordered differentiation 
leading to dysplasia in two or more cell lineage(s), and a tendency to evolve to AML 
(reflecting myeloid clonality). Paediatric MDS is very rare but may be categorised as: 
Refractory cytopenia (RC) 
Refractory anaemia with excess blasts (RfAEB) 
Myeloproliferative/myelodysplastic disease juvenile myelomonocytic leukaemia 
(JMML) 
Therapies 
The appropriate management of paediatric MDS varies according to the subtype of 
disease, but may include observation ± supportive care such as transfusion support  
(eg for RC), chemotherapy (eg for RfAEB), and HSCT (eg for JMML). 
Current HSCT  practice  
HSCT may be indicated for a variety of scenarios in MDS, including: 
Some patients with RC, especially those with transfusion dependence or a 
persistent clonal cytogenetic abnormality 
RfAEB when poor risk cytogenetics are present 
JMML 
MDS secondary to previous chemotherapy 
Donor selection in Paediatric Myelodysplasia: 
CCLG  Indications for BMT 
http://www link to be established 
Clinical advice for HLA laboratories 
Work up an allelic matched MUD at the same time as a 6/6, 5/6 UCB.  Discuss the 
options with the transplant centre and provide advice as a matter of urgency. If there 
is no obvious MUD then look for a 6/6, 5/6 UCB with a high cell dose. 
Evidence based studies or reviews, indicative of optimal regime: 
(Passmore et al. 2003) 
 7.4.10 T-Non Hodgkins Lymphoma (NHL) in Paediatrics 
Introduction 
Paediatric T-NHL presents with lymphadenopathy, most commonly as a mediastinal 
mass, and is distinguished from ALL by the lack of bone marrow infiltration. However, 
it is treated with the same type of chemotherapy strategy as ALL. 
Therapies 
In the UK, paediatric T-NHL is treated with combination chemotherapy according to 
the closed Euro-LB-02 protocol, which employs similar regimens to UKALL 2003. 
Relapsed T-NHL is usually treated with intensive combination chemotherapy along 
the lines of second line ALL therapy such as R3. 
Current HSCT  practice for T-NHL disease in Paediatrics 
HSCT is indicated in children and adolescents with an early relapse of T-NHL who 
achieve second remission with intensive chemotherapy. There is no accepted role for 
autologous HSCT in paediatric T-NHL. 
Donor selection in Paediatric T-NHL:  
CCLG  Indications for BMT 
http://www link to be established 
National Protocols:  
Clinical advice for HLA laboratories 
HLA matched sibling preferred : if not available workup an allelic matched MUD and 
a UCB simultaneously. It is difficult to maintain a long CR2 in T-NHL and the search 
for a donor should be classed as urgent. 
Evidence based studies or reviews, indicative of optimal regime: (Hochberg et 
al. 2009) 
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7.4.11 Non SCID Primary Immunodeficiencies in Paediatrics 
Introduction 
Primary immunodeficiencies (PID) are a genetically heterogeneous group of diseases 
affecting distinct components of innate and acquired immunity including development and 
function of complement proteins, phagocytes, natural killer cells and T and B lymphocytes. 
Severe combined immunodeficiencies (SCID) are the most severe PID, characterized by 
impaired T and B lymphocyte function, normally leading to death within the first year without 
hematopoietic stem cell transplantation (HSCT) and are covered in a separate document. 
Innate immune defects may present in infancy but other T lymphocyte immunodeficiencies 
may present later. 
Therapies 
Antibacterial and antiviral prophylaxis including immunoglobulin replacement together with 
antifungal prophylaxis improve outcome, but long-term outlook for many forms of PID is poor 
with many patients dying from infectious, inflammatory-related complications or malignancy 
in early adulthood.  
The aim of HSCT is to produce stable donor engraftment after partial or full ablation of the 
recipient s  marrow and immune system using chemotherapy, antibody therapy and  a graft-
versus-marrow (GvM) effect. Apart from a GvM effect, there is no advantage in producing 
significant graft-versus-host-disease (GVHD) in these patients as no graft-versus-tumour 
effect is required  to eradicate malignancy, GVHD can adversely affect thymic function and 
stable mixed chimerism can lead to cure of these diseases. 
Current HSCT practice for Non SCID Primary Immunodeficiencies in Paediatrics 
HSCT has been shown to be effective since 1968 and remains the only form of 
curative treatment for many patients with PID, but needs to be undertaken in 
specialised centres. 
Donor selection in Paediatric  Non SCID Primary 
Immunodeficiencies:  
CCLG  Indications for BMT 
http://www link to be established 
Protocols: EBMT guidelines for HSCT for primary immunodeficiencies 
http://www.ebmt.org/5WorkingParties/IEWP/wparties-ie.html 
Evidence based studies or reviews, indicative of optimal regime: (Gennery et 
al. 2010;Slatter & Gennery 2010;Szabolcs et al. 2010) 
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7.4.12 Inborn Errors of Metabolism in Paediatrics 
Introduction 
Certain inborn errors of metabolism are improved following allogeneic HSCT. The 
paradigm disorder is Hurler Syndrome (MPSIH) and is the only such disorder for 
which there is a common indication for HSCT and upon which there is sufficient 
clinical experience on which to base guidelines for management.  
HSCT is effective as engrafted donor cells secrete the enzyme that is genetically 
deficient in this illness and it is taken up by other cells of the body. This process is 
known as cross correction. Deficient enzyme can also be delivered by infusion 
Enzyme Replacement Therapy (ERT) but this is ineffective at delivering enzyme to 
the brain and in severe disease its efficacy is limited by the development of 
alloantibodies 
Therapies 
HSCT is indicated as standard therapy in MPSIH (Hurler Syndrome),      
Mannosidosis and a variety of other rarer Lysosomal Storage Disorders (LDS). It is  
also indicated in X-linked adrenoleukodystrophy (X-ALD). This practice is 
summarised below. 
In MPSIH HSCT is standard of care. Its efficacy is most when applied early in the 
course of the disease. It is usually applied before the age of 2 years 
In X-ALD some patients never develop disease of the brain for which transplant is 
indicated. Children with advanced CNS disease do not benefit from HSCT and may 
deteriorate with HSCT. The changes of the brain on MRI scan in asymptomatic 
children are used to determine when there is evidence of early brain disease so that 
transplant can be applied to those that definitely need it but in whom the window of 
opportunity for successful HSCT is not lost. 
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Current HSCT  practice for Inborn Errors of Metabolism  in Paediatrics 
This is summarised for Hurler: 
ERT is offered to diagnosed patients whilst a donor is identified. This improves 
the pre transplant performance of children 
An unaffected sibling donor is the preferred donor but there is evidence that 
outcome is less good with carrier donors where an unrelated donor is preferred 
For unrelated donors a well matched UCB donor is preferred so that the order is: 
6/6 UCB > 10/10 MUD > 5/6 UCB > 9/10 MUD 
Conditioning is with full intensity conditioning busulfan with pharmacokinetic 
monitoring and either fludarabine or cyclophosphamide 
Serotherapy is usually given to unrelated donors  
There is no ex vivo T depletion 
Donor selection in Paediatric Inborn Errors of Metabolism  :  
CCLG  Indications for BMT 
http://www link to be established 
Protocols: 
EBMT guidelines for IEM 
Clinical advice for HLA laboratories 
For unrelated donors a well matched UCB donor is preferred so that the order is: 6/6 
UCB > 10/10 MUD > 5/6 UCB > 9/10 MUD 
Evidence based studies or reviews, indicative of optimal regime: (Boelens et al. 
2009a;Boelens et al. 2009b;Wynn et al. 2009b;Wynn et al. 2009a;Wynn & 
Boelens 2009) 
  
7.4.13 Acute Lymphoblastic Leukaemia  (ALL)  in Paediatrics 
Introduction 
ALL is most common childhood leukaemia with a peak incidence at 2-5 years of age. 
Children with ALL frequently are anaemic and require platelet support. Common 
symptoms are fever, fatigue, frequent infections, swollen lymph nodes, liver, or 
spleen, paleness or pallor, easy bleeding or bruising, petechiae under the skin, bone 
or joint pain. Leukaemic cells may accumulate in the central nervous system (CNS) 
resulting in headaches with or without vomiting. Leukaemia cells also can accumulate 
in the testicles causing painless swelling. 
Children with Down syndrome have an increased risk of developing acute myeloid or 
lymphoblastic leukaemia. These leukaemias differ in presenting characteristics and 
underlying biology when compared with leukaemias occurring in non-Down syndrome 
children. Infant ALL involving MLL gene rearrangement has a particularly poor 
prognosis with chemotherapy. 
Therapies 
The cure rate in children is about 80% after contemporary front line treatments that 
incorporate systemic therapy (e.g., combination chemotherapy) and specific central 
nervous system directed therapy (e.g., intrathecal chemotherapy, occasionally with 
cranial radiation). Allo-HSCT is usually performed in first remission (CR1) in children 
with high risk disease and in patients with relapsed ALL. 
Current HSCT  practice for ALL in Paediatrics 
HSCT for ALL in CR1 is reserved for high risk patients but the definitions of this have 
evolved with time. In the UKALL2003 trial, these children are identified by adverse 
cytogenetic characteristics (e.g., Ph+ve ALL), or failure to achieve remission at the 
end of induction treatment. Most children with ALL undergoing HSCT have relapsed 
after previous chemotherapy and are transplanted in CR2. The R3 trial recommends 
HSCT in children with high-risk relapse based on timing, site and immunophenotype, 
and in those with intermediate-risk relapse and high MRD levels. 
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Donor selection in Paediatric ALL:  
CCLG  Indications for BMT 
http://www link to be established 
National Protocols: 
UKALL 2003 (soon to be 2010) 
ALL R3 
Clinical advice for HLA laboratories 
A speedy search for both a MUD donor and a UCB should be initiated when the 
patient presents for HSCT. 
Evidence based studies or reviews, indicative of optimal regime: (Eapen et al., 
2007;Mehta & Davies 2008;Roy et al. 2005a;Roy et al. 2005b;Schultz et al., 
2007;Talano et al., 2006) 
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7.4.14 Paediatric  Acute Myeloid  Leukaemia  
Introduction 
Acute myeloid leukemia (AML) is a rare disease in childhood accounting for about 
15% of childhood leukaemias with approximately 70 new cases per annum in 
children less than 16 years of age in the United Kingdom. AML occurs when the 
regulatory controls of cellular development fails and allows proliferation of immature 
malignant cells (myeloblasts) in the myeloid cell lineage. Myeloblasts multiply 
uncontrollably and symptoms evolve  rapidly (in weeks) .This uncontrolled 
proliferation of myeloblasts  replace normal haematopioetic cells (red cells, white 
cells and platelets)  and leads to anaemia, bleeding and recurrent infections. 
Myeloblasts also infiltrate other organs increasing their size and disturbing their 
normal function. This is particularly seen with the central nervous system, lymph 
nodes, spleen, liver, gums and skin.   
Therapies 
The outcome for children with AML is dependent on the cytogenetic/molecular 
status and the response to the first course of treatment. These prognostic indicators 
are likely to be complimented by additional molecular/cytogenetic abnormalities and 
minimal residual disease assessment of response. Based on these indicators 
children can be divided into good, standard and poor risk disease. All children 
initially receive two blocks of induction chemotherapy followed by post-remission 
therapy which may be with chemotherapy or HSCT. The post remission optimal 
approach in CR1 is undetermined. Whilst HSCT has resulted in a reduced relapse 
rate, this has not translated into an improvement in overall survival in MRC trials. 
The potential advantage (reduced relapse rate) must be balanced against the 
mortality and morbidity of HSCT compared with chemotherapy regimes. This 
balance is thought only to be in favour of HSCT when the relapse rate is greater 
than 35%. By this criteria, children with high risk AML are theoretically most likely to 
benefit, although even this has been difficult to prove in clinical trial. The optimal 
strategies for post remission therapy remain undefined, with the following clinical 
options available. 
intensification consolidation   
high-dose chemo+/- radiotherapy followed by allogeneic HSCT 
Patients with refractory or relapsed disease treated with HSCT have an improved 
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outcome compared to those treated with chemotherapy alone. A meta-analysis of 
autologous SCT in AML CR 1 in children failed to show a significant benefit 
compared to chemotherapy alone.  
Current HSCT  practice for paediatric AML  
There is no international agreement on the appropriate use of HSCT in children with 
AML in CR1.  The Children s Oncology Group in the US recommends HSCT in CR1 
for standard and high risk patients. Some European Groups restrict HSCT to high 
risk and refractory AML. The UK  recommends that HSCT in CR1 follows the 
guidance of the NCRI AML 17 trial which currently recommends HSCT in CR1 for 
high risk patients only. However, as data evolves from the trial, this recommendation 
may change.  
Donor selection in Paediatric AML:  
CCLG  Indications for BMT 
http://www link to be established 
National Protocols, e.g. NCR1 AML 17  : 
Clinical advice for HLA laboratories:  
 Sibling> 10/10UD = 6/6 UCB  >9/10 UD=5/5UCB 
Large evidence based studies or reviews, indicative of optimal regime:  
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7.4.15 Severe Combined Immune Deficiencies (SCID) 
Introduction 
Severe Combined Immune Deficiencies (SCID) are a rare group of inherited 
disorders (approx 1:50 000) causing defects in T-cell +/- B and NK cell differentiation. 
Over the past two decades striking progress has been made in defining the genetic 
mutations that cause the different forms of SCID, and the functional syndromes can 
now be subdivided by their genetic basis: 
                 Functional                                     Genetic 
                    T- B- NK-                           ADA deficiency    
                                               reticular dysgenesis 
                    T- B- NK+                                     RAG deficiency   
                                                          SCID with Artemis 
                                                                          Cernunnos  
                                               DNA Ligase 4  
                                               DNA PK 
                     T- B+ NK-                                      c deficiency (X linked)    
                                               Jak 3 kinase deficiency (AR) 
                     T- B+ NK+                            IL7 R  deficiency 
                      - unspecified 
                      - other 
Clinically, most SCID patients present by 3 months of age with unusually severe and 
frequent common infections, or with opportunistic infections, often accompanied by 
one or more of diarrhoea, dermatitis, and failure to thrive.                 
Therapies 
SCID was the first disease to be treated successfully by HCT more than 40 years 
ago. More recently certain types of SCID have been treated with autologous stem cell 
gene therapy. Because of the early onset of severe complications, SCID requires 
urgent HCT because survival depends on expeditious T cell reconstitution. Simple 
infusion of HLA matched bone marrow or haploidentical stem cells without 
conditioning can give rise to T-cell reconstitution in B+ SCID, and this sets SCID 
apart from all other diseases which require conditioning prior to HCT.  B - SCID 
generally requires some sort of preparative regimen, but particular care is required 
for DNA repair disorders and radiation sensitive SCID. It is recognized that as many 
of 50% of SCID patients are engrafted with maternal T cells but in most instances 
these cells do not initiate GVHD, but can mediate graft rejection in the absence of a 
conditioning regimen. 
Current HSCT  practice for SCID 
See protocols and reviews 
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Donor selection in SCID:  
CCLG  Indications for BMT 
http://www link to be established 
National Protocols: 
EBMT guidelines for HSCT for primary immunodeficiencies 
http://www.ebmt.org/5WorkingParties/IEWP/wparties-ie.html 
Clinical advice for HLA laboratories 
Urgent HCT is required. Engraftment with maternal T cells may confuse HLA typing 
of  SCID patient. 
Evidence based studies or reviews, indicative of optimal regime: (Gennery et 
al.,  2010;Szabolcs, Cavazzana-Calvo, Fischer, & Veys 2010) 
 
